<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003476.pub2" GROUP_ID="DEMENTIA" ID="003701070312210405" MERGED_FROM="" MODIFIED="2012-04-12 16:01:24 +0200" MODIFIED_BY="Sue Marcus" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2012-04-12 16:01:24 +0200" MODIFIED_BY="Sue Marcus">
<TITLE>Atypical antipsychotics for aggression and psychosis in Alzheimer's disease</TITLE>
<CONTACT MODIFIED="2012-04-12 16:01:24 +0200" MODIFIED_BY="Sue Marcus"><PERSON ID="12997" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Clive</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Ballard</LAST_NAME><POSITION>Professor of Old Age Psychiatry</POSITION><EMAIL_1>clive.ballard@kcl.ac.uk</EMAIL_1><URL>clive.ballard@kcl.ac.uk</URL><ADDRESS><DEPARTMENT>The Wolfson Centre for Age-Related Diseases</DEPARTMENT><ORGANISATION>Kings College London</ORGANISATION><ADDRESS_1>The Wolfson Wing, Hodgkin Building</ADDRESS_1><ADDRESS_2>Guy's Campus</ADDRESS_2><CITY>London</CITY><ZIP>SE1 1UL</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)20 7848 8054</PHONE_1><FAX_1>+44 (0)20 7848 6145</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-04-12 16:01:24 +0200" MODIFIED_BY="Sue Marcus"><PERSON ID="12997" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Clive</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Ballard</LAST_NAME><POSITION>Professor of Old Age Psychiatry</POSITION><EMAIL_1>clive.ballard@kcl.ac.uk</EMAIL_1><URL>clive.ballard@kcl.ac.uk</URL><ADDRESS><DEPARTMENT>The Wolfson Centre for Age-Related Diseases</DEPARTMENT><ORGANISATION>Kings College London</ORGANISATION><ADDRESS_1>The Wolfson Wing, Hodgkin Building</ADDRESS_1><ADDRESS_2>Guy's Campus</ADDRESS_2><CITY>London</CITY><ZIP>SE1 1UL</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)20 7848 8054</PHONE_1><FAX_1>+44 (0)20 7848 6145</FAX_1></ADDRESS></PERSON><PERSON ID="13088" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><LAST_NAME>Waite</LAST_NAME><POSITION>Consultant in Old Age Psychiatry</POSITION><EMAIL_1>jonwaite@ntlworld.com</EMAIL_1><ADDRESS><DEPARTMENT>Old Age Psychiatary</DEPARTMENT><ORGANISATION>The Courtyard</ORGANISATION><ADDRESS_1>Queen's Medical Centre</ADDRESS_1><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0115 849 3272</PHONE_1><FAX_1>0115 970 9350</FAX_1></ADDRESS></PERSON><PERSON ID="7198" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Jacqueline</FIRST_NAME><LAST_NAME>Birks</LAST_NAME><SUFFIX>MA (Cantab) MSc (Oxon) C Stat</SUFFIX><POSITION>NIHR Senior Medical Statistician</POSITION><EMAIL_1>jacqueline.birks@csm.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Statistics in Medicine</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Wolfson College</ADDRESS_1><ADDRESS_2>Linton Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6UD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 (0)1865 284403</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-06-20 15:21:14 +0100" MODIFIED_BY="Helen Collins">
<UP_TO_DATE>
<DATE DAY="21" MONTH="2" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="12" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="12" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2012-04-12 14:58:33 +0100" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-04-12 14:58:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>Additional table linked to text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-04-12 14:57:36 +0100" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-04-12 14:57:36 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-06-20 15:22:53 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="18" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>As of Issue 3, 2006 the review has been anonymously peer reviewed. Since that time more study results for F1D-MC-HGGU/Deberdt 2005 have been published. New data were few but these have been incorporated. They do not change the conclusions of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-06-20 15:22:05 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="21" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Kings College London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Nottinghamshire Healthcare NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-04-12 14:52:25 +0100" MODIFIED_BY="Helen Collins">
<SUMMARY MODIFIED="2008-06-20 15:23:19 +0100" MODIFIED_BY="Helen Collins">
<TITLE MODIFIED="2008-06-20 15:23:19 +0100" MODIFIED_BY="Helen Collins">Atypical antipsychotics benefit people with dementia but the risks of adverse events may outweigh the benefits, particularly with long term treatment</TITLE>
<SUMMARY_BODY>
<P>Atypical antipsychotics have become the pharmacological treatment of choice for many clinicians in the treatment of behavioural and psychiatric symptoms in people with dementia, and the largest evidence base for double blind placebo controlled trials in this area is for risperidone. Particularly in view of recent safety concerns, a meta-analysis of efficacy and adverse events to inform clinical practice is timely. Modest efficacy is evident, but the elevated risk of cerebrovascular adverse events, mortality, upper respiratory infections, oedema and extrapyramidal symptoms is a concern, particularly as selective reporting makes interpretation of other potential adverse outcomes impossible.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Aggression, agitation or psychosis occur in the majority of people with dementia at some point in the illness. There have been a number of trials of atypical antipsychotics to treat these symptoms over the last five years, and a systematic review is needed to evaluate the evidence in a balanced way. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine whether evidence supports the use of atypical antipsychotics for the treatment of aggression, agitation and psychosis in people with Alzheimer's disease.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The trials were identified from a last updated search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 7 December 2004 using the terms olanzapine, quetiapine, risperidone, clozapine, amisulpride, sertindole, zotepine, aripiprazole, ziprasidone. This Register contains articles from all major healthcare databases and many ongoing trials databases and is updated regularly.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised, placebo-controlled trials, with concealed allocation, where dementia and psychosis and/or aggression were assessed.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>1. Three reviewers extracted data from included trials<BR/>2. Data were pooled where possible, and analysed using appropriate statistical methods<BR/>3. Analysis included patients treated with an atypical antipsychotic, compared with placebo</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Sixteen placebo controlled trials have been completed with atypical antipsychotics although only nine had sufficient data to contribute to a meta-analysis and only five have been published in full in peer reviewed journals. No trials of amisulpiride, sertindole or zotepine were identified which met the criteria for inclusion. <BR/>The included trials led to the following results:<BR/>1. There was a significant improvement in aggression with risperidone and olanzapine treatment compared to placebo.<BR/>2. There was a significant improvement in psychosis amongst risperidone treated patients.<BR/>3. Risperidone and olanzapine treated patients had a significantly higher incidence of serious adverse cerebrovascular events (including stroke), extrapyramidal side effects and other important adverse outcomes.<BR/>4. There was a significant increase in drop-outs in risperidone (2 mg) and olanzapine (5-10 mg) treated patients.<BR/>5. The data were insufficient to examine impact upon cognitive function.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Evidence suggests that risperidone and olanzapine are useful in reducing aggression and risperidone reduces psychosis, but both are associated with serious adverse cerebrovascular events and extrapyramidal symptoms. Despite the modest efficacy, the significant increase in adverse events confirms that neither risperidone nor olanzapine should be used routinely to treat dementia patients with aggression or psychosis unless there is severe distress or risk of physical harm to those living and working with the patient. Although insufficient data were available from the considered trials, a meta-analysis of seventeen placebo controlled trials of atypical neuroleptics for the treatment of behavioural symptoms in people with dementia conducted by the Food and Drug Administration suggested a significant increase in mortality (OR 1.7). A peer-reviewed meta-analysis (Schneider 2005) of 15 placebo controlled studies (nine unpublished) found similarly increased risk in mortality (OR=1.54, 95% CI 0.004 to 0.02, p=0.01) for the atypical neuroleptics.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-04-12 14:52:25 +0100" MODIFIED_BY="Helen Collins">
<BACKGROUND>
<P>Five percent of people aged over 65 and 20% of those over 80 have dementia, with 700,000 suffers in the UK alone, a number that will continue to rise as the age of the population increases. More than 50% of people with dementia experience behavioural and psychological disturbances (BPSD). BPSD are distressing for the patients (<LINK REF="REF-Gilley-1991" TYPE="REFERENCE">Gilley 1991</LINK>), problematic for their carers (<LINK REF="REF-Rabins-1982" TYPE="REFERENCE">Rabins 1982</LINK>) in whom they are associated with clinically significant depression (<LINK REF="REF-Ballard-1996" TYPE="REFERENCE">Ballard 1996</LINK>) and are frequently the trigger for placement in residential or nursing home care (<LINK REF="REF-Steele-1990" TYPE="REFERENCE">Steele 1990</LINK>). </P>
<P>Pharmacological treatment with antipsychotic agents (also known as neuroleptics) is often the first line treatment for these disorders, despite evidence of only modest efficacy. Up until the last decade there were only a few double-blind placebo-controlled trials pertaining to the treatment of BPSD, the majority of which were conducted using typical antipsychotics such as haloperidol. However, these agents have a particularly high risk of harmful side effects for people with dementia, and the Chief Medical Officer for England and Wales (<LINK REF="REF-CMO-2004" TYPE="REFERENCE">CMO 2004</LINK>) has recommended that they should be used with extreme caution for these patients. Overall placebo response rates in such trials are of the order of 40% (<LINK REF="REF-Ballard-1999a" TYPE="REFERENCE">Ballard 1999a</LINK>; <LINK REF="REF-Schneider-1990" TYPE="REFERENCE">Schneider 1990</LINK>), probably reflecting high rates of spontaneous resolution and the value of the psychosocial input inherent to any pharmacological trial. </P>
<P>Over prescribing has, however, become a major problem, especially in residential and nursing home environments, where more than 40% of people with dementia are taking antipsychotic drugs, often inappropriately and usually with little monitoring (<LINK REF="REF-Furniss-1998" TYPE="REFERENCE">Furniss 1998</LINK>). Antipsychotic drugs have substantial adverse effects. An increased risk of falls and drowsiness are common to most classes of psychotropic, whilst additional problems such as parkinsonism (<LINK REF="REF-Tune-1991" TYPE="REFERENCE">Tune 1991</LINK>), akathisia, tardive dyskinesia, reduced well-being (<LINK REF="REF-Ballard-1999b" TYPE="REFERENCE">Ballard 1999b</LINK>), social withdrawal, accelerated cognitive decline (<LINK REF="REF-McShane-1997" TYPE="REFERENCE">McShane 1997</LINK>), QT prolongation (<LINK REF="REF-Reilly-2000" TYPE="REFERENCE">Reilly 2000</LINK>), severe sensitivity reactions (<LINK REF="REF-McKeith-1992" TYPE="REFERENCE">McKeith 1992</LINK>) and stroke (<LINK REF="REF-CMO-2004" TYPE="REFERENCE">CMO 2004</LINK>) may occur with antipsychotic agents. Despite being widely prescribed, these agents are not licensed for use for people with dementia.</P>
<P>Interpreting the data from clinical trials poses considerable problems, partly because of the high placebo response rates (which render trials without placebo treated patients as of very little value), but mainly because of the failure of studies to focus upon clinically meaningful syndromes. The term BPSD is useful as a global term to focus attention upon this important area, but it does not define a unitary clinical syndrome. A number of studies utilizing statistical methods such as principal components analysis (summarized in <LINK REF="REF-Ballard-1999b" TYPE="REFERENCE">Ballard 1999b</LINK>) have supported clinical opinion that the key clinical syndromes are aggression, non-aggressive agitation, psychosis and mood disorders. As antipsychotic agents have not been proposed as a treatment for mood disorders, this review will focus predominantly upon aggression (with or without agitation) and psychosis.<BR/>
<BR/>Atypical antipsychotics may offer an advance for the management of aggression and psychosis in the context of dementia. There are potential advantages over typical antipsychotics such as a better side effect profile. However, the evidence is difficult to interpret as only 6 of the 16 studies have been published in peer review journals (<LINK REF="STD-Ballard-2005" TYPE="STUDY">Ballard 2005</LINK>; <LINK REF="STD-Brodaty-2001" TYPE="STUDY">Brodaty 2001</LINK>; <LINK REF="STD-DeDeyn-2003" TYPE="STUDY">DeDeyn 2003</LINK>; <LINK REF="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TYPE="STUDY">F1D-MC-HGIV/DeDeyn</LINK>; <LINK REF="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TYPE="STUDY">F1D-MC-HGEU/Clark/St</LINK>; <LINK REF="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TYPE="STUDY">RIS-USA-63/Katz</LINK>), with additional data published in abstract only or held by pharmaceutical companies. <BR/>
<BR/>In addition, the primary outcome measure in most of these studies has grouped together BPSD, making the impact on specific syndromes difficult to determine. There is therefore a need to determine the evidence for effectiveness on key individual behavioural and psychiatric syndromes, the most frequent and distressing of which are aggression and psychosis (incorporating delusions, hallucinations and delusional misidentification). As the majority of treatment trials have been conducted with patients with Alzheimer's disease (AD) and as the issues for treatment may be different in other dementias, this review focuses specifically upon the AD patient population.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the effectiveness of atypical antipsychotics for the treatment of key psychiatric and behavioural syndromes in Alzheimer's disease.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-06-20 15:24:13 +0100" MODIFIED_BY="Helen Collins">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<UL>
<LI>Randomized, double-blind, placebo-controlled, parallel group studies</LI>
<LI>Minimum duration of treatment: 6 weeks</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<UL>
<LI>Age &gt;60, male or female </LI>
<LI>Setting: outpatients or people living in care facilities. Living with or regular contact (&gt;one time per week) with carer </LI>
<LI>Diagnoses: Operationalized clinical diagnosis of Alzheimer's disease using any commonly used criteria (e.g. NINCDS ADRDA (<LINK REF="REF-McKhann-1984" TYPE="REFERENCE">McKhann 1984</LINK>), <LINK REF="REF-ICD_x002d_10" TYPE="REFERENCE">ICD-10</LINK>, <LINK REF="REF-DSM-IV" TYPE="REFERENCE">DSM IV</LINK>, <LINK REF="REF-CAMCOG" TYPE="REFERENCE">CAMCOG</LINK>) </LI>
<LI>Inclusions: only studies which utilized a validated and published method for evaluating aggression (with or without agitation) and psychosis were included</LI>
<LI>Exclusions: patients receiving other psychotropic drugs during the course of the study.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. The atypical antipsychotics olanzapine, quetiapine, risperidone, clozapine, amisulpride, sertindole, zotepine, aripiprazole, ziprasidone. <BR/>2. The placebo <BR/>All doses and frequencies of administration were evaluated. Mode of delivery: only oral administration was examined.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Change in manifestation of psychosis<BR/>2. Change in manifestation of aggression<BR/>3. Adverse effects<BR/>4. Withdrawals<BR/>5. Reasons for withdrawals<BR/>The choice of rating scales selected for meta-analyses depended on which scales were used in the selected studies. Only scales which had been published and validated were used.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The trials were identified from a last updated search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 7 December 2004 using the terms olanzapine, quetiapine, risperidone, clozapine, amisulpride, sertindole, zotepine, aripiprazole, ziprasidone.<BR/>The Specialized Register at that time contained records from the following databases:</P>
<P>CENTRAL: July 2004 (issue 3);<BR/>MEDLINE: 1966 to 2004/08;<BR/>EMBASE: 1980 to 2004/08;<BR/>PsycINFO: 1887 to 2004/08;<BR/>CINAHL: 1982 to 2004/08;<BR/>SIGLE (Grey Literature in Europe): 1980 to 2004/06;<BR/>ISTP (Index to Scientific and Technical Proceedings): to May 2000;<BR/>INSIDE (BL database of Conference Proceedings and Journals): to June 2000;<BR/>Aslib Index to Theses (UK and Ireland theses): 1970 to March 2003;<BR/>Dissertation Abstract (USA): 1861 to March 2003;<BR/>ADEAR (Alzheimer's Disease Clinical Trials Database): to 27 September 2004; <BR/>National Research Register: issue 3/2004;<BR/>Current Controlled trials (last searched September 2004) which includes:<BR/> Alzheimer Society<BR/> GlaxoSmithKline<BR/> HongKong Health Services Research Fund<BR/> Medical Research Council (MRC)<BR/> NHS R&amp;D Health Technology Assessment Programme<BR/> Schering Health Care Ltd<BR/> South Australian Network for Research on Ageing<BR/> US Dept of Veterans Affairs Cooperative Studies<BR/> National Institutes of Health (NIH)<BR/>ClinicalTrials.gov: last searched 27 September 2004;<BR/>LILACS (Latin American and Caribbean Health Science Literature): last searched April 2003.</P>
<P>The search strategies used to identify relevant records in MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS can be found in the Group's module.<BR/>Through email alerts to many journals in the field of dementia, depression and stroke, trial reports are downloaded into the Specialized register when they appear.<BR/>The pharmaceutical companies Astra-Zeneca, E Lilly and Janssen-Cilag were approached for additional information from completed studies, as well as information regarding additional and ongoing studies. Astra-Zeneca provided some additional information, but insufficient to enable studies to be included in the meta-analysis. Eli Lilly provided a limited amount of extra data for F1D-MC-HGEU Clark/ Street which has been included in the analyses. Janssen-Cilag did agree to provide information, but no information was provided despite a number of contacts and meetings over a period of greater than 2 years. </P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-06-20 15:24:13 +0100" MODIFIED_BY="Helen Collins">
<P>References retrieved by the search strategy were examined by two reviewers (CGB, JoW) in order to discard those which are clearly not eligible for the review. The full text of remaining references was retrieved and the inclusion criteria were applied to these independently by two reviewers (CGB and JoW). An arrangement was in place for disagreements to be resolved by discussion and consultation with an independent consultant psychiatrist (RB), but this situation did not arise.</P>
<P>Individual patient data were exhaustively sought for all included studies, but unfortunately were not made available.</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>Two reviewers (CGB, JoW) independently estimated the quality of the included studies. The Cochrane approach to assessing adequacy of allocation concealment was used (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>; Mulrow &amp; Oxman 1997).</P>
<P>Category A (adequate concealment): allocation is determined by:<BR/>1) a centralized randomized scheme in which subjects are enrolled at a registry which codes and randomizes the participants and notifies the investigator by telephone about treatment or control group allocation;<BR/>2) a randomization controlled by a pharmacy;<BR/>3) coded containers with identical appearing capsules which are administered sequentially to participants;<BR/>4) an on-site or coded computer, given that allocations were in a locked, unreadable file that could be accessed only after inputting the characteristics of an enrolled subject;<BR/>5) the use of sequentially numbered and sealed, opaque envelopes;<BR/>6) combinations of the aforementioned.</P>
<P>Category B (unclear concealment): the report describes allocation of treatment by:<BR/>1) the use of a list or table to allocate assignments;<BR/>2) the use of envelopes or of sealed envelopes to distribute medications;<BR/>3) a statement in the report to the effect that the report is randomized without further characterization.</P>
<P>Category C (inadequate): allocation of treatment by:<BR/>1) alternation of subjects to treatment or control arms of the study;<BR/>2) use of 'fixed data' such as birth dates, record numbers, days of the week;<BR/>3) allocation that is transparent such as an open list of random numbers or assignments.<BR/>Unclear concealment methods have been shown to increase estimates of treatment effects compared with adequate methods of concealment. Trials conforming to Categories A and B were accepted; trials falling into category C were excluded from further study. Each of the four included studies satisfied Category B criteria for allocation concealment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data retrieval and extraction</HEADING>
<P>As it proved impossible to obtain access to individual patient data, data were extracted from reports, published or unpublished. <B>
<BR/>
</B>The summary statistics required for each trial and each outcome for continuous data are the mean change from baseline, the standard error of the mean change, and the number of patients for each treatment group at each assessment. Where changes from baseline were not reported, the mean, standard deviation and the number of people in each treatment group at each time point were extracted if available.</P>
<P>For binary data the number in each treatment group and the numbers experiencing the outcome of interest were sought.</P>
<P>The baseline assessment is defined as the latest available assessment prior to randomization, but no longer than two months before.</P>
<P>For each outcome measure, data were sought on every person assessed. To allow an intention-to-treat analysis, the data were sought irrespective of compliance, whether or not the person was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. If intention-to-treat data were not available in the publications, "on-treatment" or the data of those who complete the trial were sought and indicated as such.</P>
<P>In studies where a cross-over design was used, only data from the first treatment phase after randomization were eligible for inclusion.</P>
<P>When studies included an open period after the main comparative phase, data from non-randomized follow-on periods were not used. Data on all of the outcome measures of interest from all assessment times (including baseline) were extracted.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>The outcomes measured in trials of dementia and cognitive impairment often arise from ordinal rating scales. Where the rating scales used in the trials have a reasonably large number of categories (more than 10) the data were treated as continuous outcomes arising from a normal distribution.</P>
<P>Summary statistics (n, mean and standard deviation) are required for each rating scale at each assessment time for each treatment group in each trial for change from baseline. For cross-over trials only the data from the first treatment period are used.</P>
<P>When change from baseline results are not reported, the required summary statistics were calculated from the baseline and assessment time treatment group means and standard deviations. In this case a zero correlation between the measurements at baseline and assessment time was assumed. This method overestimates the standard deviation of the change from baseline, but this conservative approach is considered to be preferable in a meta-analysis.</P>
<P>Meta-analysis requires the combination of data from trials that may not use the same rating scale to assess an outcome. The measure of the treatment difference for any outcome is the weighted mean difference when the pooled trials use the same rating scale or test, and the standardized mean difference, which is the absolute mean difference divided by the pooled standard deviation, when they used different rating scales or tests.</P>
<P>The duration of the trials may vary considerably. If the range is considered too great to combine all trials into one meta-analysis the data are divided into smaller time periods and a separate meta-analysis conducted for each period. Some trials may contribute data to more than one time period if multiple assessments have been made.</P>
<P>For binary outcomes, such as improvement or no improvement, the odds ratio is used to measure treatment effect. A weighted estimate of the typical treatment effect across trials is calculated.</P>
<P>Overall estimates of the treatment difference are presented. In all cases the overall estimate from a fixed-effects model is presented and a tests for heterogeneity using a standard chi-square statistic and I-squared are performed. If, however, there is evidence of heterogeneity of the treatment effect between trials then either only homogeneous results are pooled, or a random-effects model used (in which case the confidence intervals would be broader than those of a fixed-effects model).</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-04-12 14:52:25 +0100" MODIFIED_BY="Helen Collins">
<STUDY_DESCRIPTION MODIFIED="2012-04-12 14:52:25 +0100" MODIFIED_BY="Helen Collins">
<P>There are 16 included studies (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), 5 for risperidone, 3 for olanzapine, 3 for quetiapine, 3 for aripiprazole, one study (<LINK REF="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TYPE="STUDY">F1D-MC-HGGU/Deberdt</LINK>) with risperidone and olanzapine arms and one study (<LINK REF="STD-CATIE" TYPE="STUDY">CATIE</LINK>) with risperidone, quetiapine and olanzapine arms. Ten trials contributed data to the meta-analyses. One study (<LINK REF="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TYPE="STUDY">RIS-INT-24/DeDeyn</LINK>) also included an arm for patients treated with haloperidol.</P>
<P>The studies are summarized as follows:</P>
<P>1. All except one (<LINK REF="STD-Ballard-2005" TYPE="STUDY">Ballard 2005</LINK>) were multi-centre; two studies were from Europe, three studies were from the United States, and one from Australasia. In two studies patients were recruited from long-term care institutions, the subjects' place of residence in the other studies was unclear.</P>
<P>2. The average age of participants ranged between 79 years and 83 years; women constituted 58% to 77% of the patients studied.</P>
<P>3. Identification of dementia: three studies used <LINK REF="REF-DSM-IV" TYPE="REFERENCE">DSM IV</LINK> to diagnose dementia, including Alzheimer's dementia. One study included patients with Alzheimer's disease and mixed dementia, and four studies included subjects with mixed and vascular dementia, although the majority of patients had Alzheimer's disease (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>4. Characterization of dementia: In three studies patients had severe dementia (Mean MMSE 5.3 to 8.4) and FAST &gt;= 4 (<LINK REF="REF-Reisberg-1987" TYPE="REFERENCE">Reisberg 1987</LINK>). One study (<LINK REF="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TYPE="STUDY">RIS-USA-232/Colon</LINK>) evaluated risperidone in patients with moderate dementia (mean MMSE 13.2), no details of diagnostic criteria are given.<BR/>
<BR/>5. Characterization of agitation and outcome measures: three studies used the CMAI scale (<LINK REF="REF-Cohen_x002d_Mansfield-1996" TYPE="REFERENCE">Cohen-Mansfield 1996</LINK>) and BEHAVE-AD (<LINK REF="REF-Reisberg-1987" TYPE="REFERENCE">Reisberg 1987</LINK>) to assess agitation and response to therapy. One study used the BEHAVE-AD alone, one study used the NPI-NH (<LINK REF="REF-Cummings-1994" TYPE="REFERENCE">Cummings 1994</LINK>)</P>
<P>6. <LINK REF="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TYPE="STUDY">RIS-USA-63/Katz</LINK> used fixed doses of risperidone (0.5 mg, 1.0 mg or 2.0 mg) for 12 weeks. <LINK REF="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TYPE="STUDY">RIS-INT-24/DeDeyn</LINK> used incremental doses of 0.25 mg, increasing every 4 days by 0.25 mg to a maximum of 2.0 mg (mean dose 1.1 mg /day). <LINK REF="STD-Brodaty-2001" TYPE="STUDY">Brodaty 2001</LINK> used doses starting at 0.25 mg bd increasing by no more than 0.25 mg alternate days to 2.0 mg /day. The mean dose administered was 0.95 mg /day.</P>
<P>7. Measurement of extrapyramidal symptoms and other adverse effects: One study used the Simpson-Angus scale (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>) and the Abnormal Involuntary Movement Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) to assess extrapyramidal adverse effects. The remaining three studies used the Extrapyramidal Symptom Rating Scale, (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>).</P>
<P>8. Three studies evaluated risperidone against placebo and one study compared risperidone against haloperidol and placebo (<LINK REF="STD-Brodaty-2001" TYPE="STUDY">Brodaty 2001</LINK>; <LINK REF="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TYPE="STUDY">RIS-INT-24/DeDeyn</LINK>; <LINK REF="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TYPE="STUDY">RIS-USA-63/Katz</LINK>)</P>
<P>9. All included studies described analyses based on "intention to treat."</P>
<SUBSECTION>
<HEADING LEVEL="3">Outcome measures</HEADING>
<UL>
<LI>Agitation and aggression</LI>
</UL>
<P>1. The Cohen-Mansfield Agitation Inventory (CMAI) (<LINK REF="REF-Cohen_x002d_Mansfield-1996" TYPE="REFERENCE">Cohen-Mansfield 1996</LINK>) scale is widely used in nursing homes to assess agitation. The scale examines 29 types of agitated behaviour, including pacing, verbal or physical aggression, performing repetitious mannerisms, screaming, and general restlessness. The frequency of these behaviours is measured on a seven-point scale, ranging from 1 (never occurs) to 7 (occurs several times an hour) and includes cluster scores for physical and verbal aggression, and total aggression.</P>
<P>2. The Behavior Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) (<LINK REF="REF-Reisberg-1987" TYPE="REFERENCE">Reisberg 1987</LINK>) examines 25 items and uses a four-point scale of increasing severity to assess seven clusters of behaviour: paranoid/delusional ideation; aggressiveness; hallucinations; activity symptoms; diurnal rhythm symptoms; affective symptoms; and anxieties and phobias. An aggressiveness subscale score sums three symptoms scores: verbal outbursts; physical threats, violence or both; and other kinds of agitation (e.g., wandering, thrashing about).</P>
<UL>
<LI>Global change</LI>
</UL>
<P>1. The Clinical Global Impression of Change (CGI-C) (<LINK REF="REF-Schneider-1997" TYPE="REFERENCE">Schneider 1997</LINK>) is a seven point scale (1 - very much improved; 4 - no change; 7 - very much worse) which makes a global rating of all aspects of the patient's condition, comparing the current state with the baseline, and using direct observation as well as information from significant others to determine the score.</P>
<P>2. The Functional Assessment Staging Scale (FAST) (<LINK REF="REF-Reisberg-1987" TYPE="REFERENCE">Reisberg 1987</LINK>) measures the level of basic activities such as bathing, dressing, and toileting, through 16 stages, ranging from independent to totally dependent.</P>
<UL>
<LI>Extrapyramidal symptoms and other side effects</LI>
</UL>
<P>1. The extrapyramidal symptom rating scale (ESRS) (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>) is a 55-item scale to measure the severity of parkinsonian symptoms (e.g., hypokinesia, muscle rigidity, tremors, excess salivation), dyskinetic movements (e.g., of head, limbs, tongue), and a global estimate of tardive dyskinesia (e.g., athetoid movements of the tongue).</P>
<P>2. The Simpson-Angus Scale (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>).</P>
<P>3. Abnormal Involuntary Movement Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) allows rating of seven body areas and global judgements of the severity of abnormal movements, the degree of handicap and the patient's awareness of abnormal movements.</P>
<P>4. Other adverse events were recorded as reported by study participants, but were not evaluated using any specific operationalized scales.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-06-20 15:24:47 +0100" MODIFIED_BY="Helen Collins">
<P>1 Randomization: All included studies were described as randomized, although the method of randomization was not specified.<BR/>2 Blindness: All studies were reported as double blind, although this may have been difficult to maintain in some patients because of the emergence of characteristic side effects (such as extrapyramidal symptoms) particularly at doses of atypical neuroleptics (e.g. risperidone 2 mg).<BR/>3 Inclusion criteria: In most of the studies the people were included on the basis of a score on a behavioural symptom rating scale, rather than the presence of specific symptoms, hence it is unclear how many people had specific clinically significant symptoms. Four of the studies included patients with Alzheimer's disease and patients with vascular dementia, but did not present the data by diagnosis, making it impossible to determine the efficacy specifically in Alzheimer's disease.<BR/>4 Outcome: The primary outcome measure in most of the studies was change in the overall behavioural symptom rating scale utilized in the particular study. Although some data were presented regarding change in scores for key symptoms such as aggression and psychosis, this is difficult to interpret as it is not clear which participants had each specific symptom at baseline.<BR/>5 Data-reporting: data reporting is very selective. This is a particular problem for non-aggressive agitation, data pertaining to which are described in only a small proportion of studies, and some key potential adverse effects. For example, incomplete reporting for key outcomes such as mortality and cognitive decline impairs interpretation. Although cerebrovascular events have subsequently emerged as a concern, these were only reported as an issue in one of the published studies (<LINK REF="STD-Brodaty-2001" TYPE="STUDY">Brodaty 2001</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-06-20 15:29:08 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="3">Risperidone</HEADING>
<P>There were seven included trials, five of which provided some results for meta-analyses (<LINK REF="STD-Brodaty-2001" TYPE="STUDY">Brodaty 2001</LINK>; <LINK REF="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TYPE="STUDY">F1D-MC-HGGU/Deberdt</LINK>; <LINK REF="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TYPE="STUDY">RIS-USA-232/Colon</LINK>; <LINK REF="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TYPE="STUDY">RIS-INT-24/DeDeyn</LINK>; <LINK REF="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TYPE="STUDY">RIS-USA-63/Katz</LINK>). The trials used different dosing regimes, fixed or flexible, with a mean dose between 0.5 - 2.0 mg/day, and the treatment periods varied from 10 to 13 weeks. Two studies included just patients with Alzheimer's disease, the other five, which are included in the meta-analyses, included both patients with AD and a small percentage of those with vascular dementia. All studies used additional inclusion criteria, related to behavioural symptoms, either psychotic symptoms, or signs of aggression. The details are in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, Included studies - inclusion criteria. The studies included in the meta-analyses examined psychosis and aggressiveness subscores, safety and tolerability. In an additional analysis two doses were compared, 2 mg/day with 1 mg/day. The only trial to include both of these doses was <LINK REF="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TYPE="STUDY">RIS-USA-63/Katz</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Total behaviour</HEADING>
<P>Risperidone, 0,5, 1.0 and 2.0 mg/day show benefit compared with placebo for BEHAVE-AD or NPI TOTAL.<BR/>
</P>
<UL>
<LI>risperidone 0.5 mg/day vs placebo (ITT, SMD -0.29, 95% CI -0.51 to -0.06, P = 0.01)</LI>
<LI>risperidone 1.0 mg/day vs placebo (ITT, SMD -0.17, 95% CI -0.29 to -0.05, P = 0.004)</LI>
<LI>risperidone 2.0 mg/day vs placebo (ITT, SMD -0.29, 95% CI -0.51 to -0.07, P = 0.01)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aggression</HEADING>
<P>Three studies assessed aggression using the Cohen-Mansfield Agitation Inventory (<LINK REF="STD-Brodaty-2001" TYPE="STUDY">Brodaty 2001</LINK>; <LINK REF="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TYPE="STUDY">F1D-MC-HGGU/Deberdt</LINK>; <LINK REF="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TYPE="STUDY">RIS-INT-24/DeDeyn</LINK>) and two using the BEHAVE-AD aggressiveness subscore, (<LINK REF="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TYPE="STUDY">RIS-USA-63/Katz</LINK>, <LINK REF="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TYPE="STUDY">RIS-INT-24/DeDeyn</LINK>). Risperidone (1.0 and 2.0 mg/day) had a significant beneficial effect compared with placebo .<BR/>BEHAVE-AD AGGRESSIVENESS<BR/>
</P>
<UL>
<LI>risperidone 1.0 mg/day vs placebo (ITT, MD -0.84, 95% CI -1.28 to -0.40, P = 0.0002)</LI>
<LI>risperidone 2.0 mg/day vs placebo (ITT, MD -1.50, 95% CI -2.05 to -0.95, P&lt;0.0001)</LI>
</UL>
<P>CMAI TOTAL AGGRESSIVENESS<BR/>
</P>
<UL>
<LI>risperidone 1.0 mg/day vs placebo (ITT, MD -1.17, 95% CI -2.02 to -0.32, P = 0.007)</LI>
</UL>
<P>There was benefit on 2 mg/day compared with 1 mg/day.<BR/>
</P>
<UL>
<LI>risperidone 2.0 mg/day versus risperidone 1 mg/day (ITT, MD -0.70, 95% CI -1.25 to -0.15, P = 0.01).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Psychosis</HEADING>
<P>Three studies assessed psychosis using the BEHAVE-AD subscore (<LINK REF="STD-Brodaty-2001" TYPE="STUDY">Brodaty 2001</LINK>; <LINK REF="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TYPE="STUDY">RIS-USA-232/Colon</LINK>; <LINK REF="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TYPE="STUDY">RIS-USA-63/Katz</LINK>) and one (<LINK REF="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TYPE="STUDY">F1D-MC-HGGU/Deberdt</LINK>) using the NPI subscore. There was a benefit associated with risperidone (1.0 mg/day).<BR/>
</P>
<UL>
<LI>risperidone 1.0 mg/day versus placebo (ITT, MD -0.14, 95% CI -0.25 to -0.03, P = 0.01).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Drop-outs by endpoint</HEADING>
<P>There was an adverse effect of risperidone 1.0 and 2.0 mg/day compared with placebo (88/764 vs 61/665, OR 1.43, 95% CI 1.01 to 2.03, P = 0.05) (69/165 vs 44/163, OR 1.94, 95% CI 1.22 to 3.09, P = 0.005).<BR/>Drop-outs were more frequent on 2 mg/day than 1 mg/day<BR/>69/165 vs 45/148, OR 1.65, 95% CI 1.03 to 2.63, P = 0.04)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Drop-outs due to adverse events by endpoint</HEADING>
<P>There was an adverse effect of risperidone 2.0 mg/day compared with placebo (40/165 vs 20/163, OR 2.29, 95% CI 1.27 to 4.12, P = 0.006).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Extrapyramidal symptoms by endpoint</HEADING>
<P>There were adverse effects of risperidone (1.0 and 2.0 mg/day) compared with placebo (32/550 versus 20/571, OR 1.78, 95% CI 1.00 to 3.17, P = 0.05) (35/165 versus 12/163, OR 3.39, 95% CI 1.69 to 6.80, P = 0.0006).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to somnolence by endpoint</HEADING>
<P>There were adverse effects of risperidone (1.0 and 2.0 mg/day) compared with placebo (175/861 vs 80/779, OR 2.38, 95% CI 1.76 to 3.20, P&lt;0.00001) (46/165 vs 13/163, OR 4.46, 95% CI 2.30 to 8.64, P&lt;0.00001).<BR/>Adverse events were more frequent on 2 mg/day than 1 mg/day<BR/>46/165 vs 25/148, OR 1.90, 95% CI 1.10 to 3.29, P = 0.02)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to pain by endpoint</HEADING>
<P>There was a beneficial effect of risperidone (1.0 mg/day) compared with placebo (4/148 vs 13/163, OR 0.32, 95% CI 0.10 to 1.01 P = 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to upper respiratory tract infection by endpoint</HEADING>
<P>There was an adverse effect of risperidone (1.0 mg/day) compared with placebo (15/149 vs 6/163, OR 2.93, 95% CI 1.11 to 7.76 P = 0.03).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to urinary tract infection by endpoint</HEADING>
<P>There was an adverse effect of risperidone (2.0 mg/day) compared with placebo (35/149 vs 21/163, OR 1.82, 95% CI 1.01 to 3.29 P = 0.05).<BR/>Adverse events were more frequent on 2 mg/day than 1 mg/day<BR/>35/165 vs 19/148, OR 1.83, 95% CI 1.00 to 3.36, P = 0.05)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to falls by endpoint</HEADING>
<P>Adverse events were more frequent on 2 mg/day than 1 mg/day<BR/>41/165 vs 19/148, OR 2.24, 95% CI 1.24 to 4.08, P = 0.008)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to extrapyramidal disorders by endpoint</HEADING>
<P>Adverse events were more frequent on 2 mg/day than 1 mg/day<BR/>35/165 vs 19/148, OR 1.83, 95% CI 1.00 to 3.36, P = 0.05)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to pain by endpoint</HEADING>
<P>Adverse events were more frequent on 2 mg/day than 1 mg/day<BR/>46/165 vs 25/148, OR 1.90, 95% CI 1.10 to 3.29, P = 0.02).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to peripheral oedema by endpoint</HEADING>
<P>There were adverse effects of risperidone (0.5, 1.0 and 2.0 mg/day) compared with placebo (24/149 vs 9/163, OR 3.29, 95% CI 1.47 to 7.32, P = 0.004) (44/511 vs 16/427, OR 2.75, 95% CI 1.51 to 5.03, P = 0.001) (30/165 vs 9/163, OR 3.80, 95% CI 1.74 to 8.29, P = 0.0008).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to fever by endpoint</HEADING>
<P>There was an adverse effect of risperidone (2.0 mg/day) compared with placebo (24/165 vs 12/163, OR 2.14, 95% CI 1.03 to 4.44 P = 0.04).<BR/>Adverse events were more frequent on 2 mg/day than 1 mg/day<BR/>24/165 vs 11/148, OR 2.12, 95% CI 1.00 to 4.49, P = 0.05)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to abnormal gait by endpoint</HEADING>
<P>There was an adverse effect of risperidone (1.0 mg/day) compared with placebo (42/598 vs 6/502, OR 5.31, 95% CI 2.24 to 12.62 P = 0.00021)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to urinary incontinence by endpoint</HEADING>
<P>There was an adverse effect of risperidone (1.0 mg/day) compared with placebo (25/196 vs 1/94, OR 13.6, 95% CI 1.81 to 101.95 P = 0.01)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to asthenia by endpoint</HEADING>
<P>There was an adverse effect of risperidone (1.0 mg/day) compared with placebo (17/196 vs 2/94, OR 4.37, 95% CI 0.99 to 19.32 P = 0.05)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse cerebrovascular events</HEADING>
<P>Five trials evaluated serious adverse cerebrovascular events. Further data on these events were taken from data published by the Committee for the Safety of Medicines. Risperidone (all doses pooled) treated patients were significantly more likely to have serious adverse cerebrovascular events (37/1175 vs 8/779, OR 3.64, 95% CI 1.72 to 7.69, P = 0.0007).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cognition</HEADING>
<P>There are insufficient data reported to evaluate the impact of risperidone upon cognition.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Olanzapine</HEADING>
<P>There were five included trials, four of which provided some results for meta-analyses (<LINK REF="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TYPE="STUDY">F1D-MC-HGGU/Deberdt</LINK>, <LINK REF="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TYPE="STUDY">F1D-MC-HGEU/Clark/St</LINK>, <LINK REF="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TYPE="STUDY">F1D-MC-HGIV/DeDeyn</LINK>, <LINK REF="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TYPE="STUDY">F1D-MC-HGAO/Satterle</LINK>). Four trials used a fixed dose regime, with a mean dose between 1.0 - 15.0 mg/day, <LINK REF="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TYPE="STUDY">F1D-MC-HGGU/Deberdt</LINK> use a flexible dose of 2.5-10 mg/day (mean dose 5.2 mg/day) and the treatment periods varied from 6 to 10 weeks. Only patients with Alzheimer's disease are included in four studies, <LINK REF="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TYPE="STUDY">F1D-MC-HGGU/Deberdt</LINK> included a small percentage of patients with vascular dementia (6%) and mixed dementia (13%). All studies used additional inclusion criteria, related to behavioural symptoms, either psychotic symptoms, or signs of aggression. The details are in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, Included studies - inclusion criteria. The studies included in the meta-analyses examined total behaviour, psychosis, anxiety and aggressiveness subscores, safety and tolerability.</P>
<SUBSECTION>
<HEADING LEVEL="4">Aggressiveness</HEADING>
<P>Olanzapine (5-10 mg/day) showed benefit compared with placebo for NPI-NH aggression (iTT, MD -0.77, 95% CI -1.44 to -0.10, P = 0.03).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anxiety</HEADING>
<P>Olanzapine (5-10 mg/day) showed benefit compared with placebo for NPI-NH anxiety (iTT, MD -0.84, 95% CI -1.51 to -0.17, P = 0.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Euphoria</HEADING>
<P>Olanzapine (5-10 mg/day) showed benefit compared with placebo for NPI-NH euphoria/elation (iTT, MD -0.27, 95% CI -0.54 to -0.00, P = 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Drop-outs due to adverse events by endpoint</HEADING>
<P>There was an adverse effect of olanzapine (5-10 mg/day ) compared with placebo (65/567 vs 10/270, OR 3.34, 95% CI 1.69 to 6.59, P = 0.0005).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events of hostility by endpoint</HEADING>
<P>There were adverse effects of olanzapine (less than 5 mg/day) compared with placebo (15/120 vs 6/118, OR 2.67, 95% CI 1.00 to 7.13, P = 0.05).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events of abnormal gait by endpoint</HEADING>
<P>There were adverse effects of olanzapine (5-10 and greater than 10 mg/day) compared with placebo (18/106 vs 1/47, OR 9.41, 95% CI 1.22 to 72.72, P = 0.03) (9/53 vs 1/47, OR 9.41 95% CI 1.14 to 77.37, P = 0.04).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events of somnolence by endpoint</HEADING>
<P>There were adverse effects of olanzapine (5-10 and greater than 10 mg/day) compared with placebo (74/309 vs 11/141, OR 3.72, 95% CI 1.90 to 7.25, P = 0.0001) (19/53 vs 3/47, OR 8.20 95% CI 2.24 to 29.99, P = 0.001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events of fever by endpoint</HEADING>
<P>There were more adverse events of olanzapine (5-10 mg/day) compared with placebo (20/511 vs 17/427, OR 4.55, 95% CI 1.04 to 19.84, P = 0.04).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events of urinary incontinence by endpoint</HEADING>
<P>There were more adverse events of olanzapine (5-10 mg/day) compared with placebo (19/203 vs 1/94, OR 9.6, 95% CI 1.27 to 72.85, P = 0.03).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Aripiprazole</HEADING>
<P>There were three included studies, but results were available from only one study,<B> </B>
<LINK REF="STD-DeDeyn-2003" TYPE="STUDY">DeDeyn 2003</LINK>. This 10 week study included outpatients diagnosed with Alzheimer's disease, and psychotic symptoms associated with AD.</P>
<SUBSECTION>
<HEADING LEVEL="4">Psychosis</HEADING>
<P>Aripiprazole (2-15 mg/day) showed benefit compared with placebo at 10 weeks for BPRS-PSYCHOSIS (ITT, MD -0.66, 95% CI -1.27 to -0.05, P = 0.03).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Number of adverse events due to somnolence by endpoint</HEADING>
<P>There was an adverse effect due to aripiprazole (2-15 mg/day) compared with placebo (8/106 vs 1/102, OR 8.24, 95% CI 1.01 to 67.15, P = 0.05).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quetiapine</HEADING>
<P>There are four included studies of quetiapine, but only one provides data for the meta-analyses (<LINK REF="STD-Ballard-2005" TYPE="STUDY">Ballard 2005</LINK>). This 26 week study included residents in nursing homes with Alzheimer's disease with significant agitation at baseline.</P>
<SUBSECTION>
<HEADING LEVEL="4">Cognition</HEADING>
<P>Quetiapine (50-100 mg/day) showed harm compared with placebo at 26 weeks for SIB (ITT, MD -14.60, 95% CI -25.71 to -3.49, P = 0.01).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Agitation and psychosis are complex and difficult problems to treat in people with Alzheimer's disease. Several questions must be addressed in considering atypical antipsychotics for the treatment of these symptoms:</P>
<P>1. Does treatment reduce aggression and psychosis among people with Alzheimer's disease, compared with controls?</P>
<P>Risperidone had a significant beneficial effect upon psychotic symptoms and aggression, but in the context of very high placebo response rates in all of the studies. Doses of 1 mg per day and 2 mg per day were effective. There are limited data to compare the 2 mg with 1 mg dose, and the 2 mg/day showed a greater effect than the 1 mg/day for the BEHAVE-AD aggression subscale only. Compared to a previous Cochrane review of the typical antipsychotic haloperidol (<LINK REF="REF-Lonergan-2002" TYPE="REFERENCE">Lonergan 2002</LINK>), the effect size was larger and significant across a wider range of symptoms. The impact of risperidone upon non-aggressive agitation was not evaluated, as it was only reported in two of the studies leading to concerns regarding potential bias, and the effectiveness of risperidone for the treatment of non-aggressive agitation has not been clearly established. </P>
<P>The data also indicate a significant benefit of olanzapine for the treatment of aggression at 5 to 10 mg day doses. There are insufficient data to undertake a meaningful evaluation of the efficacy of any of the other atypical antipsychotics.</P>
<P>2. Are side effects and adverse events more common amongst patients treated with atypical antipsychotics?</P>
<P>Of major concern, risperidone was associated with an almost four-fold increased risk of serious cerebrovascular adverse events (including stroke). These data have recently led to a recommendation by the Committee on Safety of Medicines (CSM) in the UK that risperidone should not be used to treat people with dementia (<LINK REF="REF-CSM-2004" TYPE="REFERENCE">CSM 2004</LINK>). The current evaluations emphasise the validity of these serious concerns. People treated with risperidone were also twice as likely to experience extrapyramidal symptoms seen at 1 mg per day and 2 mg per day doses. The current review also identified a significant dose related increase in somnolence and increases in the number of upper respiratory infections, oedema, urinary tract infections and fever in risperidone treated patients. The limited data comparing 2 mg with 1 mg/day showed increased frequency of extrapyramidal disorders, somnolence, falls, urinary tract infections, and fever in the higher dose group. Some of these side effects, such as upper respiratory tract infections and oedema could at least in part be secondary to the increased somnolence. Although surprisingly mortality data were not provide in all the published studies of risperidone, precluding a full meta-analysis, the Food and Drug Administration (FDA) recently published a warning pertaining to a significant increase in mortality risk (OR 1.7) for people with Alzheimer's disease treated with atypical neuroleptics compared to individuals receiving placebo in randomized controlled trials (<LINK REF="REF-FDA-2005" TYPE="REFERENCE">FDA 2005</LINK>). The FDA analysis was based on pooled data from 17 placebo controlled trials with atypical neuroleptics, but individual trial data were not provided, hence it is unclear whether the risk differs between individual drugs. The increase in cerebrovascular events, oedema and upper-respiratory tract infections associated with risperidone treatment could potentially be important in this regard. Risperidone (2 mg) was associated with a significantly increased drop-out rate overall and due to adverse events. A recent meta-analysis (<LINK REF="REF-Schneider-2005" TYPE="REFERENCE">Schneider 2005</LINK>) of fifteen placebo-controlled trials (nine unpublished) of atypical antipsychotics in dementia confirmed an increased mortality in patients treated with active medication (OR=1.54; 95% CI 1.06 to 2.23 P = 0.02). The risk difference was 0.01( 95% CI 0.004-0.02; P=0.01). <BR/>
<BR/>Although relevant data were not made available for our review, the CSM concluded that the risk of stroke was similar for olanzapine and recommended that it should not be used for the treatment of people with dementia for this reason. Olanzapine (5-10 mg) was associated with somnolence, abnormal gait and a significantly higher drop out rate because of adverse events. The manufacturers of aripiprazole have also stated that aripiprazole should not be used for treating people with dementia. The FDA warning regarding mortality risk was based upon an evaluation of all atypical neuroleptics. <BR/>
<BR/>3. What key factors influence the interpretation of the data and are hence limitations of the present evaluation?</P>
<P>A/ Incomplete access to data - The ITT data were not available across a sufficient number of the trials to permit a meta-analysis, hence the evaluation had to be undertaken on the basis of "completers", which may have led to an over-estimation of the effect size. In addition the unavailability of individualized data restricted the number and type of evaluations that could be completed. Furthermore, not all of the outcome measures were reported in all studies, again leading to the possibility of publication bias and the non-inclusion of less positive outcome data.</P>
<P>B/ The reports do not highlight the proportion of people presenting with clinically significant symptoms of agitation or psychosis - the degree of improvement in clinically significant agitation or clinically significant psychosis can not therefore be determined from the available information. This also precluded us from using our originally stipulated method for evaluating outcome.</P>
<P>C/ The required threshold of symptoms is very low in some of the studies, who may not be the group of patients in whom these treatments are being considered in clinical practice. </P>
<P>D/ Two of the risperidone studies combined patients with operationalized clinical diagnoses of either vascular dementia or Alzheimer's disease, but did not present outcome data separately for the 2 groups, making it impossible to examine outcome specifically in patients with Alzheimer's disease.</P>
<P>E/ There are insufficient data provided in the respective publications to evaluate the impact of risperidone or olanzapine on cognition.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-06-20 15:29:14 +0100" MODIFIED_BY="Helen Collins">
<IMPLICATIONS_PRACTICE MODIFIED="2008-06-20 15:29:14 +0100" MODIFIED_BY="Helen Collins">
<UL>
<LI>Risperidone and olanzapine have significant efficacy for the treatment of aggression in people with dementia and risperidone is also efficacious in the treatment of psychosis. The substantially increased risk of stroke and other adverse outcomes with risperidone and olanzapine, and the general increase in mortality associated with the use of atypical antipsychotics in people with dementia, renders the treatments unsuitable for routine use in clinical practice unless symptoms are resulting in risk of physical harm to those living and working with the patient or extreme distress.</LI>
</UL>
<UL>
<LI>There is insufficient evidence to evaluate systematically the efficacy of any of the other atypical antipsychotics at this time.</LI>
</UL>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Placebo controlled studies of potentially safer and more effective treatments are an urgent priority. <BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We gratefully acknowledge the contributions of our consumer editor, Mrs. Joyce Harris. To Roger Bullock for his comments and enabling access to some unpublished data. To Dymphna Hermans for invaluable assistance in performing the search of electronic databases.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Professor Ballard and Dr Waite have given sponsored talks for Janssen, Astra-Zeneca and Eli Lilly; and Clive Ballard has acted as a paid advisor to Janssen and Astra-Zeneca.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-06-20 15:29:24 +0100" MODIFIED_BY="Helen Collins">
<P>CB: drafting protocol; all correspondence; selection of studies; in-and exclusion of studies; data into revman; data-analyses; drafting review<BR/>JOW: commenting on review drafts; in-exclusion of studies, selection of studies, drafting of some sections of the review, data entry and correspondence, particularly with pharmaceutical companies.<BR/>JB: editorial evaluation, statistical review, construction of analyses, and helpful suggestions concerning methodology and style.</P>
<P>Consumer editor: Joyce Harris</P>
<P>Contact editors: Leon Flicker, Gordon Wilcock</P>
<P>This review has been subject to anonymous peer review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>In the review title, "agitation" has been replaced by "aggression". This is because only a small number of studies report data pertaining to specifically non-aggressive agitation and it is much more common for aggression to be reported, with or without agitation. Therefore usage has dictated the change in terminology though the scope of the review remains the same.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-06-20 15:31:10 +0100" MODIFIED_BY="Helen Collins">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ballard-2005" NAME="Ballard 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005;330(874):DOI: 10.1136/bmj.38369.459988.8F.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jocoby R</AU>
<TI>Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>330</VL>
<NO>874</NO>
<PG>DOI: 10.1136/bmj.38369.459988.8F</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breder-2004" NAME="Breder 2004" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breder C, Swanink R, Marcus R, Kostic D, Iwamoto T, Carson W, McQuade R, Bristol-Myers Squibb Company, Wallingford, CT, USA</AU>
<TI>Dose-Ranging Study of Aripiprazole in Patients With Dementia of Alzheimer's Disease</TI>
<SO>NeuroBiology of Aging</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>S2</NO>
<PG>190</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brodaty-2001" NAME="Brodaty 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F</AU>
<TI>A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia</TI>
<SO>The Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>2</NO>
<PG>134-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Brodaty H, Clarnette R, Ames D, Snowdon J, Woodward M, Kirwan J, Lee E, Lyons B, Grossman F</AU>
<TI>Psychological symptoms are improved with risperidone in patients with dementia-related psychosis</TI>
<SO>Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden</SO>
<YR>2002</YR>
<PG>Abstract No 330</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Brodaty H, Clarnette R, Ames D, Snowdon, Woodward M, Kirwan J, Lee E, Lyons B, Grossman F</AU>
<TI>Risperidone in the treatment of agitation, aggression and psychosis of dementia</TI>
<SO>Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden</SO>
<YR>2002</YR>
<PG>Abstract No 289</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodaty H, Grossman F, Bruynseels J, Lyons B</AU>
<TI>Risperidone in the treatment of agitation and psychosis of dementia</TI>
<SO>International Psychogeriatrics</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>Suppl 2</NO>
<PG>S108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Clarnette R, Brodaty H, Ames D, Snowdon J, Lee E, Woodward M, Kirwan J, Lyons B, Grossman F</AU>
<TI>Psychological symptoms are improved with risperidone in patients with dementia-related psychosis</TI>
<SO>Proceedings of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (International Journal of Neuropsychopharmacology), June 23-27 2002, Montreal, Canada</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Clarnette R, Brodaty H, Ames D, Snowdon J, Lee E, Woodward M, Kirwan J, Lyons B, Grossman F</AU>
<TI>Risperidone in the treatment of agitation, aggression and psychosis of dementia</TI>
<SO>Proceedings of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (International Journal of Neuropsychopharmacology), June 23-27 2002, Montreal, Canada</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kirwan J, Brodaty H, Ames D, Snowdon J, Woodward M, Clarnette R, Lee E</AU>
<TI>Risperidone in the treatment of agitation and psychosis of dementia</TI>
<SO>155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabinowitz J, Katz IR, De Deyn PP, Brodaty H, Greenspan A, Davidson M</AU>
<TI>Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone</TI>
<SO>Journal of Clinical Psychiatry, The</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>10</NO>
<PG>1329-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Woodward M, Brodaty H, Lee E</AU>
<TI>Risperidone in the treatment of agitation and psychosis of dementia: A multicentre, double-blind, placebo controlled study</TI>
<SO>Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva</SO>
<YR>2002</YR>
<PG>255</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CATIE" NAME="CATIE" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis SM, Koch GG, Davis CE, LaVange LM</AU>
<TI>Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>73-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ismail MS, Schneider LS, Tariot P, Dagerman KS, Davis S</AU>
<TI>NIMH Comparative Effectiveness of Antipsychotic Medications in Patients with Alzheimer's disease (CATIE-AD): Clinical course</TI>
<SO>NeuroBiology of Aging</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>S2</NO>
<PG>P1-320, p 188</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN</AU>
<TI>Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial</TI>
<SO>Schizophrenia bulletin</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>57-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schneider LS, Tariot P, Lebowitz B</AU>
<TI>Health outcomes and effectiveness of atypical antipsychotics in outpatients with psychosis or agitation associated with AD</TI>
<SO>Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington, DC</SO>
<YR>2000b</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Schneider LS, Tariot PN, Alexopoulos G, Davis K, Davis S, Jeste D, Katz I, Keefe R, LaVange L, Lebowitz B, Lyketsos C, Pollock B, Rabins P, Rosenheck R, Small G, Stroup S, Davis CE, Ferris S, Hsiao J, Krishnan R, Lieberman J, Mittelman M, Mohs R, Perkins D, Swartz M</AU>
<TI>Comparative Effectiveness of Antipsychotic Medications in patients with Alzheimer's Disease</TI>
<SO>Clinicaltrialsgov</SO>
<YR>2000a</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenbeck RA, Small GW, Lebowitz B, Lieberman JA</AU>
<TI>National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) Alzheimer disease trial methodology</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>4</NO>
<PG>346-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeDeyn-2003" NAME="DeDeyn 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>Aripiprazole improves psychotic symptoms in Alzheimer's disease outpatients</TI>
<SO>http://mblcommunications.com/newsdetail.php3?id=90</SO>
<YR>2003h</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>Safety experience in elderly patients with psychosis associated with Alzheimer's disease</TI>
<SO>http://www.healthscout.com/rxdetail/68/101/3/main.html</SO>
<YR>2003g</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>Study of aripiprazole in the treatment of patients with psychosis associated with dementia of the Alzheimer's type</TI>
<SO>Clinicaltrials.gov</SO>
<YR>2003b</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Breder C, De Deyn PP, Jeste DV, Auby P, Carson W, Marcus R, Kujawa M, McQuade RD, Schneider LS, Mintzer J</AU>
<TI>Aripiprazole for psychosis of Alzheimer's disease</TI>
<SO>NCDEU Poster abstacts</SO>
<YR>2003</YR>
<NO>Poster session II-65</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Darves B</AU>
<TI>Aripiprazole Effective in Reducing Psychotic Symptoms Associated with AD-related Dementia</TI>
<SO>Annual Meeting of the American Association for Geriatric Psychiatry, Honolulu, Hawai, March 2003</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease: A Randomized, Placebo-Controlled Study. &lt;br&gt;Journal of Clinical Psychopharmacology. 25(5):463-467, October 2005.&lt;br&gt;De Deyn, Peter MD *; Jeste, Dilip V. MD +; Swanink, Rene MSc ++; Kostic, Dusan PhD [S]; Breder, Christopher MD [//]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C</AU>
<TI>Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease: A Randomized, Placebo-Controlled Study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>5</NO>
<PG>463-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>De Deyn PP, Jeste D, Aubey P, Goyvaerts H, Breder C, Schnieder L, Mintzer J</AU>
<TI>Aripiprazole for psychosis of Alzheimer's disease</TI>
<SO>IPA, 11th International Congress, Chicago, USA 18 August 2003</SO>
<YR>2003</YR>
<PG>PA-010</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mintzer J, De Deyn PP, Jeste D</AU>
<TI>Aripripazole in dementia of the Alzheimer's Type</TI>
<SO>The International Psychogeriatric Association European Regional Meeting, Geneva, Switzerland, 1-4 April 2004</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" NAME="F1D-MC-HGAO/Satterle" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Satterlee WG, Reams SG, Burns PR, Hamilton S, Tran PV, Tollefson GD</AU>
<TI>A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1995</YR>
<VL>31</VL>
<PG>534</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" NAME="F1D-MC-HGEU/Clark/St" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Clark W, Street J, Sanger T, Breier A</AU>
<TI>Reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine</TI>
<SO>Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville</SO>
<YR>2000e</YR>
<PG>176</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WS, Street J, Gannon KS, Sanger T, Breier A</AU>
<TI>Reduction of psychotic symptoms in patients with lewy-body-like-symptoms treated with olanzapine</TI>
<SO>European Journal of Neurology</SO>
<YR>1999a</YR>
<VL>6</VL>
<NO>Suppl 3</NO>
<PG>27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WS, Street J, Gannon KS, Sanger T, Tollefson GD, Breier A</AU>
<TI>Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999c</YR>
<VL>9</VL>
<NO>suppl 5</NO>
<PG>S332</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WS, Street J, Gannon KS, Sanger T, Tollefson GD, Breier A</AU>
<TI>Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease</TI>
<SO>European Journal of Neurology</SO>
<YR>1999b</YR>
<VL>6</VL>
<NO>Suppl 3</NO>
<PG>115</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Clark WS, Street J, Sanger T, Breier A</AU>
<TI>Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease</TI>
<SO>Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville</SO>
<YR>2000a</YR>
<PG>144</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WS, Street JS, Feldman PD, Breier A</AU>
<TI>The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001a</YR>
<VL>62</VL>
<NO>1</NO>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Clark WS, Street JS, Gannon KS, Sanger TM, Breier A</AU>
<TI>Reduction of psychotic symptoms in patients with lewy body like symptoms treated with olanzapine</TI>
<SO>Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver, Canada</SO>
<YR>1999c</YR>
<PG>172</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WS, Street JS, Gannon KS, Sanger TM, Tollefson GD, Breier A</AU>
<TI>Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000a</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S357</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Clark WS, Street JS, Gannon KS, Sanger TM, Tollefson GD, Breier A</AU>
<TI>Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease</TI>
<SO>Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver, Canada</SO>
<YR>1999b</YR>
<PG>172</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WS, Street JS, Sanger TM, Breier A, Cummings JL</AU>
<TI>Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia</TI>
<SO>Schizophrenia Research</SO>
<YR>2001b</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>222</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WS, Street JS, Sanger TM, Breier A</AU>
<TI>Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000b</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S357</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WS, Street JS, Sanger TM, Feldman PD, Breier A</AU>
<TI>Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease</TI>
<SO>Biological Psychiatry</SO>
<YR>2000c</YR>
<VL>47</VL>
<NO>Suppl</NO>
<PG>S162</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WS, Street JS, Sanger TM, Feldman PD, Breier A</AU>
<TI>Reduction of psychotic symptoms in patients with Lewy body-like symptoms treated with olanzapine</TI>
<SO>Biological Psychiatry</SO>
<YR>2000d</YR>
<VL>47</VL>
<PG>163S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman PD, Clark WS, Breier A, Sanger TM, Street JS</AU>
<TI>Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with alzheimer's disease</TI>
<SO>Schizophrenia Research</SO>
<YR>2001b</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>227</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kennedy J, Basson B, Zagar A, Clark W, Sanger T, Street J, Stauffer V, Bymaster F, Tollefson G</AU>
<TI>The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioral disturbances</TI>
<SO>Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville</SO>
<YR>2000g</YR>
<PG>175</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy JS, Basson BB, Zagar AJ, Clark WS, Sanger TM, Street JS, Stauffer VL, Bymaster FP, Tollefson GD</AU>
<TI>The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioural disturbances</TI>
<SO>Clinical Neuropsychological Assessment</SO>
<YR>2000f</YR>
<VL>1</VL>
<NO>6</NO>
<PG>42-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kennedy JS, Basson BR, Zagar AJ, Gilmore JA, Wei H, Kinon BJ</AU>
<TI>The effects of olanzapine on alzheimer's disease assessment scale scores in patients with mild to moderate alzheimer's disease with psychosis and behavioral disturbances: continued improvement in quality of life despite weight change during olanzapine or haloperidol treatment</TI>
<SO>Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25-29, Philadelphia</SO>
<YR>2000c</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy JS, Clark WS, Street JS, Sanger TM, Breier A</AU>
<TI>Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia</TI>
<SO>Clinical Neuropsychological Assessment</SO>
<YR>2000d</YR>
<VL>1</VL>
<NO>6</NO>
<PG>53-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mintzer J, Faison W, Street JS, Sutton VK, Breier A</AU>
<TI>Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2001</YR>
<VL>16 Suppl 1</VL>
<PG>S71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slawson DC</AU>
<TI>Is olanzapine effective in the treatment of agitation/aggression and psychosis in patients with Alzheimer disease (AD)? [Commentary on Street JS, Clark WS, Gannon KS et al Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial Archives of General Psychiatry 2000;57: 968-76]</TI>
<SO>Evidence Based Practice</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>1</NO>
<PG>5-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street J, Clark KS, Gannon KS, Mitan S, Kadam D, Sanger T</AU>
<TI>Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disease</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999e</YR>
<VL>9</VL>
<NO>suppl 5</NO>
<PG>S331</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street J, Clark S, Juliar B, Feldman P, Kadam D, Breier A</AU>
<TI>Long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2000g</YR>
<VL>10</VL>
<NO>Suppl 4</NO>
<PG>S365-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street J, Clark SW, Gannon KS, Mitan S, Kadman D, Sanger T, Tamura R, Tollefson GD</AU>
<TI>Effect of olanzapine on psychosis and behavioural disturbances associated with alzheimer's disease</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1999g</YR>
<VL>47</VL>
<PG>S89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Street J, Clark WS, Gannon K, Mitan S, Kadam D, Sanger T, Tamura R, Tollefson GD</AU>
<TI>Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disaese</TI>
<SO>Proceedings of the 9th Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver, Canada</SO>
<YR>1999f</YR>
<PG>123</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street J, Clark WS, Gannon KS, Mitan S, Kadman D, Famura R, Tollefson GD</AU>
<TI>Olanzapine in the treatment of psychosis and behavioural disturbances assocated with alzheimer's disease</TI>
<SO>Schizophrenia Research</SO>
<YR>1999a</YR>
<VL>1,2 &amp; 3</VL>
<PG>298</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street J, Clark WS, Gannon KS, Mitan S, Sanger T, Tollefson GD</AU>
<TI>Olanzapine reduces psychotic symptoms and behavioural disturbances associated with Alzheimer's disease</TI>
<SO>Schizophrenia Research</SO>
<YR>2000a</YR>
<VL>41</VL>
<NO>1</NO>
<PG>191</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street J, Clark WS, Gannon KS, Sanger T, Breier A</AU>
<TI>Reduction of psychotic symptoms in patients with Lewy body-like symptoms treated with olanzapine</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999d</YR>
<VL>9</VL>
<NO>Suppl 5</NO>
<PG>S331-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street J, Gannon K, Mitan S, Clark WS, Tollefson GD, Sanger T</AU>
<TI>Olanzapine reduces psychotic symptoms and behavioural disturbances associated with Alzheimer's disease</TI>
<SO>Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11, Hamburg</SO>
<YR>1999b</YR>
<VL>Abstracts Volume II</VL>
<PG>72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Clark WS, Cummings JL, Kadam DL, Mitan SJ, Sanger TM, Bymaster FP, Tamura RN, Feldman PD, Gannon KS, Tollefson GD, Breier A</AU>
<TI>Olanzapine in the treatment of psychosis and behavioural disturbances associated with alzheimer's disease</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2001c</YR>
<VL>187</VL>
<NO>Suppl 1</NO>
<PG>S57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A, HGEU Study Group</AU>
<TI>Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000b</YR>
<VL>57</VL>
<NO>10</NO>
<PG>968-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Street JS, Clark WS, Gannon KS, Mitan S, Sanger TM, Tollefson GD</AU>
<TI>Olanzapine in the treatment of psychosis and behavioral disturbances associated with alzheimer's disease</TI>
<SO>Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20, Washington DC</SO>
<YR>1999c</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A, Mitan SJ</AU>
<TI>Long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer's dementia</TI>
<SO>Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville</SO>
<YR>2000f</YR>
<PG>144</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A</AU>
<TI>Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer`s dementia</TI>
<SO>Biological Psychiatry</SO>
<YR>2000c</YR>
<VL>47</VL>
<NO>8</NO>
<PG>S162</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A</AU>
<TI>Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer's dementia</TI>
<SO>Schizophrenia Research</SO>
<YR>2001a</YR>
<VL>49</VL>
<NO>Suppl 1-2</NO>
<PG>246</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Clark WS, Juliar BI, Feldman PD, Kadam DI, Breirer A</AU>
<TI>Long-term efficacy of olanzapine in the control of psychotic and behavioural symptoms in patients with alzheimer's dementia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000d</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S356</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, Breier A</AU>
<TI>Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2001b</YR>
<VL>16</VL>
<NO>Suppl 1</NO>
<PG>S62-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS/Clark SW, Juliar EJ, Feldman PD, Kadam DL, Breier A</AU>
<TI>Long term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia</TI>
<SO>Neurology</SO>
<YR>2000e</YR>
<VL>54</VL>
<NO>Suppl 2</NO>
<PG>A414</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutton G, Mintzer JE, Breier A, Clark WS, Feldman D, Street JS</AU>
<TI>Olanzapine in the treatment of anxiety in patients with alzheimer's disease</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>Suppl 1-2</NO>
<PG>247</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" NAME="F1D-MC-HGGU/Deberdt" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, Lehman DL, Dossenbach M, Degenhardt EK, Breier A</AU>
<TI>Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>8</NO>
<PG>722-730</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Eli Lilly Inc. Olanzapine versus Risperidone and Placebo in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients with Dementia. 1-38. 2005. http//www.ifpma.org/clinicaltrials.html. &lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly Inc</AU>
<TI>Olanzapine versus Risperidone and Placebo in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients with Dementia</TI>
<SO>http//www.ifpma.org/clinicaltrials.html</SO>
<YR>2005</YR>
<PG>1-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" NAME="F1D-MC-HGIV/DeDeyn" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A</AU>
<TI>Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>2</NO>
<PG>115-26</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" NAME="RIS-INT-24/DeDeyn" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeDeyn P, Lemmens P, De Smedt D</AU>
<TI>Risperidone in the treatment of behavioral disturbances in dementia</TI>
<SO>Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13, Davos, Switzerland</SO>
<YR>1998c</YR>
<VL>29</VL>
<NO>1,2</NO>
<PG>145</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>DeDeyn P, Lemmens P, De Smedt G</AU>
<TI>Risperidone in the treatment of behavioral disturbances in dementia</TI>
<SO>Proceedings of the 21st Collegium Internationale Neuropsychopharmacologium (CINP) Congress; 1998 Jul 12-16 Glasgow, Scotland</SO>
<YR>1998a</YR>
<PG>ABSTRACT REF: PW11025</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>DeDeyn P, Lemmens P, De Smedt G</AU>
<TI>Risperidone in the treatment of behavioral disturbances in dementia</TI>
<SO>Proceedings of the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 December 8-12, Waikoloa, Hawai, USA</SO>
<YR>1997b</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>DeDeyn P, Middelheim AZ, De Smedt G</AU>
<TI>Risperidone in the treatment of behavioral disturbances in dementia</TI>
<SO>Proceedings of the 10th European College of Neuropsychopharmacology Congress (ECNP); 1997 Sep 13-17, Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>DeDeyn P</AU>
<TI>Risperidone in the treatment of behavioral disturbances in dementia</TI>
<SO>Proceedings of the 8th Congress of the International Psychogeriatric Association: Jerusalem, Israel, August 17-22, 1997</SO>
<YR>1997a</YR>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>DeDeyn PP, De Smedt G</AU>
<TI>Long-term safety and efficacy of risperidone in the treatment of behavioral disturbances in elderly patients with dementia</TI>
<SO>Proceedings of the 11th European College of Neuropsychopharmacology Congress (ECNP); 1998 Oct 31-Nov 4, Paris</SO>
<YR>1998b</YR>
<PG>Abstract: P4007</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeDeyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA</AU>
<TI>A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia</TI>
<SO>Neurology</SO>
<YR>1999a</YR>
<VL>53</VL>
<NO>5</NO>
<PG>946-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lemmens P, DeDyne P, DeSmedt G</AU>
<TI>Risperidone in the treatment of behavioral disturbances in dementia</TI>
<SO>Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4, Toronto , Canada</SO>
<YR>1998</YR>
<PG>160</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" NAME="RIS-USA-232/Colon" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Colon S, Figueroa C, Thein S, Siegal A, Arias B, De La Ganadara J, Haefner G, Segal S, Steen S, Blanchette P, Mee-Lee D, Lindahl L, Rappaport SA, Kelsh D, Rayner A, Litman R, Shua-Haim J, Brenner R, Calder C, Sloan B, Gupta S, Lantz M, Levy M, Lebadeva Z, Patel M, Beckett L, Cranmer K, Richter R, Ainslie G, Rosenzweig A, Mintzer J, Fuller W, Gwirtsman H, Petrie W, Barnhart B, Demmler RW, Fedro D, Frank HD, Gazda S, Lewis R, Peters P, Schiffer R, Weiner M, Williams B, Winston J, Swerdlow R, RIS-USA-232</AU>
<TI>Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer's disease</TI>
<SO>Clinical Trials Journal</SO>
<YR>2002</YR>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" NAME="RIS-USA-63/Katz" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Brecher M, Clyde C, Risperidone Study Group</AU>
<TI>Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia</TI>
<SO>Proceedings of the 8th Congress of the International Psychogeriatric Association: Jerusalem, Israel, August 17-22, 1997</SO>
<YR>1997</YR>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Brecher M, Katz I, Clyde C, The Risperidone Study Group</AU>
<TI>Risperidone in the treatment of psychosis and aggressive behavior</TI>
<SO>Proceedings of the 21st Collegium Internationale Neuropsychopharmacologium (CINP) Congress; 1998 Jul 12-16 Glasgow, Scotland</SO>
<YR>1998b</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brecher M, Okamoto A, Napolitano J, Kane JM, Risperidone Study Group</AU>
<TI>Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>1999a</YR>
<VL>7</VL>
<NO>4</NO>
<PG>53-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brecher M, Okamoto A, Napolitano J, Kane JM, The Risperidone Study Group</AU>
<TI>Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperdione for up to one year</TI>
<SO>Schizophrenia Research</SO>
<YR>1999b</YR>
<VL>1,2 &amp; 3</VL>
<PG>362</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Brecher M</AU>
<TI>Follow-up study of risperidone in the treatment of patients with dementia: Interim results on tardive dyskinesia and dyskinesia severity</TI>
<SO>Proceedings of the 11th European College of Neuropsychopharmacology Congress (ECNP); 1998 Oct 31-Nov 4, Paris</SO>
<YR>1998a</YR>
<PG>Abstract: P4005</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brecher M</AU>
<TI>Nursing home research from industry's perspective</TI>
<SO>International Psychogeriatrics</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>Suppl 3</NO>
<PG>367-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>DeDeyn PP, DeSmedt G</AU>
<TI>Efficacy and safety of risperidone in elderly patients with dementia pooled results from phase III controlled trials</TI>
<SO>Proceedings of the 40th Annual meeting of the new clinical drug evalution unit, Boca Raton, Florida, USA, May 30-June 2, 2000</SO>
<YR>2000b</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Grossman F, Gharabawi G</AU>
<TI>Elderly patients with dementia and psychosis treated with risperidone</TI>
<SO>Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva</SO>
<YR>2002a</YR>
<PG>194</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Grossman F, Gharabawi G</AU>
<TI>Elderly patients with dementia and psychosis treated with risperidone</TI>
<SO>Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden</SO>
<YR>2002b</YR>
<PG>Abstract No 299</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janssen Pharmaceutica</AU>
<TI>Low dose risperidone helps overcome burden of Alzheimer's disease</TI>
<SO>Pharmacoeconomics</SO>
<YR>1997</YR>
<VL>143</VL>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Katz I, Brecher M, Clyde C, Jeste D, Mintzer J, Napolitano J, The Risperidone Study Group</AU>
<TI>Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia</TI>
<SO>Proceedings of the 11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 Mar 8-11, San Diego, California</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz I, Brecher M, Clyde C, Napolitano J, Risperidone Study Group</AU>
<TI>Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia</TI>
<SO>Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13, Davos, Switzerland</SO>
<YR>1998a</YR>
<VL>29</VL>
<NO>1,2</NO>
<PG>145</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Katz I, Brecher M, Clyde C, Risperidone Study Group</AU>
<TI>Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia</TI>
<SO>Proceedings of the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 December 8-12, Waikoloa, Hawai, USA</SO>
<YR>1997</YR>
<PG>292</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M, Risperidone Study Group</AU>
<TI>Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>2</NO>
<PG>107-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher MB, Risperidone Study Group</AU>
<TI>Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia</TI>
<SO>Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4, Toronto, Canada</SO>
<YR>1998b</YR>
<PG>156</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mintzer J</AU>
<TI>Pharmacological treatment of nonagressive agitated symptoms related to dementia: analysis of 617 patients in a multicenter placebo-controlled study</TI>
<SO>Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden</SO>
<YR>2002</YR>
<PG>Abstract No 336</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider L, Katz IR, Napolitano J, Martinez R, Azen SP</AU>
<TI>Psychosis of Alzheimer's disease: validity of the construct, and response to risperidone</TI>
<SO>Research and practice in Alzheimer's disease</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>2004</NO>
<PG>153-9</PG>
<PB>Serdi Publisher</PB>
<CY>Paris, France</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP</AU>
<TI>Psychosis of Alzheimer disease: validity of the construct and response to risperidone</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2003a</YR>
<VL>11</VL>
<NO>4</NO>
<PG>414-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STAR_x002f_046" NAME="STAR/046" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Astrazeneca 1</AU>
<TI>Additional results presented</TI>
<SO>http://www.astrazeneca.com/pressrelease/2577.aspx</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Astrazeneca 2</AU>
<TI>Study suggests potential benefits in agitation associated with dementia</TI>
<SO>http://www.astrazeneca.com/</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Tariot P</AU>
<TI>Medication helps quell the agitation of dementia</TI>
<SO>http://www.urmc.rochester.edu/pr/news/story.cfm?id=593</SO>
<YR>2004f</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Streim-2004" NAME="Streim 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kujawa MJ, Marcus R, Breder C, Kostic D, Archibald DG, Iwamoto T, Carson WH, Yamamoto Y, Bristol-Myers Squibb Company, Plainsboro, NJ, USA</AU>
<TI>Safety and Tolerability Profile of Aripiprazole in Elderly Patients With Psychosis of Alzheimer's Disease: A Pooled Analysis</TI>
<SO>NeuroBiology of Aging</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>S2</NO>
<PG>183</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Streim J, Breder C, Swanink R, McQuade R, Iwamoto T, Carson W, Stock E, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA</AU>
<TI>Flexible-Dose Aripiprazole in Psychosis of Alzheimer's Disease</TI>
<SO>NeuroBiology of Aging</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>S2</NO>
<PG>191</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tariot-2002_x002f_039" NAME="Tariot 2002/039" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tariot PN, Profenno LA, Ismail MS</AU>
<TI>Efficacy of atypical antipsychotics in elderly patients with dementia</TI>
<SO>Journal of clinical psychiatry, The</SO>
<YR>2004i</YR>
<VL>65 Suppl 11</VL>
<PG>11-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Allain-2003" NAME="Allain 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Not patients with dementia&lt;br&gt;No measurement of psychosis or agitation&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allain H, Tessier T, Bentue-Ferrer D et al</AU>
<TI>Effects of Risperidone on psychometric and cognitive functions in healthy elderly volunteers</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2003</YR>
<VL>165</VL>
<NO>4</NO>
<PG>419-429</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-1999" NAME="Beuzen 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beuzen JN, Taylor N, Wesnes K, Wood A</AU>
<TI>comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers</TI>
<SO>Journal of Psychopharmacology (Oxf)</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>2</NO>
<PG>152-158</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cassidy-2001" NAME="Cassidy 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Cassidy EL, Sheikh JI</AU>
<TI>Specific interventions for agitation in Alzheimer's disease</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2001" NAME="Chan 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan WC, Lam LCW, Choy CNP, Leung VPY, Li SW, Chiu HFK</AU>
<TI>A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.</TI>
<SO>Int J Geriatr Psychiatry</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>12</NO>
<PG>1156-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Onalaja D, Jainer AK</AU>
<TI>Re: Chan et al A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. author reply</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>11</NO>
<PG>1076-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2001" NAME="Davidson 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M</AU>
<TI>Long-term safety of risperidone</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>Suppl 21</NO>
<PG>26-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Defilippi-2000" NAME="Defilippi 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;200004&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Defilippi JL, Crismon ML</AU>
<TI>Antipsychotic agents in patients with dementia</TI>
<SO>Pharmacotherapy</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>1</NO>
<PG>23-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Devanand-1996" NAME="Devanand 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Devanand DP</AU>
<TI>Antipsychotic treatment in outpatients with dementia</TI>
<SO>International Psychogeriatrics</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>Suppl 3</NO>
<PG>355-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Devanand-1998" NAME="Devanand 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Devanand, DP, Michaels K, Sackeim HA, Marder K, Mayeux RP</AU>
<TI>Antipsychotics in the treatment of dementia complicated by Psychosis</TI>
<SO>Conference proceedings 151st Annual Meeting of the American Psychiatric Association.; 30th May-4th June, 1998; Toronto, Ontario, Canada</SO>
<YR>1998</YR>
<PG>No. 27D</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebell-2000" NAME="Ebell 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Unobtainable&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebell M</AU>
<TI>Which is most effective for managing the behavioral symptoms of dementia: risperidone or haloperidol?</TI>
<SO>Evidence-Based-Practice</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>1</NO>
<PG>2-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-F1D_x002d_MC_x002d_HGHX" NAME="F1D-MC-HGHX" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<TI>Clinical Study Summary: Study F1D-MC-HGHX</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fontaine-2003" NAME="Fontaine 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fontaine CS, Hynan LS, Koch K, Martin Cook K, Svetlik D, Weiner MF</AU>
<TI>A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>6</NO>
<PG>726-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grossberg-1997" NAME="Grossberg 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buckley P, Cutler N, Silber C, O'Neil J, Mack R</AU>
<TI>The safety and tolerability of Sertindole in elederly patients with dementia</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>1-2</NO>
<PG>201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cutler N, Sramek J, Kurtz N, Jhee S, O'Neil I, Mack R</AU>
<TI>The safety and tolerability of Sertindole in Elderly Patients with Dementia</TI>
<SO>Proceedings of the 10th Annual Meeting and Symposium of the American Academy of Geriatric Psychiatry; 1997 Mar 2-5, Orlando</SO>
<YR>1997</YR>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Grossberg GT, Cutler NR, Silber C, O'Neil J, Mack R</AU>
<TI>Sertindole Treatment in Elderly Patients with Dementia</TI>
<SO>Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22, San Diego</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoeltmann-2002" NAME="Hoeltmann 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hoeltmann BJ, Delius-Stute H, Rettig K, Schwalen S</AU>
<TI>Less daytime sedation, dizziness and abnormal gait under risperidone in comparison with melperone</TI>
<SO>Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden</SO>
<YR>2002</YR>
<PG>Abstract No 347</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Howard-2003" NAME="Howard 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Commenceing recruitment September  2002&lt;br&gt;4 week psychological intervention , if no better (&amp;lt;30% reduction in CMAI)&lt;br&gt;randomised to donepezil, risperidone or placebo&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Howard R, Bullock R, Burns A, Lindesay J, O'Brien JT</AU>
<TI>The CALM-AD trial - a randomised clinical trial of a cholinesterase inhibitor and atypical antipsychotic in the management of agitation in dementia</TI>
<SO>National Research Register</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2000" NAME="Jones 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jones B, Wang H, David SR, Nisivoccia JR, Beasley CM, Meehan KM</AU>
<TI>A double-blind, placebo-controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia</TI>
<SO>Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2000 Dec 10-14, San Juan, Puerto Rico</SO>
<YR>2000</YR>
<PG>190</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavretsky-1998" NAME="Lavretsky 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;199806&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Lavretsky H, Sultzer D</AU>
<TI>A structured trial of risperidone for the treatment of agitation in dementia</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>2</NO>
<PG>127-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Legangneux-1998" NAME="Legangneux 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Legangneux E, McEwen J, Wesnes K et al</AU>
<TI>Effects of low doses of amisulpride on psychomotor and memory performances in healthy elderly subjects</TI>
<SO>Proceedings of the 11th European College of Neuropsychopharmacology Congress (ECNP); 1998 Oct 31-Nov 4, Paris</SO>
<YR>1998</YR>
<PG>Abstr P.2.004</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKeith-2000" NAME="McKeith 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McKeith IG, Daniel S, Ballard CG, Swann A, Fairbairn AF, Perry EK</AU>
<TI>Recent advances in therapy in dementia with lewy bodies</TI>
<SO>Proceedings of the International Psychogeriatric Association Conference (Non-Alzheimer Cognitive Impairment); 2000 Apr 4-7, Newcastle upon Tyne</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meehan-2001" NAME="Meehan 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jones B, Wang H, David SR, Nisivoccia JR, Beasley CM, Meehan KM</AU>
<TI>A double-blind, placebo-controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia</TI>
<SO>Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2000 Dec 10-14, San Juan, Puerto Rico</SO>
<YR>2000</YR>
<PG>190</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meehan KM, Wang H, David JR, Nisivoccia, Jones B, Beasley CM, Fieldman A, Breier A</AU>
<TI>A double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine and lorazepam in acutley agitated patients with dementia</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2001b</YR>
<VL>49</VL>
<NO>4</NO>
<PG>S92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Breier A</AU>
<TI>A double-blind, placebo-controlled study of intramuscular (IM) olanzapine and IM lorazepam in acutely agitated patients with dementia</TI>
<SO>Biological Psychiatry</SO>
<YR>2001a</YR>
<VL>49</VL>
<NO>8 Suppl 1</NO>
<PG>55S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Mintzer JE, Beckett LM, Breier A</AU>
<TI>Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>4</NO>
<PG>494-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, Feldman PD, Breier A</AU>
<TI>A double-blind, placebo-controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia</TI>
<SO>Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco</SO>
<YR>2001c</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mintzer J, Meehan K, Wang H, David S, Nisivoccia J, Jones B, Beasley C Jr, Feldman P, Breier A</AU>
<TI>A double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia</TI>
<SO>Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden</SO>
<YR>2002</YR>
<PG>Abstract No 133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meguro-2004" NAME="Meguro 2004" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meguro K, Meguro M, Tanaka Y, Akanuma K, Yamaguchi K, Itoh M</AU>
<TI>Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease</TI>
<SO>Journal of geriatric psychiatry and neurology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>2</NO>
<PG>61-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mintzer-2002b" NAME="Mintzer 2002b" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mintzer J, Meehan K, Wang H et al</AU>
<TI>A double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia</TI>
<SO>Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden</SO>
<YR>2002</YR>
<NO>Abstr 133</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parsa-2000" NAME="Parsa 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Parsa MA, Poggi E, Barte L</AU>
<TI>Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil</TI>
<SO>Journal of the European College of Neuropsychopharmacology. Proceedings of the 13th ECNP Congress; 2000 Jul 9-13, Munich</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl 3</NO>
<PG>S302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pesco-2000" NAME="Pesco 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pesco-Koplowitz L, Parier JL, Zhao Q, Heron J</AU>
<TI>Pharmacokinetics of risperidone/donepezil combination</TI>
<SO>Biological Psychiatry</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>167S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruggiero-1997" NAME="Ruggiero 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruggiero U, Ovallesco V, Pizza V, Agresta A, Colucci D'amato C</AU>
<TI>Clozapine and validation therapy in the treatment of dementia</TI>
<SO>Functional Neurology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>3-4</NO>
<PG>240-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slawson-2001" NAME="Slawson 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slawson DC</AU>
<TI>Is olanzapine effective in the treatment of agitation/aggression and psychosis in patients with Alzheimer disease (AD)?</TI>
<SO>Evidence Based Practice</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>1</NO>
<PG>5-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tariot-2000" NAME="Tariot 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20001025&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW</AU>
<TI>Long-term use of quetiapine in elderly patients with psychotic disorder</TI>
<SO>Clinical-Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1068-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiser-2002" NAME="Weiser 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Weiser M, Davidson M, Rotmensch H et al</AU>
<TI>A pilot randomized open-label trial assessing safety and pharmacokinetic parameters of co-adminstration of rivastigmine with risperidone in dementia patients with behavioral disturbances</TI>
<SO>Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden</SO>
<YR>2002</YR>
<PG>abstract 633</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiser M, Rotmensch HH, Korczyn AD et al</AU>
<TI>A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>4</NO>
<PG>343-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-2000" NAME="Williams 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20000706&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Williams H, Clarke R, Bouras N, Martin J, Holt G</AU>
<TI>Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability</TI>
<SO>Journal of Intellectual Disability Research</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>2</NO>
<PG>164-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolfgang-1999" NAME="Wolfgang 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolfgang SA</AU>
<TI>Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia [letter]</TI>
<SO>American Journal of Health System Pharmacy</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>21</NO>
<PG>2245-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-DeDeyn-1999b" NAME="DeDeyn 1999b" YEAR="">
<REFERENCE NOTES="&lt;p&gt;This conference proceeding is unobtainable (DH: 260105)//Nr of part. does not fit with RIS-INT-24&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>De Deyn PP, Brecher M, and DeSmedt G</AU>
<TI>Risperidone in 969 patients with dementia</TI>
<SO>XI World Congress of Psychiatry , Hamburg, August 6-11, 1999</SO>
<YR>1999b</YR>
<PG>Abstracts Volume II:70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ballard-2002" NAME="Ballard 2002" YEAR="2002">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blanchard-2000" NAME="Blanchard 2000" YEAR="">
<REFERENCE NOTES="&lt;p&gt;. .  .&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Blanchard MR</AU>
<TI>Risperidone in the treatment of behavioural disturbances in dementia</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-Author-2000-b" NAME="No Author 2000 b" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>No author</AU>
<TI>Risperidone vs Olanzapine vs Placebo (ORP): Alzheimer's Disease with Psychosis</TI>
<SO>John Hospkins University Clinical Trials Database</SO>
<YR>2000j</YR>
<MD>Cochrane Dementia and Cognitive Improvement Group</MD>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="http:\\ww2.med.jhu.edu/jhhpsychiatry/gal.htm"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-author-2000-g" NAME="No author 2000 g" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>A study to evaluate Olanzapine for Alzheimer's disease</TI>
<SO>Centerwatch</SO>
<YR>2000n</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-Author-2004-f" NAME="No Author 2004 f" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>A Safety &amp; Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed with Dementia</TI>
<SO>Clinicaltrials.gov</SO>
<YR>2004i</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pellegrino-2000" NAME="Pellegrino 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Pellegrino M</AU>
<TI>A 10-week, double-blind, comparative study evaluation of the effectiveness of Risperidone versus Olanzapine to placebo in patients with Alzheimer's Dementia</TI>
<SO>Centerwatch</SO>
<YR>2000</YR>
<MD>Cochrane Dementia and Cognitive Improvement Group</MD>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="www.centerwatch.com/studies/stu13273.htm"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-06-20 15:31:10 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Ballard-1996" NAME="Ballard 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ballard CG, Eastwood C, Gahir M et al</AU>
<TI>A follow up study of depression in the carers of dementia sufferers</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<PG>947</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballard-1999a" NAME="Ballard 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Ballard CG, O'Brien JT</AU>
<TI>Pharmacological treatment of behavioural and psychological signs in Alzheimer's disease: how good is the evidence for current pharmacological treatment?</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>138-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballard-1999b" NAME="Ballard 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Ballard CG, Ayre G, Gray A</AU>
<TI>Psychotic symptoms and behavioural disturbances in dementia: a review</TI>
<SO>Revue Neurologique</SO>
<YR>1999b</YR>
<VL>155</VL>
<NO>suppl 4</NO>
<PG>s44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballard-2001" NAME="Ballard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ballard CG, O'Brien J, James I, et al</AU>
<TI>Quality of life for people with dementia living in nursing home and residential care</TI>
<SO>International Psychogeriatrics</SO>
<YR>2001</YR>
<VL>13</VL>
<PG>93-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CAMCOG" NAME="CAMCOG" TYPE="JOURNAL_ARTICLE">
<AU>Huppert FA, Brayne C, Gill C, Paykel ES, Beardsall L</AU>
<TI>CAMCOG--a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample</TI>
<SO>British journal of clinical psychology</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>Pt 4</NO>
<PG>529-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" NAME="Chalmers 1983" NOTES="&lt;p&gt;Chalmers TC, Celano P, Sacks HS, Smith H, Junior. Bias in Treatment Assignment in Controlled Clinical Trials. N Eng J Med, 1983; 309:1358-61.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H, Junior</AU>
<TI>Bias in Treatment Assignment in Controlled Clinical Trials</TI>
<SO>N Eng J Med</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" NAME="Chouinard 1980" NOTES="&lt;p&gt;Chouinard G, Ross-Chouinard A, Annable L et al. The Extrapyramidal Symptom Rating Scale.Canadian Journal of Neurological Sciences 1980;7:233&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Ross-Chouinard A, Annable L et al</AU>
<TI>The Extrapyramidal Symptom Rating Scale</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CMO-2004" NAME="CMO 2004" TYPE="OTHER">
<AU>Chief Medical Officer</AU>
<TI>New advice issued on risperidone and olanzapine</TI>
<SO>http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/PressReleasesNotices/fs/en?CONTENT_ID=4075751&amp;chk=f0tw6s</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen_x002d_Mansfield-1996" NAME="Cohen-Mansfield 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cohen-Mansfield J</AU>
<TI>Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behaviour Mapping Instrument</TI>
<SO>International Psychogeriatrics</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>suppl. 3</NO>
<PG>309-315</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CSM-2004" NAME="CSM 2004" TYPE="OTHER">
<AU>Anon</AU>
<TI>New advice issued on risperidone and olanzapine</TI>
<SO>http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&amp;useSecondary=true&amp;ssDocName=CON002047&amp;ssTargetNodeId=389</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cummings-1994" NAME="Cummings 1994" TYPE="JOURNAL_ARTICLE">
<AU>Cummings JL, Mega M, Gray K</AU>
<TI>The Neuropsychiatric Inventory: Comprehensive Assessment of Psychopathology in Dementia</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<PG>2308-2314</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM-IV" NAME="DSM IV" NOTES="&lt;p&gt;American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition(DSM-IV). Washington DC: American Psychiatric Press, 1994.&lt;/p&gt;" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Press</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2005" NAME="FDA 2005" TYPE="OTHER">
<AU>Food and Drug Administration</AU>
<TI>FDA Alert [4/11/2005]: Increased Mortality in Patients with Dementia-Related Psychosis</TI>
<SO>http://www.fda.gov/cder/drug/InfoSheets/HCP/risperidoneHCP.htm</SO>
<YR>April 2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furniss-1998" NAME="Furniss 1998" TYPE="JOURNAL_ARTICLE">
<AU>Furniss L, lloyd N, Craig SK, et al</AU>
<TI>Medication use in nursing homes for elderly</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>433-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilley-1991" NAME="Gilley 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gilley DW, Whalen ME, Wilson RS, et al</AU>
<TI>Hallucinations and associated factors in Alzheimer's disease</TI>
<SO>Journal of Neuropsychiatry</SO>
<YR>1991</YR>
<VL>3</VL>
<PG>371-376</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK_SECTION">
<AU>Guy W</AU>
<TI>Clinical Global Impressions</TI>
<SO>In ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration</SO>
<YR>1976</YR>
<PG>218-22</PG>
<PB>NIMH Psychopharmacology Research Branch</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICD_x002d_10" NAME="ICD-10" NOTES="&lt;p&gt;World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines. Geneva: World Health Organisation, Division of Mental Health 1992&lt;/p&gt;" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines</SO>
<YR>1992</YR>
<PB>World Health Organisation, Division of Mental Health</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" NOTES="&lt;p&gt;Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds J, Gavaghan D, McQuay H. Assessing the quality of reports of randomised clinical trials: Is blinding necessary? Controlled Clin Trials 1996; 17:1-12&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds J, Gavaghan D, McQuay H</AU>
<TI>Assessing the quality of reports of randomised clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clin Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lonergan-2002" NAME="Lonergan 2002" NOTES="&lt;p&gt;Lonergan E, Luxenberg J, Colford J, Birks J. Haloperidol for agitation in dementia. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002852. DOI: 10.1002/14651858.CD002852&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Lonergan E, Luxenberg J, Colford J, Birks J</AU>
<TI>Haloperidol for agitation in dementia</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2 Art. No.: CD002852. DOI: 10.1002/14651858.CD002852</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKeith-1992" NAME="McKeith 1992" TYPE="JOURNAL_ARTICLE">
<AU>McKeith IG, Fairbairn A, Perry R, et al</AU>
<TI>Neuroleptic sensitivity in patients with senile dementia of Lewy body type</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>305</VL>
<PG>673-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKhann-1984" NAME="McKhann 1984" NOTES="&lt;p&gt;McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical Diagnosis of Alzheimer&amp;#8217;s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&amp;#8217;s Disease, Neurology 1984; 4:939 - 944.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM</AU>
<TI>Clinical Diagnosis of Alzheimer&#8217;s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#8217;s Disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>939 - 44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McShane-1997" NAME="McShane 1997" TYPE="JOURNAL_ARTICLE">
<AU>McShane R, Keene J, Gedling K, et al</AU>
<TI>Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<PG>211-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mintzer-2001" NAME="Mintzer 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mintzer JE</AU>
<TI>Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease</TI>
<SO>The Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>suppl 21</NO>
<PG>23-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-_x0026_-Oxman-1997" NAME="Mulrow &amp; Oxman 1997" NOTES="&lt;p&gt;Mulrow CD, Oxman AD (eds). Cochrane Collaboration Handbook [updated 9 December 1996]. Available in The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration; Issue 1. Oxford: Update Software; 1997. Updated quarterly.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Mulrow CD, Oxman AD</AU>
<TI>Cochrane Collaboration Handbook [updated 9 December 1996].</TI>
<SO>Available in The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration; Issue 1</SO>
<YR>1997</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rabins-1982" NAME="Rabins 1982" TYPE="JOURNAL_ARTICLE">
<AU>Rabins PV, Mace NL, Lucas MJ</AU>
<TI>The impact of dementia on the family</TI>
<SO>Journal of the American Medical Society</SO>
<YR>1982</YR>
<VL>248</VL>
<PG>333-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reilly-2000" NAME="Reilly 2000" TYPE="JOURNAL_ARTICLE">
<AU>Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH</AU>
<TI>QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<PG>1048-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reisberg-1987" NAME="Reisberg 1987" TYPE="JOURNAL_ARTICLE">
<AU>Reisberg B</AU>
<TI>Behavioral symptoms in Alzheimer's disease: phenomenology and treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1987</YR>
<VL>48</VL>
<NO>suppl. 5</NO>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-1990" NAME="Schneider 1990" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Pollock VE, Lyness SA</AU>
<TI>A meta-analysis of controlled trials of neuroleptic treatment in dementia</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1990</YR>
<VL>38</VL>
<PG>552-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-1997" NAME="Schneider 1997" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH and the Alzheimer's Disease Cooperative Group Study</AU>
<TI>Validity and reliability of the Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change</TI>
<SO>Alzheimer Disease and Associated disorders</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>suppl 2</NO>
<PG>S22-S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-2005" NAME="Schneider 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schneider Ls, Dagerman KS Insel P</AU>
<TI>Risk of death with atypical antipsychotic drug treatment</TI>
<SO>Jouranl of the American Medical Association</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>15</NO>
<PG>1934-1943</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" NOTES="&lt;p&gt;Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>212</VL>
<NO>suppl 44</NO>
<PG>11-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steele-1990" NAME="Steele 1990" TYPE="JOURNAL_ARTICLE">
<AU>Steele C, Rovner B, Chase BA, et al</AU>
<TI>Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<PG>1049-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tune-1991" NAME="Tune 1991" TYPE="JOURNAL_ARTICLE">
<AU>Tune LE, Steele C, Cooper T</AU>
<TI>Neuroleptic drugs in the management of behavioural symptoms of Alzheimer's disease</TI>
<SO>Psychiatr Clinics North Am</SO>
<YR>1991</YR>
<VL>14</VL>
<PG>353-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waite-2002" NAME="Waite 2002" TYPE="JOURNAL_ARTICLE">
<AU>Waite J</AU>
<TI>Keep taking the medicine</TI>
<SO>Age and Ageing</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>6</NO>
<PG>423-425</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12446286 Medline 20050101"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-06-20 15:31:10 +0100" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-Ballard-2006" MODIFIED="2008-06-20 15:31:10 +0100" MODIFIED_BY="Helen Collins" NAME="Ballard 2006" TYPE="COCHRANE_REVIEW">
<AU>Ballard C, Waite J, Birks J</AU>
<TI>Atypical antipsychotics for aggression and psychosis in Alzheimer's disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-06-20 15:31:10 +0100" MODIFIED_BY="Helen Collins">
<IDENTIFIER MODIFIED="2008-06-20 15:31:10 +0100" MODIFIED_BY="Helen Collins" TYPE="DOI" VALUE="10.1002/14651858.CD003476.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-06-20 15:29:45 +0100" MODIFIED_BY="Helen Collins">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-06-20 15:29:45 +0100" MODIFIED_BY="Helen Collins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Ballard-2005">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group<BR/>double blind<BR/>duration of 26 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>people with Alzheimer's disease living in care facilities<BR/>N=93<BR/>Inclusion: age&gt; 60, diagnosis of probable or possible Alzheimer&#8217;s disease via NINCDS-ADRDA criteria; clinically significant agitation for at least 6 weeks, and NPI irritability or motor aberrant behaviour score &gt;=4; no use of antipsychotics or cholinesterase inhibitors for four weeks before entry into the study<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. quetiapine (25-50 mg twice a day)<BR/>2. rivastigmine (3-6 mg twice a day)<BR/>3. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>SIB</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Breder-2004">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group<BR/>double blind<BR/>duration of 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA multicentre<BR/>N=487 institutionalized patients with psychotic symptoms associated with AD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. aripiprazole 2 mg/day<BR/>2. aripiprazole 5 mg/day<BR/>3. aripiprazole 10 mg/day<BR/>4. placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>NPI-NH psychosis subscale<BR/>BPRS<BR/>CMAI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Kujawa is pooled analysis of Breder 2004 and Streim 2004.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brodaty-2001">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group<BR/>double blind<BR/>duration of 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Australia and New Zealand multicentred<BR/>N=337 nursing home residents<BR/>71% female<BR/>Mean age 83<BR/>mean MMSE 5.3<BR/>60% Alzheimer's disease, 40% Vascular dementia or mixed dementia <BR/>Inclusion: CMAI frequency of &gt;= 4 on at least one, or &gt;=3 on at least 2, or &gt;=2 on at least 3 aggressive items<BR/>Exclusion: history of tardive dyskinesia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. risperidone 0.25 - 2 mg/day (mean dose 0.95 mg)<BR/>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CMAI <BR/>BEHAVE-AD (total, psychosis)<BR/>CGI<BR/>EPS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>completers analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CATIE">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group<BR/>double blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA; N=450; AD patients with Delusions/ Behavioral Symptoms; main diagnostic criteria: DSM-IV//NINCDS-ADRDA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Risperidone v Olanzapine v Quetiapine v Citalopram v Placebos</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Behavioural Symptoms // Compliance // Residual Disability // Function // Quality of Life // Cost-Effectiveness // Psychotic Symptoms // Alzheimers Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) // Cognitive Performance Change//Vital signs // Adverse effects // Electrocardiogram (ECG)// Brief Psychiatric Rating Scale (BPRS) // Target symptoms rating // Cornell Scale for Depression in Dementia // Neuropsychiatric Inventory (NPI) // Abnormal Involuntary Movement Scale (AIMS) // Barnes Akathisia Scale (BAS) // Simpson-Angus Scale (SAS) // General Medical Health Rating // Mini Mental State Examination (MMSE) // Alzheimer's Disease Assessment Scale (ADAS) // Activities of Daily Living Inventory // Dependence Scale // AD-Related Quality of Life // Beck Depression Inventory (BDI) // Caregiver Burden Inventory // Caregiver Activities Survey // Service Use and Resources Form, AD version (SURF- AD) // Health Utilities Index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-DeDeyn-2003">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA multicentre<BR/>N=208 outpatients<BR/>AD patients (DSM-IV) with psychotic symptoms <BR/>mean MMSE = 14.2<BR/>mean age 81.5 years <BR/>mean MMSE 14.2<BR/>main diagnostic criteria: DSM-IV<BR/>Exclusion: psychotic symptoms due to another medical condition, delirium, amnestic disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. aripiprazole (flexible dose of 2 - 15 mg/day)<BR/>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Neuropsychiatric Inventory (NPI) psychosis subscale<BR/>Brief Psychiatric Rating Scale (BPRS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Initial dose of 2 mg/day for 2 weeks, with option to increase dose at 2 week intervals to 5, 10 or 15 mg/day.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: North America<BR/>28 centres<BR/>N = 238, Age &gt; 65, mean age = 78.6<BR/>all with Alzheimer's disease (DSM-III-R)<BR/>BEHAVE-AD&gt;= 8<BR/>CGI-S &gt;=4<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. olanzapine (1-8 mg/day)<BR/>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BEHAVE-AD<BR/>BPRS<BR/>MMSE<BR/>CGI-S<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: US 28 centres<BR/>N =206 nursing home residents with AD<BR/>61% female<BR/>mean age 83 (6.6)<BR/>mean MMSE 6.7 (6.4)<BR/>Alzheimer's disease diagnosis NINCDS-ADRDA<BR/>Inclusion: NPI-NH (agitation/aggression, hallucinations, or delusion items) &gt;= 3<BR/>Exclusion: history of schizophrenia, bipolar disorder, severe or recurrent depression, neurological condition other than AD that could contribute to dementia or psychosis<BR/>MMSE&gt;24<BR/>21% discontinued previous neuroleptics within 30 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. olanzapine 5 mg/day<BR/>2. olanzapine 10 mg/day<BR/>3. olanzapine 15 mg/day<BR/>4. placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>NPI-NH (sum of subscores for agitation/aggression, hallucinations and delusions, anxiety)<BR/>BPRS <BR/>MMSE<BR/>Simpson-Angus scale for tolerability<BR/>Abnormal Involuntary Movement Scale<BR/>EPS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All patients assigned to olanzapine therapy began at 5 mg/day, with increases every 7 days for those in 10 and 15 mg/day groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group<BR/>double blind<BR/>duration of 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA; N=494; patients with AD, VD or MIXED dementia with Delusions/ hallucinations symptoms scored on the NPI( &gt;=6) Symptoms; main diagnostic criteria: DSM-IV//NINCDS-ADRDA<BR/>Exclusion criteria: Parkinson's disease, Lewy-body dementia, Pick disease, frontotemporal dementia, MMSE &lt;5, MMSE &gt;24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. olanzapine (2.5-10 mg/day)<BR/>2. risperidone (0.5-2 mg/day)<BR/>3. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>NPI or NPI-NH psychosis subscale<BR/>CGI-S psychosis<BR/>BPRS<BR/>CMAI<BR/>PDS<BR/>CSDD<BR/>MMSE<BR/>Simpson-Angus scale<BR/>Barnes Akathisia scale<BR/>AIMS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Australia, Europe, Israel, Lebanon, South Africa<BR/>N=652 inpatients or in residential care with Alzheimer's disease (DSM-IV-TR and NINCDS-ADRDA) and clinically significant psychotic symptoms<BR/>MMSE &gt; 5 (mean = 13.7(5.1))<BR/>mean age = 76.6 (10.4)<BR/>Exclusion: current primary mood disorder or other Axis 1 disorder with onset prior to diagnosis to AD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. olanzapine 1.0 mg/day<BR/>2. olanzapine 2.5 mg/day<BR/>3. olanzapine 5.0 mg/day<BR/>4. olanzapine 7.5 mg/day<BR/>5. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>NPI-NH<BR/>Clinical Global Impression of Change (CGI-C)<BR/>Clinical global impression of severity (CGI-S)<BR/>Brief Psychiatric Rating Scale (BPRS)<BR/>Mini mental state examination (MMSE)<BR/>Severe Impairment Battery (SIB)<BR/>Simpson-Angus Scale<BR/>Abnormal Involuntary Movement Scale (AIMS)<BR/>Modified Performance-Oriented Mobility Assessment-II (POMA)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 13 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Europe, 51 centres<BR/>N = 344<BR/>58% F, Mean age 81, mean MMSE 8.4, 67% Alzheimer's disease, 26% vascular dementia, 7% mixed dementia <BR/>Inclusion: DSM-IV criteria, FAST&gt;= 4, MMSE &lt;= 23, BEHAVE-AD global&gt;1, BEHAVE-AD total &gt;=8<BR/>Exclusion: other conditions that affect cognitive function, other psychiatric conditions, clinically relevant organic or neurologic disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. risperidone (flexible dose 0.5 -4.0 mg/day divided into 2 doses, mean dose 1.1 mg/day)<BR/>2. haloperidol (flexible dose 0.5 -4.0 mg/day divided into 2 doses, mean dose 1.2 mg/day)<BR/>3. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BEHAVE-AD (aggression, psychosis, total)<BR/>CMAI<BR/>CGI<BR/>ESRS<BR/>MMSE<BR/>FAST</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>main analysis reported on people completing at least 1 post-baseline assessment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 13 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>44 centres<BR/>N = 473 (institutionalized)<BR/>mean age = 83.3 (7.3)<BR/>mean MMSE = 13.2 (5.0)<BR/>77% female<BR/>Inclusion: AD patients (DSM-IV) with or without a vascular component (not the primary source of dementia) with psychosis as defined by modified diagnostic criteria from Jeste</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. risperidone (flexible dose 1-1.5 mg/day divided into two doses, mean dose=1.09 mg)<BR/>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BEHAVE-AD psychosis<BR/>CGI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The study was completed in 2003. The project grant ran until June 2004.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: North America<BR/>nursing home patients N=625, 68% F, Mean age 83, mean MMSE 6.6, previous neuroleptics 82%, 73% Alzheimer's disease, 27% vascular dementia or mixed dementia (DSM-IV)<BR/>Inclusion criteria: Age &gt; 55 years<BR/>MMSE &lt;23, significant psychotic and behaviour symptoms as rated by BEHAVE-AD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. risperidone 0.5 mg/day<BR/>1. risperidone 1.0 mg/day<BR/>1. risperidone 2.0 mg/day<BR/>4. placebo</P>
<P>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BEHAVE-AD (total, psychosis subscale, aggressiveness subscale)<BR/>CMAI<BR/>CGI<BR/>MMSE<BR/>PSMS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>main analysis reported on people completing at least 1 post-baseline assessment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-STAR_x002f_046">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA; N = 333; institutionalized patients with dementia<BR/>mean age = 83<BR/>AD subgroup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. quetiapine 100 mg/day<BR/>2. quetiapine 200 mg/day <BR/>3. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CGI<BR/>PANSS-EC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Streim-2004">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA; N=256<BR/>AD patients with psychosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. aripiprazole (2-15 mg/day) <BR/>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>NPI-NH<BR/>BPRS<BR/>CG1<BR/>Cornell score for deprerssion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tariot-2002_x002f_039">
<CHAR_METHODS>
<P>Randomized<BR/>placebo controlled<BR/>parallel group <BR/>double blind<BR/>duration of 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: North America <BR/>N=378 nursing home residents with various psychotic disorders including Alzheimer's disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. quetiapine<BR/>2. haloperidol<BR/>3. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BPRS <BR/>NPI agitation score<BR/>PSMS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Allain-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of risperidone on healthy elderly volunteers. Not a trial of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beuzen-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of effect of haloperidol and olanzapine on healthy volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cassidy-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a placebo controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davidson-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No new data included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Defilippi-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of published and unpublished studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Devanand-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of other studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Devanand-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of other studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ebell-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No new data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-F1D_x002d_MC_x002d_HGHX">
<CHAR_REASON_FOR_EXCLUSION>
<P>A RCT of one dose of short acting intramuscular olanzapine compared with placebo and lorazepam. Excluded because treatment lasted less than one day.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fontaine-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a placebo controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grossberg-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data the same as Buckley 1997</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoeltmann-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a placebo controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Howard-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>CALM-AD trial; risperidone arm dropped</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of im medication in acute agitation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lavretsky-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Legangneux-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of healthy volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McKeith-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meehan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of olanzapine or lorazepam on participants with mixed or vascular dementia or AD .</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meguro-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of risperidone versus placebos in AD patients. No blinding reported, no usable outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mintzer-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data the same as Street 2000b</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Parsa-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pesco-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruggiero-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Slawson-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data the same as Street 2000b</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tariot-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weiser-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Williams-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study in patients with learning disability</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolfgang-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-DeDeyn-1999b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Ballard-2002">
<CHAR_STUDY_NAME>
<P>No information</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Blanchard-2000">
<CHAR_STUDY_NAME>
<P>Risperidone in the treatment of behavioural disturbances in dementia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>UK; dementia patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Risperidone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Behavioural Symptoms</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>NRR;Dept of Psychgeriatrics, The Royal Free Hampstead NHS Trust, Hampstead, London</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ongoing in 2000</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-No-Author-2000-b">
<CHAR_STUDY_NAME>
<P>Risperidone vs Olanzapine vs Placebo (ORP): Alzheimer's Disease with Psychosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>USA; Alzheimer's Disease with Psychosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Risperidone vs Olanzapine vs Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>John Hopkins University Clinical Trials Database</P>
<P>http:\\ww2medjhuedu/jhhpsychiatry/galhtm</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ongoing in 2000//checked and is not part of CATIE trial</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-No-author-2000-g">
<CHAR_STUDY_NAME>
<P>A study to evaluate Olanzapine for Alzheimer's disease</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>USA; AD patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Olanzapine v placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Efficacy // Safety // Adverse Effects</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>Neurological Assessment &amp; Clinical Research Center of Miriam Hospital, Brown University, Providence, RI, USA</P>
<P>email: pepple@cns-researchcom</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-No-Author-2004-f">
<CHAR_STUDY_NAME>
<P>A Safety &amp; Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed with Dementia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>USA; dementia patients with acute agitation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>aripripazole v placebos</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE>
<P>recruiting as at december 2004//</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>http://www.clinicaltrials.gov/ct/gui/show/NCT00095719</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Study ID Numbers: CN138-131</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Pellegrino-2000">
<CHAR_STUDY_NAME>
<P>A 10-week, double-blind, comparative study evaluation of the effectiveness of Risperidone versus Olanzapine to placebo in patients with Alzheimer's Dementia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>USA; Alzheimer Disease patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Risperidone v Olanzapine v Placebos</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug Efficacy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>www.centerwatchcom/studies/stu13273htm</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-06-20 15:29:45 +0100" MODIFIED_BY="Helen Collins">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-06-20 15:29:45 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Study Objective</TITLE>
<TABLE COLS="2" ROWS="17">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Objective</P>
</TH>
</TR>
<TR>
<TD>
<P>Ballard 2005</P>
</TD>
<TD>
<P>To determine the respective efficacy of quetiapine and rivastigmine for agitation in people with dementia in institutional care and to evaluate these treatments with respect to change in cognitive performance</P>
</TD>
</TR>
<TR>
<TD>
<P>Breder 2004</P>
</TD>
<TD>
<P>To evaluate fixed-dose aripiprazole for the treatment of institutionalized patients with psychotic symptoms associated with dementia of Alzheimer's disease.</P>
</TD>
</TR>
<TR>
<TD>
<P>Brodaty 2001</P>
</TD>
<TD>
<P>To compare the efficacy of risperidone and placebo in the treatment of behavioural and psychological symptoms of dementia with specific attention to symptoms of agitation/aggression and psychosis.</P>
</TD>
</TR>
<TR>
<TD>
<P>CATIE</P>
</TD>
<TD>
<P>To compare the acute efficacy and effectiveness of risperidone, olanzapine, and quetipine using sequential treatment algorithms in outpatients with dementia complicated by agitation and/or psychosis.</P>
</TD>
</TR>
<TR>
<TD>
<P>F1D-MC-HGEU/Clark/Street 1999</P>
</TD>
<TD>
<P>To assess the efficacy and safety of olanzapine in treating psychosis and/or agitation/aggression in patients with Alzheimer's disease.</P>
</TD>
</TR>
<TR>
<TD>
<P>Deberdt 2005</P>
</TD>
<TD>
<P>To compare olanzapine and risperidone with placebo for treating patients with dementia and the associated behavioural and psychotic symptoms.</P>
</TD>
</TR>
<TR>
<TD>
<P>DeDeyn 2003</P>
</TD>
<TD>
<P>To evaluate the efficacy of aripiprazole in patients with psychosis associated with Alzheimer's disease.</P>
</TD>
</TR>
<TR>
<TD>
<P>F1D-MC-HGIV/DeDeyn 2004</P>
</TD>
<TD>
<P>To compare the efficacy of olanzapine versus placebo in patients with psychotic symptoms associated with Alzheimer's disease in long-term or continuing care settings</P>
</TD>
</TR>
<TR>
<TD>
<P>Megura 2004</P>
</TD>
<TD>
<P>To evaluate the efficacy of risperidone for wandering and disturbed sleep/wake patterns in Alzheimer's disease.</P>
</TD>
</TR>
<TR>
<TD>
<P>RIS-USA-232</P>
</TD>
<TD>
<P>To evaluate the efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer's disease</P>
</TD>
</TR>
<TR>
<TD>
<P>RIS-INT-24</P>
</TD>
<TD>
<P>To compare effects of risperidone with placebo (efficacy and tolerability) for treating demented patients with aggression and other behavioural symptoms.</P>
</TD>
</TR>
<TR>
<TD>
<P>RIS-USA-63</P>
</TD>
<TD>
<P>To evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioural symptoms in institutionalized elderly patients with dementia</P>
</TD>
</TR>
<TR>
<TD>
<P>F1D-MC-HGAO/Satterlee 1995</P>
</TD>
<TD>
<P>To assess the efficacy and safety of olanzapine in patients aged 65 or older with psychotic and bahavioural manifestations associated with Alzheimer's dementia.</P>
</TD>
</TR>
<TR>
<TD>
<P>STAR/046</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Streim 2004</P>
</TD>
<TD>
<P>To examine the safety and efficacy of of aripiporazole vs placebo in community-dwelling patients with Alzheimer's disease</P>
</TD>
</TR>
<TR>
<TD>
<P>Tariot 2002/039</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Included studies - inclusion criteria</TITLE>
<TABLE COLS="6" ROWS="17">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Residence</P>
</TH>
<TH>
<P>Age</P>
</TH>
<TH>
<P>Diagnosis</P>
</TH>
<TH>
<P>Inclusion criteria</P>
</TH>
<TH>
<P>Mean MMSE</P>
</TH>
</TR>
<TR>
<TD>
<P>Ballard 2005</P>
</TD>
<TD>
<P>Residents of residential or nursing home</P>
</TD>
<TD>
<P>Age &gt; 65 years</P>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>No severe behavioural symptoms at baseline</P>
</TD>
<TD>
<P>2.8</P>
</TD>
</TR>
<TR>
<TD>
<P>Breder 2004</P>
</TD>
<TD>
<P>Residents in an institution</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>Psychotic symptoms associated with AD</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Brodaty 2001</P>
</TD>
<TD>
<P>Nursing home residency &gt; 1 month. .</P>
</TD>
<TD>
<P>Age &gt; 55 years</P>
</TD>
<TD>
<P>AD, VD or MIXED</P>
</TD>
<TD>
<P>CMAI minimum score: frequency of &gt;=4 on at least one aggressive item, or &gt;= 3 on at least 2 aggressive item, of &gt;= 2 on at least 3 aggressive items</P>
</TD>
<TD>
<P>5.3 (5.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>CATIE</P>
</TD>
<TD>
<P>At home, residential care or assisted living but not nursing home</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>Delusion, hallucinations, or agitation/aggression severe enough to disrupt function</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>F1D-MC-HGEU/Clark/Street</P>
</TD>
<TD>
<P>Resident in a nursing care facility</P>
</TD>
<TD>
<P>Age &gt; 40 years, mean age=82.8(6.6)</P>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>Clinically significant psychotic or behavioural problems</P>
</TD>
<TD>
<P>6.9 (6.5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Deberdt 2005</P>
</TD>
<TD>
<P>Outpatients or residential settings</P>
</TD>
<TD>
<P>Age &gt;= 40 years, mean age=78.3 (7.4)</P>
</TD>
<TD>
<P>AD, VD or MIXED (81%:6%:13%)</P>
</TD>
<TD>
<P>&gt;= 6 on the sum of the hallucinations and delusions items of the NPI or the NPI-NH</P>
</TD>
<TD>
<P>14.4 (5.6)</P>
</TD>
</TR>
<TR>
<TD>
<P>DeDeyn 2003</P>
</TD>
<TD>
<P>Outpatients</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>Psychotic symptoms associated with AD</P>
</TD>
<TD>
<P>14.2</P>
</TD>
</TR>
<TR>
<TD>
<P>F1D-MC-HGIV/DeDeyn 2004</P>
</TD>
<TD>
<P>Residents in long-term nursing home or continuous care hospitals</P>
</TD>
<TD>
<P>Age &gt; 40 years, mean age=76.6(10.4)</P>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>Clinically significant psychotic symptoms due to AD</P>
</TD>
<TD>
<P>13.7 (5.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>Megura 2004</P>
</TD>
<TD>
<P>Residents in an institution</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>Wandering</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>RIS-INT-24/DeDeyn</P>
</TD>
<TD>
<P>Residents in an institution</P>
</TD>
<TD>
<P>Age &gt; 55 years</P>
</TD>
<TD>
<P>AD, VD or MIXED</P>
</TD>
<TD>
<P>Behavioural symptoms</P>
</TD>
<TD>
<P>8.7 (6.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>RIS-USA-232/Colon</P>
</TD>
<TD>
<P>Residents in nursing home or long-term care facility</P>
</TD>
<TD>
<P>Age &gt; 55 years</P>
</TD>
<TD>
<P>AD with or without vascular component</P>
</TD>
<TD>
<P>BEHAVE-AD psychotic score &gt;2 on any pstchotic item</P>
</TD>
<TD>
<P>13.2 (5.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>RIS-USA-63/Katz</P>
</TD>
<TD>
<P>Residents in a nursing home or chronic disease hospital</P>
</TD>
<TD>
<P>Age &gt; 55 years</P>
</TD>
<TD>
<P>AD, VD or MIXED</P>
</TD>
<TD>
<P>BEHAVE-AD &gt;= 8 indicating significant psychotic and behavioural problems</P>
</TD>
<TD>
<P>6.6 (6.4)</P>
</TD>
</TR>
<TR>
<TD>
<P>F1D-MC-HGAO/Satterlee 1995</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>Age &gt; 65 years, mean age=78.6(6.7)</P>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>Psychotic or behavioural symptoms associated with AD, BEHAVE-AD &gt;=8, CGI-S &gt;=4</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>STAR/046</P>
</TD>
<TD>
<P>Residents in an institution</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>dementia</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Streim 2004</P>
</TD>
<TD>
<P>Residents in an institution</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>Psychotic symptoms associated with AD</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tariot 2002/039</P>
</TD>
<TD>
<P>Residents in a nursing home</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>AD</P>
</TD>
<TD>
<P>Psychotic symptoms associated with AD</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-06-20 15:32:27 +0100" MODIFIED_BY="Helen Collins">
<COMPARISON ID="CMP-001" NO="1">
<NAME>RISPERIDONE VS PLACEBO</NAME>
<CONT_OUTCOME CHI2="10.102427955045869" CI_END="-0.12095708488333731" CI_START="-0.3111731327689341" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21606510882613572" ESTIMABLE="YES" I2="50.50694721853824" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.07238452153730868" P_Q="0.5221894790465823" P_Z="8.482904439619092E-6" Q="1.299449662136533" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="910" TOTAL_2="840" UNITS="" WEIGHT="300.0" Z="4.452619390658882">
<NAME>BEHAVE-AD or NPI TOTAL (change from baseline at 10-13 weeks) ITT</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.06359507767196848" CI_START="-0.5139274818030111" DF="0" EFFECT_SIZE="-0.2887612797374898" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="0.011953005595127977" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="161" WEIGHT="100.0" Z="2.513528687802293">
<NAME>Risperidone 0.5 mg/day</NAME>
<CONT_DATA CI_END="-0.06359507767196848" CI_START="-0.5139274818030111" EFFECT_SIZE="-0.2887612797374898" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-4.2" ORDER="21097" SD_1="7.6" SD_2="7.6" SE="0.11488282633844477" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="146" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.802978292909335" CI_END="-0.0544850802036075" CI_START="-0.29348487512558685" DF="3" EFFECT_SIZE="-0.17398497766459717" ESTIMABLE="YES" I2="65.9206248138036" ID="CMP-001.01.02" NO="2" P_CHI2="0.032028497928379474" P_Z="0.004322762365083852" STUDIES="4" TAU2="0.0" TOTAL_1="602" TOTAL_2="518" WEIGHT="100.0" Z="2.853594834128924">
<NAME>Risperidone 1.0 mg/day</NAME>
<CONT_DATA CI_END="-0.1168880863111903" CI_START="-0.5721764090105712" EFFECT_SIZE="-0.34453224766088075" ESTIMABLE="YES" MEAN_1="-6.8" MEAN_2="-2.3" ORDER="21098" SD_1="14.0" SD_2="12.0" SE="0.11614711451093926" STUDY_ID="STD-Brodaty-2001" TOTAL_1="149" TOTAL_2="152" WEIGHT="27.556371648480532"/>
<CONT_DATA CI_END="0.377572075002379" CI_START="-0.1226067090306924" EFFECT_SIZE="0.12748268298584328" ESTIMABLE="YES" MEAN_1="-9.7" MEAN_2="-12.3" ORDER="21099" SD_1="19.5" SD_2="22.0" SE="0.1275989732409416" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="190" TOTAL_2="91" WEIGHT="22.832029860385294"/>
<CONT_DATA CI_END="0.1311619811959728" CI_START="-0.3874559677303353" EFFECT_SIZE="-0.12814699326718124" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-4.2" ORDER="21100" SD_1="6.94" SD_2="8.54" SE="0.13230292827243262" STUDY_ID="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TOTAL_1="115" TOTAL_2="114" WEIGHT="21.23733267064342"/>
<CONT_DATA CI_END="-0.060906118131068" CI_START="-0.5095845690353455" EFFECT_SIZE="-0.28524534358320675" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-4.2" ORDER="21101" SD_1="8.5" SD_2="7.6" SE="0.11446089174173502" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="161" WEIGHT="28.37426582049075"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.06953718052536337" CI_START="-0.5080564528175419" DF="0" EFFECT_SIZE="-0.2887968166714526" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="1.0" P_Z="0.009835560348373478" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="161" WEIGHT="100.0" Z="2.581557506319704">
<NAME>Risperidone 2.0 mg/day</NAME>
<CONT_DATA CI_END="-0.06953718052536337" CI_START="-0.5080564528175419" EFFECT_SIZE="-0.2887968166714526" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-4.2" ORDER="21102" SD_1="7.6" SD_2="7.6" SE="0.111869216922138" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="162" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.523496208862652" CI_END="-0.0384715612893448" CI_START="-0.21879161730702917" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.128631589298187" ESTIMABLE="YES" I2="23.353983202946758" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.2585572584395399" P_Q="0.5850038902326742" P_Z="0.005169352947819345" Q="1.072273923534863" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="996" TOTAL_2="938" UNITS="" WEIGHT="300.0" Z="2.796286645716981">
<NAME>BEHAVE-AD or NPI PSYCHOSIS (change from baseline at 8-13 weeks) ITT</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.19708493293334142" CI_START="-0.2509148244036161" DF="0" EFFECT_SIZE="-0.026914945735137353" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.8138194565392137" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="161" WEIGHT="100.0" Z="0.23550157527001572">
<NAME>Risperidone 0.5 mg/day</NAME>
<CONT_DATA CI_END="0.19708493293334142" CI_START="-0.2509148244036161" EFFECT_SIZE="-0.026914945735137353" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-1.5" ORDER="21103" SD_1="3.6" SD_2="3.8" SE="0.1142877524461476" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="146" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.45122228532779" CI_END="-0.02893088728916013" CI_START="-0.24958138938896865" DF="3" EFFECT_SIZE="-0.1392561383390644" ESTIMABLE="YES" I2="44.96647094955869" ID="CMP-001.02.02" NO="2" P_CHI2="0.14158543277474644" P_Z="0.013363564923269827" STUDIES="4" TAU2="0.0" TOTAL_1="688" TOTAL_2="616" WEIGHT="100.0" Z="2.473930611290737">
<NAME>Risperidone 1.0 mg/day</NAME>
<CONT_DATA CI_END="-0.01811040333659905" CI_START="-0.4717279142675809" EFFECT_SIZE="-0.24491915880208995" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.8" ORDER="21104" SD_1="6.5" SD_2="5.7" SE="0.1157208791868266" STUDY_ID="STD-Brodaty-2001" TOTAL_1="149" TOTAL_2="152" WEIGHT="23.660843208539944"/>
<CONT_DATA CI_END="0.3383306317322211" CI_START="-0.16161400990357339" EFFECT_SIZE="0.08835831091432385" ESTIMABLE="YES" MEAN_1="-4.2" MEAN_2="-4.7" ORDER="21105" SD_1="5.8" SD_2="5.3" SE="0.12753924193997798" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="190" TOTAL_2="91" WEIGHT="19.47897068779677"/>
<CONT_DATA CI_END="0.09096733528241407" CI_START="-0.2951973244015632" EFFECT_SIZE="-0.10211499455957457" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-2.5" ORDER="21106" SD_1="3.91" SD_2="3.91" SE="0.09851320297974729" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="201" TOTAL_2="212" WEIGHT="32.64861687059526"/>
<CONT_DATA CI_END="-0.04498897744578825" CI_START="-0.4934177297101897" EFFECT_SIZE="-0.26920335357798897" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.5" ORDER="21107" SD_1="3.6" SD_2="3.8" SE="0.11439719193861474" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="161" WEIGHT="24.211569233068023"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.03479748399841423" CI_START="-0.4023570688529904" DF="0" EFFECT_SIZE="-0.18377979242728806" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="1.0" P_Z="0.09936541852820545" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="161" WEIGHT="100.0" Z="1.6479378832692593">
<NAME>Risperidone 2.0 mg/day</NAME>
<CONT_DATA CI_END="0.03479748399841423" CI_START="-0.4023570688529904" EFFECT_SIZE="-0.18377979242728806" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="-1.5" ORDER="21108" SD_1="3.8" SD_2="3.8" SE="0.11152106781033322" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="162" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.579556213363343" CI_END="-0.655160978339862" CI_START="-1.270243781252863" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9627023797963625" ESTIMABLE="YES" I2="54.40421963556023" I2_Q="69.3920482101812" ID="CMP-001.03" NO="3" P_CHI2="0.08657743820389607" P_Q="0.03811593027656901" P_Z="8.499301997013282E-10" Q="6.534249706526476" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="571" TOTAL_2="597" UNITS="" WEIGHT="300.0" Z="6.1353105087503295">
<NAME>BEHAVE-AD AGGRESSIVENESS (change from baseline at 12-13 weeks) ITT</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3000858539926087" CI_START="-1.1000858539926086" DF="0" EFFECT_SIZE="-0.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="1.0" P_Z="0.26278108508019615" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="161" WEIGHT="100.0" Z="1.1198420727185538">
<NAME>Risperidone 0.5 mg/day</NAME>
<CONT_DATA CI_END="0.3000858539926087" CI_START="-1.1000858539926086" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-0.9" ORDER="21109" SD_1="3.6" SD_2="2.5" SE="0.35719322370961737" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="146" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0453065068368664" CI_END="-0.3953905693367276" CI_START="-1.2750508953303343" DF="1" EFFECT_SIZE="-0.835220732333531" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.8314415741404307" P_Z="1.9773170026057135E-4" STUDIES="2" TAU2="0.0" TOTAL_1="263" TOTAL_2="275" WEIGHT="100.0" Z="3.721896978054202">
<NAME>Risperidone 1.0 mg/day</NAME>
<CONT_DATA CI_END="-0.15888463293825572" CI_START="-1.6411153670617442" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-0.8" ORDER="21110" SD_1="2.95" SD_2="2.77" SE="0.3781270334085563" STUDY_ID="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TOTAL_1="115" TOTAL_2="114" WEIGHT="35.22073233353109"/>
<CONT_DATA CI_END="-0.2535291603457206" CI_START="-1.3464708396542793" EFFECT_SIZE="-0.7999999999999999" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-0.9" ORDER="21111" SD_1="2.4" SD_2="2.5" SE="0.27881677620852807" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="161" WEIGHT="64.77926766646891"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9547208201020118" CI_START="-2.0452791798979884" DF="0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" NO="3" P_CHI2="1.0" P_Z="6.981971428971814E-8" STUDIES="1" TAU2="0.0" TOTAL_1="162" TOTAL_2="161" WEIGHT="100.0" Z="5.391634386921011">
<NAME>Risperidone 2.0 mg/day</NAME>
<CONT_DATA CI_END="-0.9547208201020118" CI_START="-2.0452791798979884" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-0.9" ORDER="21112" SD_1="2.5" SD_2="2.5" SE="0.2782087753647928" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="162" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.613767401201798" CI_END="-0.3157296058514457" CI_START="-2.016432493498485" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1660810496749654" ESTIMABLE="YES" I2="79.19650105379101" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.008173333017989948" P_Q="1.0" P_Z="0.0071949224164979805" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="453" TOTAL_2="356" UNITS="" WEIGHT="99.99999999999999" Z="2.6876850471861107">
<NAME>CMAI TOTAL AGGRESSIVENESS (change from baseline at 10-13 weeks) ITT</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.613767401201798" CI_END="-0.3157296058514457" CI_START="-2.016432493498485" DF="2" EFFECT_SIZE="-1.1660810496749654" ESTIMABLE="YES" I2="79.19650105379101" ID="CMP-001.04.01" NO="1" P_CHI2="0.008173333017989948" P_Z="0.0071949224164979805" STUDIES="3" TAU2="0.0" TOTAL_1="453" TOTAL_2="356" WEIGHT="99.99999999999999" Z="2.6876850471861107">
<NAME>Risperidone 1.0 mg/day</NAME>
<CONT_DATA CI_END="-2.2877477576668155" CI_START="-7.712252242333184" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-7.8" MEAN_2="-2.8" ORDER="21113" SD_1="12.2" SD_2="11.8" SE="1.3838275926124581" STUDY_ID="STD-Brodaty-2001" TOTAL_1="149" TOTAL_2="152" WEIGHT="9.829620546188552"/>
<CONT_DATA CI_END="0.3372697366298705" CI_START="-1.5372697366298704" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.9" ORDER="21114" SD_1="4.8" SD_2="3.1" SE="0.4782076323967861" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="189" TOTAL_2="90" WEIGHT="82.31286500424267"/>
<CONT_DATA CI_END="0.7335828419065784" CI_START="-5.333582841906578" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="-3.9" MEAN_2="-1.6" ORDER="21115" SD_1="11.38" SD_2="12.03" SE="1.547774788636471" STUDY_ID="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TOTAL_1="115" TOTAL_2="114" WEIGHT="7.857514449568766"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="13.075668974508483" CI_END="1.387433199263982" CI_START="0.9620136203335368" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1553049965246773" ESTIMABLE="YES" EVENTS_1="359" EVENTS_2="306" I2="54.113246429706734" I2_Q="74.19095661712821" ID="CMP-001.05" LOG_CI_END="0.14221208232485488" LOG_CI_START="-0.01681877911206011" LOG_EFFECT_SIZE="0.06269665160639741" METHOD="MH" NO="5" P_CHI2="0.041849961951552994" P_Q="0.0207624472976059" P_Z="0.12224944161426032" Q="7.74922173724309" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1175" TOTAL_2="1105" WEIGHT="300.0" Z="1.5454004083168473">
<NAME>Number of dropouts before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2466727718748358" CI_START="0.4388987345242117" DF="0" EFFECT_SIZE="0.7397047397047397" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="44" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.09575247431375332" LOG_CI_START="-0.35763567135357804" LOG_EFFECT_SIZE="-0.13094159851991233" NO="1" P_CHI2="1.0" P_Z="0.2575915655699048" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="1.1321020173537526">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="1.2466727718748358" CI_START="0.4388987345242117" EFFECT_SIZE="0.7397047397047397" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="44" LOG_CI_END="0.09575247431375332" LOG_CI_START="-0.35763567135357804" LOG_EFFECT_SIZE="-0.13094159851991233" ORDER="21116" O_E="0.0" SE="0.26632244107250724" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.07092764261881909" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.303857770891938" CI_END="1.3824883667546717" CI_START="0.8955113238104029" DF="4" EFFECT_SIZE="1.1126697566955606" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="218" I2="24.58319636788961" ID="CMP-001.05.02" LOG_CI_END="0.14066148552790456" LOG_CI_START="-0.047928918092695574" LOG_EFFECT_SIZE="0.04636628371760451" NO="2" P_CHI2="0.25751615305219755" P_Z="0.3351753049148466" STUDIES="5" TAU2="0.0" TOTAL_1="861" TOTAL_2="779" WEIGHT="100.0" Z="0.9637419978833344">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="1.2338290290482654" CI_START="0.4854266186643943" EFFECT_SIZE="0.7739079102715466" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="56" LOG_CI_END="0.09125498393938157" LOG_CI_START="-0.3138764125485893" LOG_EFFECT_SIZE="-0.11131071430460385" ORDER="21117" O_E="0.0" SE="0.23797618772978993" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.05663266592640422" WEIGHT="25.992849092000004"/>
<DICH_DATA CI_END="3.2087188796514683" CI_START="0.9914613487766741" EFFECT_SIZE="1.7836257309941521" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="19" LOG_CI_END="0.5063316696152433" LOG_CI_START="-0.0037242117059793226" LOG_EFFECT_SIZE="0.25130372895463204" ORDER="21118" O_E="0.0" SE="0.29960934950541845" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.08976576231105998" WEIGHT="11.43404140341686"/>
<DICH_DATA CI_END="2.183168366521696" CI_START="0.7489177387820756" EFFECT_SIZE="1.2786764705882352" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="40" LOG_CI_END="0.33908722990597623" LOG_CI_START="-0.1255658826409864" LOG_EFFECT_SIZE="0.10676067363249492" ORDER="21119" O_E="0.0" SE="0.272939538380088" STUDY_ID="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TOTAL_1="115" TOTAL_2="114" VAR="0.07449599161113554" WEIGHT="15.354787505665309"/>
<DICH_DATA CI_END="1.5425585254243064" CI_START="0.6705622117819137" EFFECT_SIZE="1.0170454545454546" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="59" LOG_CI_END="0.18824165036275053" LOG_CI_START="-0.17356092403126389" LOG_EFFECT_SIZE="0.007340363165743365" ORDER="21120" O_E="0.0" SE="0.21252462315067142" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.0451667154453349" WEIGHT="28.38010040889795"/>
<DICH_DATA CI_END="1.9329645146809504" CI_START="0.7222960945171458" EFFECT_SIZE="1.1815975286849074" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="44" LOG_CI_END="0.28622388133341126" LOG_CI_START="-0.14128473338038153" LOG_EFFECT_SIZE="0.07246957397651484" ORDER="21121" O_E="0.0" SE="0.25112067648465436" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.06306159415811044" WEIGHT="18.83822159001988"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.091542468689756" CI_START="1.2222753925107606" DF="0" EFFECT_SIZE="1.9438920454545454" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="44" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.4901752168031721" LOG_CI_START="0.08716906840488838" LOG_EFFECT_SIZE="0.28867214260403024" NO="3" P_CHI2="1.0" P_Z="0.004987606750183458" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="2.80783310672845">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="3.091542468689756" CI_START="1.2222753925107606" EFFECT_SIZE="1.9438920454545454" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="44" LOG_CI_END="0.4901752168031721" LOG_CI_START="0.08716906840488838" LOG_EFFECT_SIZE="0.28867214260403024" ORDER="21122" O_E="0.0" SE="0.23672780648176" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.05604005436166561" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.459279955554564" CI_END="1.8665202226868225" CI_START="1.0757885332646375" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4170324811637316" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="101" I2="47.141854099962856" I2_Q="71.70755041850113" ID="CMP-001.06" LOG_CI_END="0.271032699621937" LOG_CI_START="0.03172691086380971" LOG_EFFECT_SIZE="0.15137980524287334" METHOD="MH" NO="6" P_CHI2="0.09208883159793158" P_Q="0.029173033958435513" P_Z="0.013150626491322264" Q="7.069023819372109" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1060" TOTAL_2="991" WEIGHT="300.0" Z="2.479663929589274">
<NAME>Number of dropouts due to adverse events before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.329890992367488" CI_START="0.29492894474766246" DF="0" EFFECT_SIZE="0.6262773722627737" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.12381604446072696" LOG_CI_START="-0.5302826030761296" LOG_EFFECT_SIZE="-0.20323327930770135" NO="1" P_CHI2="1.0" P_Z="0.22324278276234033" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="1.217950562665303">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="1.329890992367488" CI_START="0.29492894474766246" EFFECT_SIZE="0.6262773722627737" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.12381604446072696" LOG_CI_START="-0.5302826030761296" LOG_EFFECT_SIZE="-0.20323327930770135" ORDER="21123" O_E="0.0" SE="0.3842207834036741" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.14762561039933306" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3991583838817823" CI_END="2.028451874337147" CI_START="1.006102880767692" DF="3" EFFECT_SIZE="1.4285766602703645" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="61" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.3071647083885082" LOG_CI_START="0.002642392514323867" LOG_EFFECT_SIZE="0.15490355045141607" NO="2" P_CHI2="0.4937914993679403" P_Z="0.046154472605211355" STUDIES="4" TAU2="0.0" TOTAL_1="746" TOTAL_2="665" WEIGHT="100.0" Z="1.9939778737765514">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="3.429102198449945" CI_START="0.8335315708631585" EFFECT_SIZE="1.6906403940886698" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" LOG_CI_END="0.5351804287024233" LOG_CI_START="-0.07907794617551357" LOG_EFFECT_SIZE="0.22805124126345488" ORDER="21124" O_E="0.0" SE="0.36081841003129433" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.13018992501751123" WEIGHT="22.726689975950244"/>
<DICH_DATA CI_END="10.085740704642149" CI_START="0.8228567903411238" EFFECT_SIZE="2.8808193668528865" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="3" LOG_CI_END="1.0037077986445857" LOG_CI_START="-0.0846757426449619" LOG_EFFECT_SIZE="0.45951602799981195" ORDER="21125" O_E="0.0" SE="0.6393218797388995" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.40873246591288" WEIGHT="6.986285643379888"/>
<DICH_DATA CI_END="1.9179689680462135" CI_START="0.5874960012607395" EFFECT_SIZE="1.0615079365079365" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.2828415761843227" LOG_CI_START="-0.23099508503291633" LOG_EFFECT_SIZE="0.025923245575703156" ORDER="21126" O_E="0.0" SE="0.3018301983315008" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.09110146862483312" WEIGHT="40.20123974458385"/>
<DICH_DATA CI_END="2.6252568980397744" CI_START="0.7294900764907868" EFFECT_SIZE="1.3838709677419354" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" LOG_CI_END="0.41917180829131695" LOG_CI_START="-0.13698061159041394" LOG_EFFECT_SIZE="0.14109559835045155" ORDER="21127" O_E="0.0" SE="0.32668668443740695" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.10672418978870592" WEIGHT="30.085784636086004"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.119140087837187" CI_START="1.2708827299798588" DF="0" EFFECT_SIZE="2.288" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.6148065621288179" LOG_CI_START="0.10410547811315524" LOG_EFFECT_SIZE="0.35945602012098654" NO="3" P_CHI2="1.0" P_Z="0.0057972484874959825" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="2.759034102389459">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="4.119140087837187" CI_START="1.2708827299798588" EFFECT_SIZE="2.288" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" LOG_CI_END="0.6148065621288179" LOG_CI_START="0.10410547811315524" LOG_EFFECT_SIZE="0.35945602012098654" ORDER="21128" O_E="0.0" SE="0.29998834476193736" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.089993006993007" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.842311762033781" CI_END="1.6201467654682098" CI_START="0.980984299498079" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2606897079800843" ESTIMABLE="YES" EVENTS_1="724" EVENTS_2="723" I2="17.39482716990549" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.20955435808947293" LOG_CI_START="-0.008337943380411095" LOG_EFFECT_SIZE="0.10060820735453091" METHOD="MH" NO="7" P_CHI2="0.303863569995375" P_Q="0.5882795664714991" P_Z="0.07030158048129856" Q="1.0611063125824955" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="864" TOTAL_2="897" WEIGHT="300.0" Z="1.8099626433224199">
<NAME>Number of adverse events before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7367849735362746" CI_START="0.5125937825320867" DF="0" EFFECT_SIZE="0.9435386473429952" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="138" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.2397460529967384" LOG_CI_START="-0.29022666586223544" LOG_EFFECT_SIZE="-0.025240306432748497" NO="1" P_CHI2="1.0" P_Z="0.8519043241343277" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.1866892004307329">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="1.7367849735362746" CI_START="0.5125937825320867" EFFECT_SIZE="0.9435386473429952" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="138" LOG_CI_END="0.2397460529967384" LOG_CI_START="-0.29022666586223544" LOG_EFFECT_SIZE="-0.025240306432748497" ORDER="21129" O_E="0.0" SE="0.31130859846502934" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.09691304347826087" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.781529141620763" CI_END="1.7982950786816372" CI_START="0.9765342966288993" DF="2" EFFECT_SIZE="1.3251780332436784" ESTIMABLE="YES" EVENTS_1="453" EVENTS_2="447" I2="47.111342393548234" ID="CMP-001.07.02" LOG_CI_END="0.25486095576682155" LOG_CI_START="-0.010312499355013858" LOG_EFFECT_SIZE="0.12227422820590383" NO="2" P_CHI2="0.15095645834233617" P_Z="0.07068133114945989" STUDIES="3" TAU2="0.0" TOTAL_1="550" TOTAL_2="571" WEIGHT="99.99999999999999" Z="1.8075194095946994">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="3.052412803821989" CI_START="0.553660369227883" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="157" LOG_CI_END="0.48464326660223234" LOG_CI_START="-0.25675656198855884" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="21130" O_E="0.0" SE="0.4355019293025711" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.18966193042626164" WEIGHT="12.969571410519977"/>
<DICH_DATA CI_END="2.4492226287815066" CI_START="1.1118726816831088" EFFECT_SIZE="1.650219298245614" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="152" LOG_CI_END="0.3890282633022962" LOG_CI_START="0.04605505990059584" LOG_EFFECT_SIZE="0.217541661601446" ORDER="21131" O_E="0.0" SE="0.20146415742289647" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.040587806726117615" WEIGHT="53.67716507446509"/>
<DICH_DATA CI_END="1.4737789846317262" CI_START="0.4472318220090661" EFFECT_SIZE="0.8118625872249061" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="138" LOG_CI_END="0.16843235940379753" LOG_CI_START="-0.3494673025472697" LOG_EFFECT_SIZE="-0.0905174715717361" ORDER="21132" O_E="0.0" SE="0.3042168250747295" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.09254787665854859" WEIGHT="33.353263515014916"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.640829732236092" CI_START="0.7338037946909588" DF="0" EFFECT_SIZE="1.3920671243325706" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="138" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.42174040092895765" LOG_CI_START="-0.13442004672413907" LOG_EFFECT_SIZE="0.14366017710240925" NO="3" P_CHI2="1.0" P_Z="0.31127749934616156" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="1.0125451183072822">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="2.640829732236092" CI_START="0.7338037946909588" EFFECT_SIZE="1.3920671243325706" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="138" LOG_CI_END="0.42174040092895765" LOG_CI_START="-0.13442004672413907" LOG_EFFECT_SIZE="0.14366017710240925" ORDER="21133" O_E="0.0" SE="0.3266913999900453" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.10672727082745578" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.14835116022884" CI_END="3.185400311537163" CI_START="1.916154970446653" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="2.4705709137392216" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="106" I2="40.877095153014956" I2_Q="65.48381440773612" ID="CMP-001.08" LOG_CI_END="0.5031640181994864" LOG_CI_START="0.28243063004951097" LOG_EFFECT_SIZE="0.3927973241244987" METHOD="MH" NO="8" P_CHI2="0.11854215487124298" P_Q="0.055178047347234305" P_Z="3.0467226046665698E-12" Q="5.794383028373391" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1175" TOTAL_2="1105" WEIGHT="300.0" Z="6.975551953967587">
<NAME>Number of adverse events of somnolence before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8130625427900235" CI_START="0.593047319025382" DF="0" EFFECT_SIZE="1.2916188289322619" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.44917938793720297" LOG_CI_START="-0.22691065305776678" LOG_EFFECT_SIZE="0.11113436743971812" NO="1" P_CHI2="1.0" P_Z="0.5193484101207035" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.6443501439717525">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="2.8130625427900235" CI_START="0.5930473190253821" EFFECT_SIZE="1.2916188289322619" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.44917938793720297" LOG_CI_START="-0.2269106530577667" LOG_EFFECT_SIZE="0.11113436743971812" ORDER="21134" O_E="0.0" SE="0.39713863678012296" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.15771909682357443" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.288144445369953" CI_END="3.201064539473067" CI_START="1.7645987609659484" DF="4" EFFECT_SIZE="2.3766772014992292" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="80" I2="6.719560151036239" ID="CMP-001.08.02" LOG_CI_END="0.5052944304248121" LOG_CI_START="0.24664596994577337" LOG_EFFECT_SIZE="0.37597020018529276" NO="2" P_CHI2="0.3684120771572089" P_Z="1.2122881448817537E-8" STUDIES="5" TAU2="0.0" TOTAL_1="861" TOTAL_2="779" WEIGHT="100.0" Z="5.697989079530643">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="2.7133421935561555" CI_START="1.0646672668710089" EFFECT_SIZE="1.699648968845985" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="43" LOG_CI_END="0.4335045683290956" LOG_CI_START="0.0272139019156386" LOG_EFFECT_SIZE="0.2303592351223671" ORDER="21135" O_E="0.0" SE="0.23865714862249912" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.05695723458862163" WEIGHT="45.32650538977366"/>
<DICH_DATA CI_END="5.611964192550362" CI_START="1.115093377776626" EFFECT_SIZE="2.501572327044025" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="8" LOG_CI_END="0.7491148913250677" LOG_CI_START="0.04731123667126757" LOG_EFFECT_SIZE="0.39821306399816764" ORDER="21136" O_E="0.0" SE="0.41224294072776047" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.16994424217987184" WEIGHT="14.699309366178403"/>
<DICH_DATA CI_END="8.690550023998492" CI_START="1.0507007620207711" EFFECT_SIZE="3.021782178217822" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.9390472637706683" LOG_CI_START="0.0214790472297324" LOG_EFFECT_SIZE="0.48026315550020027" ORDER="21137" O_E="0.0" SE="0.5389841124320706" STUDY_ID="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TOTAL_1="115" TOTAL_2="114" VAR="0.2905038734541868" WEIGHT="7.390327980132471"/>
<DICH_DATA CI_END="7.99728906071322" CI_START="1.9813367328189364" EFFECT_SIZE="3.9806183664051686" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="11" LOG_CI_END="0.9029427938044197" LOG_CI_START="0.2969582911758101" LOG_EFFECT_SIZE="0.5999505424901149" ORDER="21138" O_E="0.0" SE="0.3559582965157114" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.12670630885836714" WEIGHT="15.353436157850156"/>
<DICH_DATA CI_END="4.776516730165784" CI_START="1.1514744469569724" EFFECT_SIZE="2.345215759849906" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.6791113032386783" LOG_CI_START="0.06125430472429" LOG_EFFECT_SIZE="0.3701828039814841" ORDER="21139" O_E="0.0" SE="0.36293225936882023" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.13171982489055659" WEIGHT="17.230421106065307"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.638130775875984" CI_START="2.303020370495458" DF="0" EFFECT_SIZE="4.460245636716225" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="13" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.936419774707009" LOG_CI_START="0.36229777936876667" LOG_EFFECT_SIZE="0.6493587770378878" NO="3" P_CHI2="1.0" P_Z="9.266323994693986E-6" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="4.43362151728542">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="8.638130775875984" CI_START="2.303020370495458" EFFECT_SIZE="4.460245636716225" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="13" LOG_CI_END="0.936419774707009" LOG_CI_START="0.36229777936876667" LOG_EFFECT_SIZE="0.6493587770378878" ORDER="21140" O_E="0.0" SE="0.3372421020113948" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.11373223536906402" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6408796037188257" CI_END="0.9717802533626406" CI_START="0.6063662084777697" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7676292775194747" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="218" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.012431930075206116" LOG_CI_START="-0.21726500902598447" LOG_EFFECT_SIZE="-0.1148484695505953" METHOD="MH" NO="9" P_CHI2="0.9584144875314021" P_Q="0.9422695487523723" P_Z="0.027957936740961826" Q="0.11892781284538159" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="893" TOTAL_2="821" WEIGHT="300.0" Z="2.1978760964951705">
<NAME>Number of adverse events of injury before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4023708123808032E-31" CI_END="1.3061214876140248" CI_START="0.5139835968721594" DF="0" EFFECT_SIZE="0.8193442622950821" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="61" I2="100.0" ID="CMP-001.09.01" LOG_CI_END="0.11598357429475147" LOG_CI_START="-0.2890507407354231" LOG_EFFECT_SIZE="-0.08653358322033576" NO="1" P_CHI2="0.0" P_Z="0.40232660276989685" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.8374732721222521">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="1.3061214876140248" CI_START="0.5139835968721594" EFFECT_SIZE="0.819344262295082" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="61" LOG_CI_END="0.11598357429475147" LOG_CI_START="-0.2890507407354231" LOG_EFFECT_SIZE="-0.08653358322033582" ORDER="21141" O_E="0.0" SE="0.23791916160091936" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.05660552745688439" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5226541636367303" CI_END="1.0412041141735964" CI_START="0.5261923106535377" DF="2" EFFECT_SIZE="0.7401848409005514" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="96" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.01753587549497801" LOG_CI_START="-0.27885550263028136" LOG_EFFECT_SIZE="-0.13065981356765166" NO="2" P_CHI2="0.7700290290743197" P_Z="0.08398050854491064" STUDIES="3" TAU2="0.0" TOTAL_1="579" TOTAL_2="495" WEIGHT="100.0" Z="1.728043038492762">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="1.7148304391854983" CI_START="0.32511150862000976" EFFECT_SIZE="0.7466666666666667" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.23422118387344898" LOG_CI_START="-0.48796765664444813" LOG_EFFECT_SIZE="-0.1268732363854996" ORDER="21142" O_E="0.0" SE="0.42421729981262846" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.1799603174603175" WEIGHT="16.224711209185884"/>
<DICH_DATA CI_END="1.609257008553416" CI_START="0.4812158629006806" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.20662540922213257" LOG_CI_START="-0.3176600649217954" LOG_EFFECT_SIZE="-0.05551732784983137" ORDER="21143" O_E="0.0" SE="0.307967882767096" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.09484421681604781" WEIGHT="29.428013019480037"/>
<DICH_DATA CI_END="1.0684172854609597" CI_START="0.410853147212462" EFFECT_SIZE="0.6625425301577482" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="61" LOG_CI_END="0.02874090566867774" LOG_CI_START="-0.3863133819001162" LOG_EFFECT_SIZE="-0.17878623811571925" ORDER="21144" O_E="0.0" SE="0.24380494306976844" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.059440850265253024" WEIGHT="54.34727577133408"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.214799314367653" CI_START="0.4874004610617025" DF="0" EFFECT_SIZE="0.7694762802843464" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="61" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.08450453813062918" LOG_CI_START="-0.3121140643255692" LOG_EFFECT_SIZE="-0.11380476309747004" NO="3" P_CHI2="1.0" P_Z="0.26068463867031155" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.00000000000001" Z="1.1247744586805544">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="1.214799314367653" CI_START="0.4874004610617025" EFFECT_SIZE="0.7694762802843464" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="61" LOG_CI_END="0.08450453813062918" LOG_CI_START="-0.3121140643255692" LOG_EFFECT_SIZE="-0.11380476309747004" ORDER="21145" O_E="0.0" SE="0.2329757303765167" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.0542776909444714" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.433599084527255" CI_END="1.672486631412673" CI_START="0.7714142177415713" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1358608922110325" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.22336265503363595" LOG_CI_START="-0.11271236102376597" LOG_EFFECT_SIZE="0.055325147004934995" METHOD="MH" NO="10" P_CHI2="0.4883126539042085" P_Q="0.4883147752824426" P_Z="0.5187301298243565" Q="1.4335903959233853" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="462" TOTAL_2="489" WEIGHT="300.0" Z="0.645304115974725">
<NAME>Number of adverse events of purpura before end of treatment at 12-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.906662949370012" CI_START="0.8032666836485451" DF="0" EFFECT_SIZE="1.5280135823429541" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="19" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.4633946747992154" LOG_CI_START="-0.09514024549476885" LOG_EFFECT_SIZE="0.18412721465222323" NO="1" P_CHI2="1.0" P_Z="0.19627140699779616" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="1.2922476148924875">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="2.906662949370012" CI_START="0.8032666836485451" EFFECT_SIZE="1.5280135823429541" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="19" LOG_CI_END="0.4633946747992154" LOG_CI_START="-0.09514024549476885" LOG_EFFECT_SIZE="0.18412721465222323" ORDER="21146" O_E="0.0" SE="0.32808617697313175" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.10764053952084512" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0857015838907698" CI_START="0.5279878356807125" DF="0" EFFECT_SIZE="1.0493927125506073" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.3192521709454802" LOG_CI_START="-0.2773760830677002" LOG_EFFECT_SIZE="0.020938043938889993" NO="2" P_CHI2="1.0" P_Z="0.8905836113524228" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="163" WEIGHT="100.0" Z="0.13756576813418891">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="2.0857015838907698" CI_START="0.5279878356807125" EFFECT_SIZE="1.0493927125506073" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.3192521709454802" LOG_CI_START="-0.2773760830677002" LOG_EFFECT_SIZE="0.020938043938889993" ORDER="21147" O_E="0.0" SE="0.3504623897648307" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.12282388663967611" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7415237136910502" CI_START="0.4351738614949302" DF="0" EFFECT_SIZE="0.8705547652916074" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.2409293924635352" LOG_CI_START="-0.3613371982120608" LOG_EFFECT_SIZE="-0.060203902874262784" NO="3" P_CHI2="1.0" P_Z="0.6951729766789467" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="0.3918446853574865">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="1.74152371369105" CI_START="0.43517386149493026" EFFECT_SIZE="0.8705547652916074" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.24092939246353515" LOG_CI_START="-0.36133719821206073" LOG_EFFECT_SIZE="-0.060203902874262784" ORDER="21148" O_E="0.0" SE="0.3537743766305501" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.12515630956033433" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.230568645939815" CI_END="1.4259972313850475" CI_START="0.5424006873601048" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8794668148809575" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="39" I2="52.7250313756414" I2_Q="52.47647055973361" ID="CMP-001.11" LOG_CI_END="0.15411868232134213" LOG_CI_START="-0.26567976877869315" LOG_EFFECT_SIZE="-0.05578054322867551" METHOD="MH" NO="11" P_CHI2="0.12059905334488152" P_Q="0.12194070540087687" P_Z="0.6024651500343352" Q="4.208441636292722" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="462" TOTAL_2="489" WEIGHT="300.0" Z="0.5208587858283044">
<NAME>Number of adverse events of pain before end of treatment at 12-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.290338579804575" CI_START="0.44598215592864515" DF="0" EFFECT_SIZE="1.0106681639528354" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.35989968865936267" LOG_CI_START="-0.3506825173792376" LOG_EFFECT_SIZE="0.004608585640062508" NO="1" P_CHI2="1.0" P_Z="0.9797173498028606" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.025423270657301874">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="2.290338579804575" CI_START="0.44598215592864515" EFFECT_SIZE="1.0106681639528354" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.35989968865936267" LOG_CI_START="-0.3506825173792376" LOG_EFFECT_SIZE="0.004608585640062508" ORDER="21149" O_E="0.0" SE="0.41739950526572217" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.17422234699606962" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.005927501212379" CI_START="0.1021231331177163" DF="0" EFFECT_SIZE="0.32051282051282054" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.002566681556888898" LOG_CI_START="-0.9908758695937745" LOG_EFFECT_SIZE="-0.49415459401844275" NO="2" P_CHI2="1.0" P_Z="0.051195625552137136" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="163" WEIGHT="100.0" Z="1.9498363663794296">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="1.005927501212379" CI_START="0.1021231331177163" EFFECT_SIZE="0.32051282051282054" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="0.002566681556888898" LOG_CI_START="-0.9908758695937745" LOG_EFFECT_SIZE="-0.49415459401844275" ORDER="21150" O_E="0.0" SE="0.5835530721658382" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.340534188034188" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8254702335768953" CI_START="0.6216980270074492" DF="0" EFFECT_SIZE="1.3253638253638254" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="0.4510907363511723" LOG_CI_START="-0.20642051088685026" LOG_EFFECT_SIZE="0.12233511273216101" NO="3" P_CHI2="1.0" P_Z="0.4657978293887609" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.00000000000001" Z="0.7293332730257742">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="2.8254702335768953" CI_START="0.6216980270074492" EFFECT_SIZE="1.3253638253638254" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.4510907363511723" LOG_CI_START="-0.20642051088685026" LOG_EFFECT_SIZE="0.12233511273216101" ORDER="21151" O_E="0.0" SE="0.38622536136077995" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.14917002975826504" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5102885112275652" CI_END="1.646756535515192" CI_START="0.6480856384004887" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0330727276477394" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.21662939571006085" LOG_CI_START="-0.18836760242052036" LOG_EFFECT_SIZE="0.01413089664477024" METHOD="MH" NO="12" P_CHI2="0.46994292973891383" P_Q="0.4699878149844724" P_Z="0.8912113139459023" Q="1.5100974955631923" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="462" TOTAL_2="489" WEIGHT="300.0" Z="0.13677162359646755">
<NAME>Number of adverse events of coughing before end of treatment at 12-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.992450910336359" CI_START="0.6438807809406043" DF="0" EFFECT_SIZE="1.3880855986119145" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.47602703475266595" LOG_CI_START="-0.19119453787729895" LOG_EFFECT_SIZE="0.1424162484376835" NO="1" P_CHI2="1.0" P_Z="0.4027636325597824" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.00000000000001" Z="0.8366957220850286">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="2.992450910336359" CI_START="0.6438807809406043" EFFECT_SIZE="1.3880855986119145" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.47602703475266595" LOG_CI_START="-0.19119453787729895" LOG_EFFECT_SIZE="0.1424162484376835" ORDER="21152" O_E="0.0" SE="0.39192925456289274" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.15360854058222478" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6385799644722088" CI_START="0.2653090569185637" DF="0" EFFECT_SIZE="0.6593406593406593" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.21446764027538556" LOG_CI_START="-0.5762479241502856" LOG_EFFECT_SIZE="-0.18089014193744998" NO="2" P_CHI2="1.0" P_Z="0.3698508962466691" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="163" WEIGHT="100.0" Z="0.896752711863604">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="1.638579964472209" CI_START="0.2653090569185637" EFFECT_SIZE="0.6593406593406593" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.21446764027538565" LOG_CI_START="-0.5762479241502856" LOG_EFFECT_SIZE="-0.18089014193744998" ORDER="21153" O_E="0.0" SE="0.4644702366488091" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.21573260073260073" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.352453280739111" CI_START="0.48649343392676275" DF="0" EFFECT_SIZE="1.0697911360163015" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="0.37152100718168424" LOG_CI_START="-0.3129230169138581" LOG_EFFECT_SIZE="0.029298995133913028" NO="3" P_CHI2="1.0" P_Z="0.8667403429640864" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="0.16780035539522167">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="2.352453280739111" CI_START="0.48649343392676275" EFFECT_SIZE="1.0697911360163015" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.37152100718168424" LOG_CI_START="-0.3129230169138581" LOG_EFFECT_SIZE="0.029298995133913028" ORDER="21154" O_E="0.0" SE="0.4020458078062827" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.1616408315746064" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7410539116006514" CI_END="2.2088469326958267" CI_START="0.7709048278104258" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3049179147783447" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.34416562144462404" LOG_CI_START="-0.11299923454052042" LOG_EFFECT_SIZE="0.1155831934520518" METHOD="MH" NO="13" P_CHI2="0.41873120104865025" P_Q="0.4188544392381486" P_Z="0.3216563064492731" Q="1.7404653661542626" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="462" TOTAL_2="489" WEIGHT="300.0" Z="0.9910599794289906">
<NAME>Number of adverse events of rhinitis before end of treatment at 12-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3245349026205298" CI_START="0.3060833758387506" DF="0" EFFECT_SIZE="0.8435054773082942" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.36633607144907" LOG_CI_START="-0.5141602573923929" LOG_EFFECT_SIZE="-0.07391209297166147" NO="1" P_CHI2="1.0" P_Z="0.7421155241313359" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.32905313855661994">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="2.3245349026205293" CI_START="0.30608337583875067" EFFECT_SIZE="0.8435054773082942" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3663360714490699" LOG_CI_START="-0.5141602573923929" LOG_EFFECT_SIZE="-0.07391209297166147" ORDER="21155" O_E="0.0" SE="0.5172079020885965" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.2675040139828872" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8703794685445008" CI_START="0.42763429419418675" DF="0" EFFECT_SIZE="1.1079136690647482" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="0.45793931492248513" LOG_CI_START="-0.36892747375774915" LOG_EFFECT_SIZE="0.044505920582367985" NO="2" P_CHI2="1.0" P_Z="0.8328956606101092" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="163" WEIGHT="100.0" Z="0.21098924913762554">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="2.8703794685445008" CI_START="0.42763429419418675" EFFECT_SIZE="1.1079136690647482" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.45793931492248513" LOG_CI_START="-0.36892747375774915" LOG_EFFECT_SIZE="0.044505920582367985" ORDER="21156" O_E="0.0" SE="0.48570564472738553" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.23590997332004526" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.547582395484811" CI_START="0.849474327232183" DF="0" EFFECT_SIZE="1.9654654654654655" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="0.0" ID="CMP-001.13.03" LOG_CI_END="0.6577805765821862" LOG_CI_START="-0.07084974182127678" LOG_EFFECT_SIZE="0.29346541738045473" NO="3" P_CHI2="1.0" P_Z="0.1143813872732836" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="1.578802402936003">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="4.5475823954848105" CI_START="0.8494743272321831" EFFECT_SIZE="1.9654654654654655" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.6577805765821862" LOG_CI_START="-0.07084974182127672" LOG_EFFECT_SIZE="0.29346541738045473" ORDER="21157" O_E="0.0" SE="0.4280010558084396" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.18318490377313906" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.647597218277504" CI_END="2.1908181347116216" CI_START="0.9586142229827077" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4491892298464706" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="42" I2="35.45051649050039" I2_Q="27.530685176094398" ID="CMP-001.14" LOG_CI_END="0.34060632718672373" LOG_CI_START="-0.01835613165856218" LOG_EFFECT_SIZE="0.1611250977640808" METHOD="MH" NO="14" P_CHI2="0.19949684631837084" P_Q="0.2516053727352139" P_Z="0.07849057280083288" Q="2.759788753156882" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="697" TOTAL_2="727" WEIGHT="300.0" Z="1.7595120650719869">
<NAME>Number of adverse events of upper respiratory tract infection before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.760969558111434" CI_START="1.1054872688940303" DF="0" EFFECT_SIZE="2.9291044776119404" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.8899159799482337" LOG_CI_START="0.04355374548469372" LOG_EFFECT_SIZE="0.46673486271646375" NO="1" P_CHI2="1.0" P_Z="0.030642601708508355" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="2.1616832226294775">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="7.760969558111434" CI_START="1.1054872688940303" EFFECT_SIZE="2.9291044776119404" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.8899159799482337" LOG_CI_START="0.04355374548469372" LOG_EFFECT_SIZE="0.46673486271646375" ORDER="21158" O_E="0.0" SE="0.49715736608451233" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.24716544665208984" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8505814959144549" CI_END="1.9313998044451355" CI_START="0.6881263097743338" DF="1" EFFECT_SIZE="1.1528430162566372" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" I2="45.962930991814794" ID="CMP-001.14.02" LOG_CI_END="0.28587218309680046" LOG_CI_START="-0.1623318370506045" LOG_EFFECT_SIZE="0.06177017302309801" NO="2" P_CHI2="0.17371596139583234" P_Z="0.5890363189610615" STUDIES="2" TAU2="0.0" TOTAL_1="383" TOTAL_2="401" WEIGHT="100.0" Z="0.5402330590620906">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="1.6929788516376252" CI_START="0.5010022600758437" EFFECT_SIZE="0.9209702660406885" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.22865153302066196" LOG_CI_START="-0.30016031497855533" LOG_EFFECT_SIZE="-0.03575439097894669" ORDER="21159" O_E="0.0" SE="0.3106266971756049" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.09648894499822497" WEIGHT="80.3498163888493"/>
<DICH_DATA CI_END="5.830904633298742" CI_START="0.7570160748679586" EFFECT_SIZE="2.1009732360097324" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.7657359384248501" LOG_CI_START="-0.12089489837003324" LOG_EFFECT_SIZE="0.3224205200274084" ORDER="21160" O_E="0.0" SE="0.5208113424267397" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.2712444544003426" WEIGHT="19.650183611150702"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.342029142461985" CI_START="0.5248556687888256" DF="0" EFFECT_SIZE="1.5096153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-001.14.03" LOG_CI_END="0.6376927339889576" LOG_CI_START="-0.2799601077680508" LOG_EFFECT_SIZE="0.17886631311045337" NO="3" P_CHI2="1.0" P_Z="0.44483069339705394" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="0.7640613438797226">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="4.342029142461985" CI_START="0.5248556687888256" EFFECT_SIZE="1.5096153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6376927339889576" LOG_CI_START="-0.2799601077680508" LOG_EFFECT_SIZE="0.17886631311045337" ORDER="21161" O_E="0.0" SE="0.5390338217028933" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.29055746093962653" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.306376740458868" CI_END="1.1463338948031208" CI_START="0.717219088464118" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.906737310970612" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="181" I2="5.773746483601047" I2_Q="18.57855245136525" ID="CMP-001.15" LOG_CI_END="0.05931113381811496" LOG_CI_START="-0.14434816040333504" LOG_EFFECT_SIZE="-0.04251851329261001" METHOD="MH" NO="15" P_CHI2="0.37964459176837184" P_Q="0.2928258085953276" P_Z="0.41314356382060446" Q="2.45635524817384" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1060" TOTAL_2="991" WEIGHT="300.0" Z="0.8183741876183536">
<NAME>Number of adverse events of a fall before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3513020530885083" CI_START="0.42335904774633853" DF="0" EFFECT_SIZE="0.7563636363636363" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="33" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.13075243660702307" LOG_CI_START="-0.3732911543420253" LOG_EFFECT_SIZE="-0.1212693588675011" NO="1" P_CHI2="1.0" P_Z="0.3456260727024687" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.9431072235678586">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="1.3513020530885083" CI_START="0.4233590477463386" EFFECT_SIZE="0.7563636363636363" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="33" LOG_CI_END="0.13075243660702307" LOG_CI_START="-0.37329115434202526" LOG_EFFECT_SIZE="-0.1212693588675011" ORDER="21162" O_E="0.0" SE="0.29607770037948594" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.08766200466200466" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8430032640861294" CI_END="1.1358846527152116" CI_START="0.6284323968836928" DF="3" EFFECT_SIZE="0.8448826633854084" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="115" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.05533423169831153" LOG_CI_START="-0.20174143434952088" LOG_EFFECT_SIZE="-0.07320360132560469" NO="2" P_CHI2="0.41646976498534727" P_Z="0.2643282527331189" STUDIES="4" TAU2="0.0" TOTAL_1="746" TOTAL_2="665" WEIGHT="100.00000000000001" Z="1.1162193944106558">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="1.4732904757344056" CI_START="0.5568239162014683" EFFECT_SIZE="0.9057391304347826" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="46" LOG_CI_END="0.16828838131080495" LOG_CI_START="-0.2542821195697949" LOG_EFFECT_SIZE="-0.042996869129494956" ORDER="21163" O_E="0.0" SE="0.24822000397497918" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.061613170373338674" WEIGHT="35.77830970450678"/>
<DICH_DATA CI_END="3.868063270569679" CI_START="0.5686882823317357" EFFECT_SIZE="1.4831460674157304" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.5874935692978683" LOG_CI_START="-0.24512572017599402" LOG_EFFECT_SIZE="0.17118392456093712" ORDER="21164" O_E="0.0" SE="0.4890846921689008" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.23920383611394846" WEIGHT="7.722450444142287"/>
<DICH_DATA CI_END="1.508703019162645" CI_START="0.4930994575476522" EFFECT_SIZE="0.8625199362041467" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.17860375943607884" LOG_CI_START="-0.30706547523035266" LOG_EFFECT_SIZE="-0.06423085789713695" ORDER="21165" O_E="0.0" SE="0.2852845125445463" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.0813872530977794" WEIGHT="27.796382249297103"/>
<DICH_DATA CI_END="1.072941647848096" CI_START="0.3137693389543313" EFFECT_SIZE="0.5802208127789523" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="33" LOG_CI_END="0.030576103413591328" LOG_CI_START="-0.5033894972485328" LOG_EFFECT_SIZE="-0.2364066969174707" ORDER="21166" O_E="0.0" SE="0.3136540370012835" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.09837885492720254" WEIGHT="28.70285760205384"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1913977947965497" CI_START="0.7742156531859231" DF="0" EFFECT_SIZE="1.3025415444770283" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="33" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="0.34072122028271973" LOG_CI_START="-0.11113805230982034" LOG_EFFECT_SIZE="0.1147915839864497" NO="3" P_CHI2="1.0" P_Z="0.3193330643227471" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="0.9958293831213529">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="2.1913977947965497" CI_START="0.7742156531859231" EFFECT_SIZE="1.3025415444770283" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="33" LOG_CI_END="0.34072122028271973" LOG_CI_START="-0.11113805230982034" LOG_EFFECT_SIZE="0.1147915839864497" ORDER="21167" O_E="0.0" SE="0.26542437346033104" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.07045009802680928" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.067496945012327" CI_END="2.853355319289956" CI_START="1.314398471888202" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.936606793189777" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="44" I2="34.07495650594228" I2_Q="63.55452787782458" ID="CMP-001.16" LOG_CI_END="0.4553558563393321" LOG_CI_START="0.11872704551913299" LOG_EFFECT_SIZE="0.2870414509292326" METHOD="MH" NO="16" P_CHI2="0.19416409127423173" P_Q="0.06432387049622079" P_Z="8.302734497892037E-4" Q="5.48765013468735" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="864" TOTAL_2="897" WEIGHT="300.0" Z="3.342500034507797">
<NAME>Number of adverse events of extrapyramidal disorder before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.16136391460447" CI_START="0.3791699450463438" DF="0" EFFECT_SIZE="0.9052757793764988" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.33472789635965805" LOG_CI_START="-0.42116609437675895" LOG_EFFECT_SIZE="-0.043219099008550456" NO="1" P_CHI2="1.0" P_Z="0.8226589961140924" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.22412634189221275">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="2.16136391460447" CI_START="0.3791699450463438" EFFECT_SIZE="0.9052757793764988" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.33472789635965805" LOG_CI_START="-0.42116609437675895" LOG_EFFECT_SIZE="-0.043219099008550456" ORDER="21168" O_E="0.0" SE="0.44401587189417147" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.19715009449394127" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5699441344327183" CI_END="3.1739342331908738" CI_START="0.9965048301444139" DF="2" EFFECT_SIZE="1.7784377396848652" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="20" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.501597923534705" LOG_CI_START="-0.0015205918957746948" LOG_EFFECT_SIZE="0.25003866581946516" NO="2" P_CHI2="0.7520352840750565" P_Z="0.0514010063597631" STUDIES="3" TAU2="0.0" TOTAL_1="550" TOTAL_2="571" WEIGHT="99.99999999999999" Z="1.9481166552945708">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="6.2863295456309585" CI_START="0.7027994789171226" EFFECT_SIZE="2.1019108280254777" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7983971441167567" LOG_CI_START="-0.1531685691794492" LOG_EFFECT_SIZE="0.3226142874686537" ORDER="21169" O_E="0.0" SE="0.5589544103164393" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.31243003281219844" WEIGHT="26.535542570847046"/>
<DICH_DATA CI_END="5.07029991692505" CI_START="0.2023606684869562" EFFECT_SIZE="1.0129310344827587" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7050336493556595" LOG_CI_START="-0.6938738945939863" LOG_EFFECT_SIZE="0.00557987738083662" ORDER="21170" O_E="0.0" SE="0.8217252160200447" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.675232330643189" WEIGHT="16.76240444130113"/>
<DICH_DATA CI_END="3.962791751283933" CI_START="0.866798065656531" EFFECT_SIZE="1.853359173126615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.5980012503194029" LOG_CI_START="-0.06208206652115373" LOG_EFFECT_SIZE="0.2679595918991246" ORDER="21171" O_E="0.0" SE="0.38773620777725837" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.15033936682148927" WEIGHT="56.702052987851815"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.9061930147994207E-31" CI_END="6.797201361116912" CI_START="1.6885372695802408" DF="0" EFFECT_SIZE="3.387820512820513" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="12" I2="100.0" ID="CMP-001.16.03" LOG_CI_END="0.8323301357051979" LOG_CI_START="0.22751065087276928" LOG_EFFECT_SIZE="0.5299203932889835" NO="3" P_CHI2="0.0" P_Z="5.936580299017673E-4" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="3.4344954538211363">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="6.797201361116911" CI_START="1.6885372695802405" EFFECT_SIZE="3.3878205128205128" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="12" LOG_CI_END="0.8323301357051978" LOG_CI_START="0.22751065087276923" LOG_EFFECT_SIZE="0.5299203932889834" ORDER="21172" O_E="0.0" SE="0.35527395929530353" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.12621958615336099" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.390377899089139" CI_END="1.9939686559911343" CI_START="1.0907030098458517" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4747296751024637" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="88" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.2997183271766996" LOG_CI_START="0.037706511593079146" LOG_EFFECT_SIZE="0.1687124193848894" METHOD="MH" NO="17" P_CHI2="0.49542847147936575" P_Q="0.7030760394966754" P_Z="0.011599932535532802" Q="0.704580736947155" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="629" TOTAL_2="659" WEIGHT="300.0" Z="2.5240866714536994">
<NAME>Number of adverse events of urinary tract infection before end of treatment at 12-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4451585030480745" CI_START="0.6893400954650618" DF="0" EFFECT_SIZE="1.2982857142857143" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.3883070167389754" LOG_CI_START="-0.16156646003360178" LOG_EFFECT_SIZE="0.11337027835268682" NO="1" P_CHI2="1.0" P_Z="0.41898009068976283" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.8081919636958511">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="2.4451585030480745" CI_START="0.6893400954650618" EFFECT_SIZE="1.2982857142857143" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.3883070167389754" LOG_CI_START="-0.16156646003360178" LOG_EFFECT_SIZE="0.11337027835268682" ORDER="21173" O_E="0.0" SE="0.3229984021738204" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.10432796780684105" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6830779732227898" CI_END="2.134274898484707" CI_START="0.9159706229079408" DF="1" EFFECT_SIZE="1.3981892247552974" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="46" I2="40.58504621237596" ID="CMP-001.17.02" LOG_CI_END="0.3292503566095557" LOG_CI_START="-0.03811845484040975" LOG_EFFECT_SIZE="0.145565950884573" NO="2" P_CHI2="0.19451604407963274" P_Z="0.12036833755872055" STUDIES="2" TAU2="0.0" TOTAL_1="315" TOTAL_2="333" WEIGHT="100.0" Z="1.5532294098838986">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="3.080101156162222" CI_START="1.0139120443847431" EFFECT_SIZE="1.7671875" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="25" LOG_CI_END="0.48856497976072316" LOG_CI_START="0.006000282122412971" LOG_EFFECT_SIZE="0.2472826309415681" ORDER="21174" O_E="0.0" SE="0.2834608921265217" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.08035007736516357" WEIGHT="52.15569354966347"/>
<DICH_DATA CI_END="1.9361797345796148" CI_START="0.5122951099905814" EFFECT_SIZE="0.9959394610557402" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.28694567017949874" LOG_CI_START="-0.2904797895740642" LOG_EFFECT_SIZE="-0.0017670596972827735" ORDER="21175" O_E="0.0" SE="0.33918257336136676" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.11504481807203892" WEIGHT="47.84430645033653"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.287480397532932" CI_START="1.0081480431453567" DF="0" EFFECT_SIZE="1.8205128205128205" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="21" I2="0.0" ID="CMP-001.17.03" LOG_CI_END="0.516863171910389" LOG_CI_START="0.003524311474763067" LOG_EFFECT_SIZE="0.2601937416925761" NO="3" P_CHI2="1.0" P_Z="0.046936126067590386" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="1.9868761242326352">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="3.287480397532932" CI_START="1.0081480431453567" EFFECT_SIZE="1.8205128205128205" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="21" LOG_CI_END="0.516863171910389" LOG_CI_START="0.003524311474763067" LOG_EFFECT_SIZE="0.2601937416925761" ORDER="21176" O_E="0.0" SE="0.30153778768822764" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.09092503740391064" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2844270692403992" CI_END="4.752504417095687" CI_START="2.096424026613646" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="3.156463914982536" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.6769225291817503" LOG_CI_START="0.32147912840411547" LOG_EFFECT_SIZE="0.4992008287929329" METHOD="MH" NO="18" P_CHI2="0.8640121452358208" P_Q="0.8084574450988231" P_Z="3.6848872019264765E-8" Q="0.42525473617407894" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="825" TOTAL_2="753" WEIGHT="300.0" Z="5.505324579644062">
<NAME>Number of adverse events of peripheral oedema before end of treatment at 12-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.323366364717646" CI_START="1.473832466324693" DF="0" EFFECT_SIZE="3.2853333333333334" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="0.8647107610514057" LOG_CI_START="0.16844811914996985" LOG_EFFECT_SIZE="0.5165794401006878" NO="1" P_CHI2="1.0" P_Z="0.003633769166894795" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="2.9083194668788286">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="7.323366364717646" CI_START="1.473832466324693" EFFECT_SIZE="3.2853333333333334" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.8647107610514057" LOG_CI_START="0.16844811914996985" LOG_EFFECT_SIZE="0.5165794401006878" ORDER="21177" O_E="0.0" SE="0.40898812240856613" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.16727128427128427" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7335188988593346" CI_END="5.028316110424772" CI_START="1.5089224638019338" DF="2" EFFECT_SIZE="2.754512503895581" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="16" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.7014225722553235" LOG_CI_START="0.178666924064448" LOG_EFFECT_SIZE="0.44004474815988576" NO="2" P_CHI2="0.6929764494422178" P_Z="9.678367966144231E-4" STUDIES="3" TAU2="0.0" TOTAL_1="511" TOTAL_2="427" WEIGHT="99.99999999999999" Z="3.2997132062146832">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="6.2222147289911565" CI_START="0.8556289368240458" EFFECT_SIZE="2.3073593073593073" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.7939449945590583" LOG_CI_START="-0.06771453629020244" LOG_EFFECT_SIZE="0.36311522913442795" ORDER="21178" O_E="0.0" SE="0.5061430737043231" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.2561808110588598" WEIGHT="38.56617661997146"/>
<DICH_DATA CI_END="47.35868179287324" CI_START="0.7767712404806961" EFFECT_SIZE="6.065217391304348" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.6753996054959321" LOG_CI_START="-0.10970686231188535" LOG_EFFECT_SIZE="0.7828463715920234" ORDER="21179" O_E="0.0" SE="1.0485803756098395" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="1.099520804114072" WEIGHT="8.924509179919355"/>
<DICH_DATA CI_END="5.761724080907717" CI_START="1.1023810708129165" EFFECT_SIZE="2.520241171403962" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.760552456823878" LOG_CI_START="0.042331747277558514" LOG_EFFECT_SIZE="0.4014421020507182" ORDER="21180" O_E="0.0" SE="0.4218864000373586" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.17798813453648216" WEIGHT="52.50931420010917"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.294327848287402" CI_START="1.7432119628253901" DF="0" EFFECT_SIZE="3.802469135802469" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="9" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="0.9187811976409863" LOG_CI_START="0.24135019760260268" LOG_EFFECT_SIZE="0.5800656976217945" NO="3" P_CHI2="1.0" P_Z="7.892788345834053E-4" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="3.356527457235942">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="8.294327848287402" CI_START="1.7432119628253901" EFFECT_SIZE="3.802469135802469" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="9" LOG_CI_END="0.9187811976409863" LOG_CI_START="0.24135019760260268" LOG_EFFECT_SIZE="0.5800656976217945" ORDER="21181" O_E="0.0" SE="0.3979263227600787" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.15834535834535834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.194795810262707" CI_END="2.3087271526500803" CI_START="1.0112875092948272" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5280009593730097" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="41" I2="4.643749519014308" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.3633726106563789" LOG_CI_START="0.004874643176724395" LOG_EFFECT_SIZE="0.18412362691655162" METHOD="MH" NO="19" P_CHI2="0.38028458657316555" P_Q="0.5140226409999271" P_Z="0.04408677464217071" Q="1.3309760828102863" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="825" TOTAL_2="753" WEIGHT="300.0" Z="2.013264844966305">
<NAME>Number of adverse events of fever before end of treatment at 12-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1158894916514956" CI_START="0.6367695350953314" DF="0" EFFECT_SIZE="1.4085820895522387" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.4935820465560422" LOG_CI_START="-0.19601772268320578" LOG_EFFECT_SIZE="0.1487821619364182" NO="1" P_CHI2="1.0" P_Z="0.3977032744361403" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.8457302103191865">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="3.1158894916514956" CI_START="0.6367695350953314" EFFECT_SIZE="1.4085820895522387" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.4935820465560422" LOG_CI_START="-0.19601772268320578" LOG_EFFECT_SIZE="0.1487821619364182" ORDER="21182" O_E="0.0" SE="0.40507431802504534" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.16408520312345556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.912374117148275" CI_END="2.3385122126502815" CI_START="0.6320877745327558" DF="2" EFFECT_SIZE="1.2157898585741644" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" I2="31.327503969223883" ID="CMP-001.19.02" LOG_CI_END="0.3689396423107094" LOG_CI_START="-0.19922260945756987" LOG_EFFECT_SIZE="0.08485851642656975" NO="2" P_CHI2="0.23312351814664178" P_Z="0.5582349084788079" STUDIES="3" TAU2="0.0" TOTAL_1="511" TOTAL_2="427" WEIGHT="100.0" Z="0.5854652802432552">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="7.83100470867564" CI_START="0.7135913110829638" EFFECT_SIZE="2.3639240506329116" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8938174851028522" LOG_CI_START="-0.14655044670886216" LOG_EFFECT_SIZE="0.373633519196995" ORDER="21183" O_E="0.0" SE="0.6111172730505201" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.3734643214207039" WEIGHT="22.95165290086615"/>
<DICH_DATA CI_END="3.930445865165074" CI_START="0.006400498260092029" EFFECT_SIZE="0.15860899067005937" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5944418190261862" LOG_CI_START="-2.1937862161433666" LOG_EFFECT_SIZE="-0.7996721985585902" ORDER="21184" O_E="0.0" SE="1.6378189498099645" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="2.682450912356615" WEIGHT="12.353719960457724"/>
<DICH_DATA CI_END="2.3642922774499526" CI_START="0.43175211610911307" EFFECT_SIZE="1.0103406326034063" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.37370116368022355" LOG_CI_START="-0.36476552518549776" LOG_EFFECT_SIZE="0.004467819247362888" ORDER="21185" O_E="0.0" SE="0.43377898850878926" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.18816421087170834" WEIGHT="64.69462713867613"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.444398024081187" CI_START="1.0321972906018773" DF="0" EFFECT_SIZE="2.141843971631206" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" I2="0.0" ID="CMP-001.19.03" LOG_CI_END="0.6478129458407366" LOG_CI_START="0.013762714762805047" LOG_EFFECT_SIZE="0.3307878303017708" NO="3" P_CHI2="1.0" P_Z="0.0408499223003402" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="2.04505006744783">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="4.444398024081187" CI_START="1.0321972906018773" EFFECT_SIZE="2.141843971631206" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.6478129458407366" LOG_CI_START="0.013762714762805047" LOG_EFFECT_SIZE="0.3307878303017708" ORDER="21186" O_E="0.0" SE="0.3724442443344395" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.1387147151378517" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7003811414414733" CI_END="1.091191358767303" CI_START="0.6250636828213091" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8258717148406759" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="122" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.037900918112864994" LOG_CI_START="-0.20407573355359412" LOG_EFFECT_SIZE="-0.0830874077203646" METHOD="MH" NO="20" P_CHI2="0.5933074759753423" P_Q="0.8692380244475648" P_Z="0.1783077407872557" Q="0.2802765916053276" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1061" TOTAL_2="992" WEIGHT="300.0" Z="1.3459838011576435">
<NAME>Number of adverse events of agitation before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.513377955718454" CI_START="0.3096618205187905" DF="0" EFFECT_SIZE="0.6845694799658995" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="0.17994740362417472" LOG_CI_START="-0.5091123372978713" LOG_EFFECT_SIZE="-0.16458246683684827" NO="1" P_CHI2="1.0" P_Z="0.34913012912155694" STUDIES="1" TAU2="0.0" TOTAL_1="149" TOTAL_2="163" WEIGHT="100.0" Z="0.9362779112746735">
<NAME>Risperidone 0.5 mg/day</NAME>
<DICH_DATA CI_END="1.513377955718454" CI_START="0.3096618205187905" EFFECT_SIZE="0.6845694799658995" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.17994740362417472" LOG_CI_START="-0.5091123372978713" LOG_EFFECT_SIZE="-0.16458246683684827" ORDER="21187" O_E="0.0" SE="0.4047571027183377" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="149" TOTAL_2="163" VAR="0.163828312200943" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4093560716970996" CI_END="1.18911322576916" CI_START="0.6204891800947365" DF="3" EFFECT_SIZE="0.8589714142492247" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="88" I2="12.006844198392324" ID="CMP-001.20.02" LOG_CI_END="0.07522320952665787" LOG_CI_START="-0.20726578719687183" LOG_EFFECT_SIZE="-0.06602128883510701" NO="2" P_CHI2="0.3327101088028164" P_Z="0.3595949155158269" STUDIES="5" TAU2="0.0" TOTAL_1="747" TOTAL_2="666" WEIGHT="99.99999999999999" Z="0.9161372643223233">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21188" O_E="0.0" SE="0.0" STUDY_ID="STD-Ballard-2005" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.257736096510036" CI_START="0.4478680855746216" EFFECT_SIZE="0.7505330490405118" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="42" LOG_CI_END="0.09958952516904812" LOG_CI_START="-0.3488498836429525" LOG_EFFECT_SIZE="-0.12463017923695223" ORDER="21189" O_E="0.0" SE="0.2634155285470435" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.06938774067971828" WEIGHT="42.71070434572918"/>
<DICH_DATA CI_END="2.274227731553771" CI_START="0.5575395953708984" EFFECT_SIZE="1.1260426320667285" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" LOG_CI_END="0.35683395094325104" LOG_CI_START="-0.2537242844404104" LOG_EFFECT_SIZE="0.05155483325142034" ORDER="21190" O_E="0.0" SE="0.358644929776371" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.12862618565429812" WEIGHT="19.031191880875276"/>
<DICH_DATA CI_END="2.4355262283457426" CI_START="0.6116075984231466" EFFECT_SIZE="1.2204861111111112" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.3865928108794541" LOG_CI_START="-0.21352712768623017" LOG_EFFECT_SIZE="0.08653284159661193" ORDER="21191" O_E="0.0" SE="0.3525134225550887" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.12426571308150254" WEIGHT="18.68637838132994"/>
<DICH_DATA CI_END="1.173411513676155" CI_START="0.20524917785199137" EFFECT_SIZE="0.4907563025210084" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.06945034525877584" LOG_CI_START="-0.6877185738190383" LOG_EFFECT_SIZE="-0.30913411428013127" ORDER="21192" O_E="0.0" SE="0.44476477111290524" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="148" TOTAL_2="163" VAR="0.197815701623115" WEIGHT="19.57172539206559"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.673992561477137" CI_START="0.3787533839827856" DF="0" EFFECT_SIZE="0.7962602259446825" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="0.0" ID="CMP-001.20.03" LOG_CI_END="0.2237535238384775" LOG_CI_START="-0.42164347825601395" LOG_EFFECT_SIZE="-0.09894497720876826" NO="3" P_CHI2="1.0" P_Z="0.5478672497587053" STUDIES="1" TAU2="0.0" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="0.6009590721709908">
<NAME>Risperidone 2.0 mg/day</NAME>
<DICH_DATA CI_END="1.6739925614771372" CI_START="0.3787533839827855" EFFECT_SIZE="0.7962602259446825" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.22375352383847755" LOG_CI_START="-0.42164347825601406" LOG_EFFECT_SIZE="-0.09894497720876826" ORDER="21193" O_E="0.0" SE="0.37910939379698927" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="163" VAR="0.1437239324651207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7828263075848327" CI_END="7.417286424980837" CI_START="0.7967441752710637" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="2.430983289827516" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="43.90928629751462" I2_Q="100.0" ID="CMP-001.21" LOG_CI_END="0.8702450499955963" LOG_CI_START="-0.09868110282364585" LOG_EFFECT_SIZE="0.38578197358597516" METHOD="MH" NO="21" P_CHI2="0.18180278737656574" P_Q="0.0" P_Z="0.11858614600161116" Q="3.805080936240086E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="402" TOTAL_2="408" WEIGHT="100.00000000000001" Z="1.5607356079991197">
<NAME>Number of adverse events of tremor before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7828263075848327" CI_END="7.417286424980837" CI_START="0.7967441752710637" DF="1" EFFECT_SIZE="2.430983289827516" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="43.90928629751462" ID="CMP-001.21.01" LOG_CI_END="0.8702450499955963" LOG_CI_START="-0.09868110282364585" LOG_EFFECT_SIZE="0.38578197358597516" NO="1" P_CHI2="0.18180278737656574" P_Z="0.11858614600161116" STUDIES="2" TAU2="0.0" TOTAL_1="402" TOTAL_2="408" WEIGHT="100.00000000000001" Z="1.5607356079991197">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="13.120741132455416" CI_START="0.9581483607808111" EFFECT_SIZE="3.545647558386412" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.1179583671010043" LOG_CI_START="-0.018567239063630104" LOG_EFFECT_SIZE="0.5496955640186871" ORDER="21194" O_E="0.0" SE="0.6676007669535899" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.4456907840370215" WEIGHT="65.26966678117486"/>
<DICH_DATA CI_END="8.293924331884392" CI_START="0.013625198144175411" EFFECT_SIZE="0.3361641896673744" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9187600688390709" LOG_CI_START="-1.8656571732864549" LOG_EFFECT_SIZE="-0.47344855222369203" ORDER="21195" O_E="0.0" SE="1.635580471112173" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="2.6751234774835178" WEIGHT="34.73033321882515"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9189701459531616" CI_END="12.622115591154369" CI_START="2.2368084419098664" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="5.313497408398374" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="1.1011321530508178" LOG_CI_START="0.34962879313387835" LOG_EFFECT_SIZE="0.7253804730923481" METHOD="MH" NO="22" P_CHI2="0.6316088270116342" P_Q="1.0" P_Z="1.5453393875981854E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="598" TOTAL_2="502" WEIGHT="100.0" Z="3.783667986545702">
<NAME>Number of adverse events of abnormal gait before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9189701459531616" CI_END="12.622115591154369" CI_START="2.2368084419098664" DF="2" EFFECT_SIZE="5.313497408398374" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="6" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="1.1011321530508178" LOG_CI_START="0.34962879313387835" LOG_EFFECT_SIZE="0.7253804730923481" NO="1" P_CHI2="0.6316088270116342" P_Z="1.5453393875981854E-4" STUDIES="3" TAU2="0.0" TOTAL_1="598" TOTAL_2="502" WEIGHT="100.0" Z="3.783667986545702">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="24.80009263183654" CI_START="1.154266162215388" EFFECT_SIZE="5.350318471337579" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3944533029802617" LOG_CI_START="0.06230596432503401" LOG_EFFECT_SIZE="0.7283796336526479" ORDER="21196" O_E="0.0" SE="0.7825099409617575" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.6123218077039733" WEIGHT="28.975335594709463"/>
<DICH_DATA CI_END="12.527621292497528" CI_START="1.0576309492956057" EFFECT_SIZE="3.64" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" LOG_CI_END="1.0978686162764073" LOG_CI_START="0.024334151021704848" LOG_EFFECT_SIZE="0.561101383649056" ORDER="21197" O_E="0.0" SE="0.6305994589719196" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.39765567765567766" WEIGHT="56.29761970232782"/>
<DICH_DATA CI_END="90.88149497203321" CI_START="1.490426498143283" EFFECT_SIZE="11.638392857142858" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.958475462433455" LOG_CI_START="0.17331056323487715" LOG_EFFECT_SIZE="1.0658930128341662" ORDER="21198" O_E="0.0" SE="1.0486146984980123" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="1.099592785906077" WEIGHT="14.727044702962711"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.298844778393984" CI_START="0.646168429187977" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.6333517640041909" LOG_CI_START="-0.18965426477147818" LOG_EFFECT_SIZE="0.2218487496163564" METHOD="MH" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.29067037016909414" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.0566521849424326">
<NAME>Number of adverse events of confusion before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.298844778393984" CI_START="0.646168429187977" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="0.6333517640041909" LOG_CI_START="-0.18965426477147818" LOG_EFFECT_SIZE="0.2218487496163564" NO="1" P_CHI2="1.0" P_Z="0.29067037016909414" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.0566521849424326">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="4.298844778393984" CI_START="0.646168429187977" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" LOG_CI_END="0.6333517640041909" LOG_CI_START="-0.18965426477147818" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="21199" O_E="0.0" SE="0.4834378152483742" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.2337121212121212" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.730573436064438" CI_START="0.6041127429404002" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6905027932960894" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.6749137887343623" LOG_CI_START="-0.21888200331981267" LOG_EFFECT_SIZE="0.22801589270727476" METHOD="MH" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.31730506181174556" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="94" WEIGHT="99.99999999999999" Z="1.0000112812836335">
<NAME>Number of adverse events of hallucination before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.730573436064438" CI_START="0.6041127429404002" DF="0" EFFECT_SIZE="1.6905027932960894" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.6749137887343623" LOG_CI_START="-0.21888200331981267" LOG_EFFECT_SIZE="0.22801589270727476" NO="1" P_CHI2="1.0" P_Z="0.31730506181174556" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="94" WEIGHT="99.99999999999999" Z="1.0000112812836335">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="4.7305734360644385" CI_START="0.6041127429404001" EFFECT_SIZE="1.6905027932960894" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.6749137887343623" LOG_CI_START="-0.21888200331981275" LOG_EFFECT_SIZE="0.22801589270727476" ORDER="21200" O_E="0.0" SE="0.5250200726131483" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.2756460766467155" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="101.94973891809217" CI_START="1.8132912911480026" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="13.596491228070175" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="2.008386117935865" LOG_CI_START="0.2584675757317728" LOG_EFFECT_SIZE="1.133426846833819" METHOD="MH" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.011118645399091005" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="2.5389476656519614">
<NAME>Number of adverse events of urinary incontinence before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.94973891809217" CI_START="1.8132912911480026" DF="0" EFFECT_SIZE="13.596491228070175" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="2.008386117935865" LOG_CI_START="0.2584675757317728" LOG_EFFECT_SIZE="1.133426846833819" NO="1" P_CHI2="1.0" P_Z="0.011118645399091005" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="2.5389476656519614">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="101.94973891809217" CI_START="1.8132912911480035" EFFECT_SIZE="13.596491228070175" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="2.008386117935865" LOG_CI_START="0.258467575731773" LOG_EFFECT_SIZE="1.133426846833819" ORDER="21201" O_E="0.0" SE="1.02791081392717" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="1.0566006413884172" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.318180055421635" CI_START="0.9879642610565429" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.368715083798882" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="1.2859662095992694" LOG_CI_START="-0.005258765439359784" LOG_EFFECT_SIZE="0.6403537220799548" METHOD="MH" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.05189553386444225" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.9439993136832492">
<NAME>Number of adverse events of asthenia before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.318180055421635" CI_START="0.9879642610565429" DF="0" EFFECT_SIZE="4.368715083798882" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="0.0" ID="CMP-001.26.01" LOG_CI_END="1.2859662095992694" LOG_CI_START="-0.005258765439359784" LOG_EFFECT_SIZE="0.6403537220799548" NO="1" P_CHI2="1.0" P_Z="0.05189553386444225" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.9439993136832492">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="19.318180055421635" CI_START="0.9879642610565429" EFFECT_SIZE="4.368715083798882" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.2859662095992694" LOG_CI_START="-0.005258765439359784" LOG_EFFECT_SIZE="0.6403537220799548" ORDER="21202" O_E="0.0" SE="0.7584719420044007" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.575279686807927" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="51.278453392991366" CI_START="0.8511684243231966" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="6.60655737704918" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="1.7099349179729544" LOG_CI_START="-0.06998449571226974" LOG_EFFECT_SIZE="0.8199752111303424" METHOD="MH" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.07094385419055892" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.805836679654661">
<NAME>Number of adverse events of hostility before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="51.278453392991366" CI_START="0.8511684243231966" DF="0" EFFECT_SIZE="6.60655737704918" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="1.7099349179729544" LOG_CI_START="-0.06998449571226974" LOG_EFFECT_SIZE="0.8199752111303424" NO="1" P_CHI2="1.0" P_Z="0.07094385419055892" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.805836679654661">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="51.278453392991366" CI_START="0.8511684243231966" EFFECT_SIZE="6.60655737704918" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.7099349179729544" LOG_CI_START="-0.06998449571226974" LOG_EFFECT_SIZE="0.8199752111303424" ORDER="21203" O_E="0.0" SE="1.0455334743418963" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="1.0931402459694368" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3012406016157907" CI_START="0.0034006614080286505" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.06652126499454744" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.11435760577996351" LOG_CI_START="-2.4684366070984716" LOG_EFFECT_SIZE="-1.177039500659254" METHOD="MH" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.0740341098513172" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.7864025079273549">
<NAME>Number of adverse events of flu syndrome before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3012406016157907" CI_START="0.0034006614080286505" DF="0" EFFECT_SIZE="0.06652126499454744" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.28.01" LOG_CI_END="0.11435760577996351" LOG_CI_START="-2.4684366070984716" LOG_EFFECT_SIZE="-1.177039500659254" NO="1" P_CHI2="1.0" P_Z="0.0740341098513172" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.7864025079273549">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="1.3012406016157902" CI_START="0.0034006614080286505" EFFECT_SIZE="0.06652126499454744" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11435760577996336" LOG_CI_START="-2.4684366070984716" LOG_EFFECT_SIZE="-1.177039500659254" ORDER="21204" O_E="0.0" SE="1.5171461056823408" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="2.3017323059870924" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.916624815194924" CI_START="0.23427373572011148" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9578947368421052" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.5929119712173657" LOG_CI_START="-0.6302763971528741" LOG_EFFECT_SIZE="-0.018682212967754176" METHOD="MH" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.9522587558346776" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="0.059870524467286496">
<NAME>Number of adverse events of dyspnea before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.916624815194924" CI_START="0.23427373572011148" DF="0" EFFECT_SIZE="0.9578947368421052" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-001.29.01" LOG_CI_END="0.5929119712173657" LOG_CI_START="-0.6302763971528741" LOG_EFFECT_SIZE="-0.018682212967754176" NO="1" P_CHI2="1.0" P_Z="0.9522587558346776" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="0.059870524467286496">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="3.916624815194924" CI_START="0.23427373572011148" EFFECT_SIZE="0.9578947368421052" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5929119712173657" LOG_CI_START="-0.6302763971528741" LOG_EFFECT_SIZE="-0.018682212967754176" ORDER="21205" O_E="0.0" SE="0.7185069024607542" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="0.5162521688837478" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9808235970117456" CI_START="0.004474788840913504" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.09414758269720101" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="0.29684580100265984" LOG_CI_START="-2.3492274536195232" LOG_EFFECT_SIZE="-1.0261908263084316" METHOD="MH" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.12845753082482705" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.520212682938066">
<NAME>Number of adverse events of angina pectoris before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9808235970117456" CI_START="0.004474788840913504" DF="0" EFFECT_SIZE="0.09414758269720101" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.30.01" LOG_CI_END="0.29684580100265984" LOG_CI_START="-2.3492274536195232" LOG_EFFECT_SIZE="-1.0261908263084316" NO="1" P_CHI2="1.0" P_Z="0.12845753082482705" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="94" WEIGHT="100.0" Z="1.520212682938066">
<NAME>Risperidone 1.0 mg/day</NAME>
<DICH_DATA CI_END="1.9808235970117438" CI_START="0.004474788840913504" EFFECT_SIZE="0.09414758269720101" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.29684580100265945" LOG_CI_START="-2.3492274536195232" LOG_EFFECT_SIZE="-1.0261908263084316" ORDER="21206" O_E="0.0" SE="1.5543165280389266" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="2.4158998693349836" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3938706410889012" CI_END="7.685619667389455" CI_START="1.7214096352621104" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="3.637320407718322" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="0.8856788890483195" LOG_CI_START="0.2358842295169751" LOG_EFFECT_SIZE="0.5607815592826472" METHOD="MH" NO="31" P_CHI2="0.49419813863434137" P_Q="1.0" P_Z="7.17114959107234E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1175" TOTAL_2="779" WEIGHT="100.0" Z="3.3829507314846863">
<NAME>Number of cerebrovascular adverse events before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3938706410889012" CI_END="7.685619667389455" CI_START="1.7214096352621104" DF="4" EFFECT_SIZE="3.637320407718322" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="8" I2="0.0" ID="CMP-001.31.01" LOG_CI_END="0.8856788890483195" LOG_CI_START="0.2358842295169751" LOG_EFFECT_SIZE="0.5607815592826472" NO="1" P_CHI2="0.49419813863434137" P_Z="7.17114959107234E-4" STUDIES="5" TAU2="0.0" TOTAL_1="1175" TOTAL_2="779" WEIGHT="100.0" Z="3.3829507314846863">
<NAME>Risperidone 0.5-2.0 mg/day</NAME>
<DICH_DATA CI_END="19.34556217210423" CI_START="1.559927522034548" EFFECT_SIZE="5.493421052631579" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="1.2865813546153047" LOG_CI_START="0.19310442046235438" LOG_EFFECT_SIZE="0.7398428875388295" ORDER="21207" O_E="0.0" SE="0.6423137639195635" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.41256697132051684" WEIGHT="29.67830714349023"/>
<DICH_DATA CI_END="82.91560370845538" CI_START="0.23542409034551592" EFFECT_SIZE="4.418181818181818" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9186362671823858" LOG_CI_START="-0.6281490989742493" LOG_EFFECT_SIZE="0.6452435841040683" ORDER="21208" O_E="0.0" SE="1.4959943308712897" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="2.237999037999038" WEIGHT="7.229729858229955"/>
<DICH_DATA CI_END="22.51451815178713" CI_START="1.0041224696994555" EFFECT_SIZE="4.754716981132075" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3524626567726692" LOG_CI_START="0.0017866855888407768" LOG_EFFECT_SIZE="0.677124671180755" ORDER="21209" O_E="0.0" SE="0.7933937514272679" STUDY_ID="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TOTAL_1="115" TOTAL_2="114" VAR="0.6294736448038334" WEIGHT="20.305073312260745"/>
<DICH_DATA CI_END="36.992798315066814" CI_START="0.45527681058705005" EFFECT_SIZE="4.103896103896104" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5681171847034898" LOG_CI_START="-0.3417244698116459" LOG_EFFECT_SIZE="0.6131963574459219" ORDER="21210" O_E="0.0" SE="1.1218504417308506" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="1.2585484136117047" WEIGHT="10.711616669445142"/>
<DICH_DATA CI_END="4.584330542800312" CI_START="0.1692089947393903" EFFECT_SIZE="0.8807439824945296" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.6612759239110797" LOG_CI_START="-0.7715765546430056" LOG_EFFECT_SIZE="-0.05515031536596289" ORDER="21211" O_E="0.0" SE="0.8416646386368287" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="462" TOTAL_2="163" VAR="0.7083993639316635" WEIGHT="32.07527301657394"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5093036738323673" CI_END="2.155965563729083" CI_START="0.7273477328158631" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.252252636175074" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="22" I2="0.0" I2_Q="100.0" ID="CMP-001.32" LOG_CI_END="0.33364181977913776" LOG_CI_START="-0.138257910547217" LOG_EFFECT_SIZE="0.09769195461596035" METHOD="MH" NO="32" P_CHI2="0.47646515867984096" P_Q="0.0" P_Z="0.4170800673222014" Q="1.0025956468175599E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1175" TOTAL_2="779" WEIGHT="99.99999999999999" Z="0.8114974445702089">
<NAME>Number of deaths before end of treatment at 8-13 weeks</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5093036738323673" CI_END="2.155965563729083" CI_START="0.7273477328158631" DF="4" EFFECT_SIZE="1.252252636175074" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="22" I2="0.0" ID="CMP-001.32.01" LOG_CI_END="0.33364181977913776" LOG_CI_START="-0.138257910547217" LOG_EFFECT_SIZE="0.09769195461596035" NO="1" P_CHI2="0.47646515867984096" P_Z="0.4170800673222014" STUDIES="5" TAU2="0.0" TOTAL_1="1175" TOTAL_2="779" WEIGHT="99.99999999999999" Z="0.8114974445702089">
<NAME>Risperidone 0.5-2.0 mg/day</NAME>
<DICH_DATA CI_END="4.109810185700445" CI_START="0.36800766490142556" EFFECT_SIZE="1.2298136645962734" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6138217641615878" LOG_CI_START="-0.4341431357022251" LOG_EFFECT_SIZE="0.08983931422968143" ORDER="21212" O_E="0.0" SE="0.6155797696899211" STUDY_ID="STD-Brodaty-2001" TOTAL_1="167" TOTAL_2="170" VAR="0.37893845285149635" WEIGHT="20.04184454821608"/>
<DICH_DATA CI_END="17.578044507077905" CI_START="0.21355653346357545" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.244970559758104" LOG_CI_START="-0.670487137401408" LOG_EFFECT_SIZE="0.2872417111783479" ORDER="21213" O_E="0.0" SE="1.1251493329800166" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="196" TOTAL_2="94" VAR="1.2659610215053763" WEIGHT="5.554883313976325"/>
<DICH_DATA CI_END="1.6631935320971452" CI_START="0.021986722601616375" EFFECT_SIZE="0.1912280701754386" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2209427874225102" LOG_CI_START="-1.6578395028862456" LOG_EFFECT_SIZE="-0.7184483577318678" ORDER="21214" O_E="0.0" SE="1.1036060174496907" STUDY_ID="STD-RIS_x002d_INT_x002d_24_x002f_DeDeyn" TOTAL_1="115" TOTAL_2="114" VAR="1.2179462417511668" WEIGHT="20.8838749044825"/>
<DICH_DATA CI_END="4.396353470988422" CI_START="0.5393230808735281" EFFECT_SIZE="1.5398230088495575" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6430926028434512" LOG_CI_START="-0.2681509932450912" LOG_EFFECT_SIZE="0.18747080479918" ORDER="21215" O_E="0.0" SE="0.5352689990709586" STUDY_ID="STD-RIS_x002d_USA_x002d_232_x002f_Colon" TOTAL_1="235" TOTAL_2="238" VAR="0.28651290136642593" WEIGHT="24.053055787394847"/>
<DICH_DATA CI_END="4.429171296775105" CI_START="0.6188399181012951" EFFECT_SIZE="1.6555808656036446" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="5" LOG_CI_END="0.6463224768089425" LOG_CI_START="-0.20842168002119188" LOG_EFFECT_SIZE="0.2189503983938753" ORDER="21216" O_E="0.0" SE="0.5020809487738348" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="462" TOTAL_2="163" VAR="0.2520852791216341" WEIGHT="29.46634144593025"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>RISPERIDONE 2 mg/day vs 1 mg/day</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.9013752562726853" CI_START="-1.701375256272686" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9133581426353519" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="162" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="0.10880375855697638">
<NAME>BEHAVE-AD (change from baseline at 12 weeks) ITT</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.901375256272685" CI_START="-1.7013752562726858" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-6.5" ORDER="21217" SD_1="7.6" SD_2="8.5" SE="0.9190858967214212" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="162" TOTAL_2="148" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1238924198424647" CI_START="-0.523892419842465" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.47542984610113315" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="162" TOTAL_2="148" UNITS="" WEIGHT="99.99999999999999" Z="0.7136722965292537">
<NAME>BEHAVE-AD PSYCHOSIS (change from baseline at 12 weeks) ITT</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1238924198424647" CI_START="-0.523892419842465" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="-2.5" ORDER="21218" SD_1="3.8" SD_2="3.6" SE="0.4203609996618423" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="162" TOTAL_2="148" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.15437205516607677" CI_START="-1.2456279448339231" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.01192054401447008" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="162" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="2.5144877606949474">
<NAME>BEHAVE-AD AGGRESSION(change from baseline at 12 weeks) ITT</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.15437205516607677" CI_START="-1.2456279448339231" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-1.7" ORDER="21219" SD_1="2.5" SD_2="2.4" SE="0.2783867199284103" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="162" TOTAL_2="148" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.625061043641684" CI_START="1.0310167720823478" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.645138888888889" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.419139407021401" LOG_CI_START="0.013265730233629893" LOG_EFFECT_SIZE="0.21620256862751544" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.03679022136003577" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="2.088084407092779">
<NAME>Number of dropouts before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.625061043641684" CI_START="1.0310167720823478" EFFECT_SIZE="1.645138888888889" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="45" LOG_CI_END="0.419139407021401" LOG_CI_START="0.013265730233629893" LOG_EFFECT_SIZE="0.21620256862751544" ORDER="21220" O_E="0.0" SE="0.23841220685223935" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.056840380376154964" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.905305238167805" CI_START="0.9408688199780914" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6533333333333333" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.46319176711808696" LOG_CI_START="-0.02647092357701708" LOG_EFFECT_SIZE="0.21836042177053502" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.08045457134992644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="1.748054611682522">
<NAME>Number of dropouts due to adverse events before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.905305238167805" CI_START="0.9408688199780915" EFFECT_SIZE="1.6533333333333333" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="24" LOG_CI_END="0.46319176711808696" LOG_CI_START="-0.02647092357701703" LOG_EFFECT_SIZE="0.21836042177053502" ORDER="21221" O_E="0.0" SE="0.28763028838371474" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.08273118279569891" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2909299425958256" CI_START="1.0990901328846614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.9018487394957984" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.5173186371202937" LOG_CI_START="0.04103330899251364" LOG_EFFECT_SIZE="0.2791759730564036" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.021580196149602455" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="2.2976767085828733">
<NAME>Number of adverse events of somnolence before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2909299425958256" CI_START="1.0990901328846614" EFFECT_SIZE="1.9018487394957984" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="25" LOG_CI_END="0.5173186371202937" LOG_CI_START="0.04103330899251364" LOG_EFFECT_SIZE="0.2791759730564036" ORDER="21222" O_E="0.0" SE="0.27977235939265593" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.07827257308013343" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8869917695662712" CI_START="0.7148138260566655" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1613990729034978" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.2757700059202322" LOG_CI_START="-0.14580705588373372" LOG_EFFECT_SIZE="0.06498147501824925" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5457014743391397" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="0.6042138542977988">
<NAME>Number of adverse events of injury before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8869917695662712" CI_START="0.7148138260566655" EFFECT_SIZE="1.1613990729034978" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="42" LOG_CI_END="0.2757700059202322" LOG_CI_START="-0.14580705588373372" LOG_EFFECT_SIZE="0.06498147501824925" ORDER="21223" O_E="0.0" SE="0.24763645294376163" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.061323812826567875" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.079003378884947" CI_START="1.2354992802551064" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.24490662139219" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.6105540650696024" LOG_CI_START="0.09184249673823844" LOG_EFFECT_SIZE="0.3511982809039204" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.007953861822551821" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="2.6540220963968997">
<NAME>Number of adverse events of fall before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.079003378884947" CI_START="1.2354992802551064" EFFECT_SIZE="2.24490662139219" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="19" LOG_CI_END="0.6105540650696024" LOG_CI_START="0.09184249673823844" LOG_EFFECT_SIZE="0.3511982809039204" ORDER="21224" O_E="0.0" SE="0.30469374290151713" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.09283827696333583" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.361890316415849" CI_START="0.9938894085775594" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8279352226720649" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.5265835402300426" LOG_CI_START="-0.0026619374503247992" LOG_EFFECT_SIZE="0.2619608013898589" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.05234955930878291" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="1.9402479860034132">
<NAME>Number of adverse events of extrapyramidal disorder before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.361890316415849" CI_START="0.9938894085775594" EFFECT_SIZE="1.8279352226720649" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" LOG_CI_END="0.5265835402300426" LOG_CI_START="-0.0026619374503247992" LOG_EFFECT_SIZE="0.2619608013898589" ORDER="21225" O_E="0.0" SE="0.3108814133968141" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.0966472531956008" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.361890316415849" CI_START="0.9938894085775594" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8279352226720649" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.5265835402300426" LOG_CI_START="-0.0026619374503247992" LOG_EFFECT_SIZE="0.2619608013898589" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.05234955930878291" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="1.9402479860034132">
<NAME>Number of adverse events of urinary tract infection before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.361890316415849" CI_START="0.9938894085775594" EFFECT_SIZE="1.8279352226720649" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" LOG_CI_END="0.5265835402300426" LOG_CI_START="-0.0026619374503247992" LOG_EFFECT_SIZE="0.2619608013898589" ORDER="21226" O_E="0.0" SE="0.3108814133968141" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.0966472531956008" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8138829706521267" CI_START="0.808986286909782" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5087719298245614" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.4493060311737457" LOG_CI_START="-0.09205884003159308" LOG_EFFECT_SIZE="0.17862359557107632" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.1958789416116475" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="1.2933820893434633">
<NAME>Number of adverse events of peripheral oedema before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8138829706521267" CI_START="0.808986286909782" EFFECT_SIZE="1.5087719298245614" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" LOG_CI_END="0.4493060311737457" LOG_CI_START="-0.09205884003159308" LOG_EFFECT_SIZE="0.17862359557107632" ORDER="21227" O_E="0.0" SE="0.3180004051453477" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.10112425767260529" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.676396500187165" CI_START="0.4105247647430642" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8295795795795796" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.22437674548619915" LOG_CI_START="-0.38666063911250464" LOG_EFFECT_SIZE="-0.08114194681315275" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.6026859050083859" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="0.5205419419425205">
<NAME>Number of adverse events of purpura before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.676396500187165" CI_START="0.4105247647430642" EFFECT_SIZE="0.8295795795795796" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.22437674548619915" LOG_CI_START="-0.38666063911250464" LOG_EFFECT_SIZE="-0.08114194681315275" ORDER="21228" O_E="0.0" SE="0.35892638439711383" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.1288281494163847" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.494063749850187" CI_START="1.0000018267907702" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.1199226305609282" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.6526392287443892" LOG_CI_START="7.933644264386532E-7" LOG_EFFECT_SIZE="0.32632001105440783" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.04999944300342675" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="1.9599687497074674">
<NAME>Number of adverse events of fever before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.494063749850187" CI_START="1.0000018267907702" EFFECT_SIZE="2.1199226305609282" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.6526392287443892" LOG_CI_START="7.933644264386532E-7" LOG_EFFECT_SIZE="0.32632001105440783" ORDER="21229" O_E="0.0" SE="0.3833630475545479" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.14696722623031055" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2909299425958256" CI_START="1.0990901328846614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.9018487394957984" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.5173186371202937" LOG_CI_START="0.04103330899251364" LOG_EFFECT_SIZE="0.2791759730564036" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.021580196149602455" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="2.2976767085828733">
<NAME>Number of adverse events of pain before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2909299425958256" CI_START="1.0990901328846614" EFFECT_SIZE="1.9018487394957984" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="25" LOG_CI_END="0.5173186371202937" LOG_CI_START="0.04103330899251364" LOG_EFFECT_SIZE="0.2791759730564036" ORDER="21230" O_E="0.0" SE="0.27977235939265593" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.07827257308013343" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9850958344676157" CI_START="0.6606014220963818" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6225165562913908" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.6004387698676417" LOG_CI_START="-0.18006049572491553" LOG_EFFECT_SIZE="0.21018913707136305" METHOD="MH" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.29113271534061547" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="1.0556400416050635">
<NAME>Number of adverse events of coughing before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9850958344676157" CI_START="0.6606014220963818" EFFECT_SIZE="1.6225165562913908" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6004387698676417" LOG_CI_START="-0.18006049572491553" LOG_EFFECT_SIZE="0.21018913707136305" ORDER="21231" O_E="0.0" SE="0.45846913214274304" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.21019394512771997" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9850958344676157" CI_START="0.6606014220963818" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6225165562913908" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.6004387698676417" LOG_CI_START="-0.18006049572491553" LOG_EFFECT_SIZE="0.21018913707136305" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.29113271534061547" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="1.0556400416050635">
<NAME>Number of adverse events of agittion before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9850958344676157" CI_START="0.6606014220963818" EFFECT_SIZE="1.6225165562913908" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6004387698676417" LOG_CI_START="-0.18006049572491553" LOG_EFFECT_SIZE="0.21018913707136305" ORDER="21232" O_E="0.0" SE="0.45846913214274304" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.21019394512771997" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.111220774048054" CI_START="0.7655052868191223" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.774024024024024" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.6139707991779052" LOG_CI_START="-0.11605180558173185" LOG_EFFECT_SIZE="0.2489594967980867" METHOD="MH" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.18128386969237728" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="1.3368124333468414">
<NAME>Number of adverse events of rhinitis before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1112207740480535" CI_START="0.7655052868191224" EFFECT_SIZE="1.774024024024024" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.6139707991779051" LOG_CI_START="-0.11605180558173178" LOG_EFFECT_SIZE="0.2489594967980867" ORDER="21233" O_E="0.0" SE="0.4288188917059848" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.18388564188394912" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.785668935348649" CI_START="0.2891283266733788" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7185314685314685" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.2518009434221573" LOG_CI_START="-0.5389093572560674" LOG_EFFECT_SIZE="-0.143554206916955" METHOD="MH" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.47667122916125393" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="148" WEIGHT="100.0" Z="0.7116666499604409">
<NAME>Number of adverse events of upper respiratory tract infection before end of treatment at 12 weeks</NAME>
<GROUP_LABEL_1>Risperidone 2mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone 1mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2mg/day</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 1mg/day</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.785668935348649" CI_START="0.2891283266733788" EFFECT_SIZE="0.7185314685314685" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2518009434221573" LOG_CI_START="-0.5389093572560674" LOG_EFFECT_SIZE="-0.143554206916955" ORDER="21234" O_E="0.0" SE="0.46446714469750294" STUDY_ID="STD-RIS_x002d_USA_x002d_63_x002f_Katz" TOTAL_1="165" TOTAL_2="148" VAR="0.21572972850345112" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-06-20 15:32:27 +0100" MODIFIED_BY="Helen Collins" NO="3">
<NAME>OLANZAPINE VS PLACEBO</NAME>
<CONT_OUTCOME CHI2="2.249083658529199" CI_END="0.3712668038488054" CI_START="-4.370606612398193" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.999669904274694" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.6900538695608556" P_Q="0.8327109279811645" P_Z="0.09832033887295841" Q="0.3661375519131027" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="861" TOTAL_2="439" UNITS="" WEIGHT="300.0" Z="1.6530517157706037">
<NAME>NPI-NH TOTAL (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.374177198324497" CI_START="-5.5741771983245" DF="0" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="1.0" P_Z="0.430065458674302" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0" Z="0.78907965567972">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="2.374177198324497" CI_START="-5.5741771983245" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" MEAN_1="-15.3" MEAN_2="-13.7" ORDER="21235" SD_1="15.5" SD_2="20.3" SE="2.027678686788278" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8829461066160964" CI_END="0.6137996659514644" CI_START="-5.530653681482811" DF="2" EFFECT_SIZE="-2.4584270077656734" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="0.3900529076016186" P_Z="0.11679175279979324" STUDIES="3" TAU2="0.0" TOTAL_1="548" TOTAL_2="265" WEIGHT="100.0" Z="1.5683830998092978">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="2.935044325869029" CI_START="-15.135044325869028" EFFECT_SIZE="-6.1" ESTIMABLE="YES" MEAN_1="-16.5" MEAN_2="-10.4" ORDER="21236" SD_1="21.5" SD_2="27.5" SE="4.609801198969116" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="104" TOTAL_2="45" WEIGHT="11.562345320351875"/>
<CONT_DATA CI_END="6.047824359875196" CI_START="-5.047824359875196" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-11.8" MEAN_2="-12.3" ORDER="21237" SD_1="22.8" SD_2="22.0" SE="2.830574645062729" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="193" TOTAL_2="91" WEIGHT="30.666280558004726"/>
<CONT_DATA CI_END="0.7420055609865432" CI_START="-7.342005560986545" EFFECT_SIZE="-3.3000000000000007" ESTIMABLE="YES" MEAN_1="-17.0" MEAN_2="-13.7" ORDER="21238" SD_1="16.3" SD_2="20.3" SE="2.0622856301796197" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="251" TOTAL_2="129" WEIGHT="57.77137412164339"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.464220411238868" CI_START="-10.064220411238866" DF="0" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" NO="3" P_CHI2="1.0" P_Z="0.898578737814478" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="0.12745695802973045">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="11.464220411238868" CI_START="-10.064220411238866" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" MEAN_1="-9.7" MEAN_2="-10.4" ORDER="21239" SD_1="26.1" SD_2="27.5" SE="5.492050107117102" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.047363992106849" CI_END="0.15137905127372808" CI_START="-1.2012334751549516" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5249272119406118" ESTIMABLE="YES" I2="1.1702429581134286" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.3996340156123491" P_Q="0.7630709221217464" P_Z="0.1281943205379986" Q="0.5408086441093007" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="861" TOTAL_2="439" UNITS="" WEIGHT="300.0" Z="1.5212611295639533">
<NAME>NPI-NH PSYCHOSIS (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3083473366868501" CI_START="-2.108347336686851" DF="0" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="1.0" P_Z="0.1443400106186558" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0" Z="1.459818325848796">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="0.3083473366868501" CI_START="-2.108347336686851" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-5.0" ORDER="21240" SD_1="4.9" SD_2="6.1" SE="0.6165150718166966" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.506555347997548" CI_END="0.5004043918821774" CI_START="-1.2200324328474026" DF="2" EFFECT_SIZE="-0.3598140204826126" ESTIMABLE="YES" I2="42.963968866422746" ID="CMP-003.02.02" NO="2" P_CHI2="0.1732053485108812" P_Z="0.41231988721789814" STUDIES="3" TAU2="0.0" TOTAL_1="548" TOTAL_2="265" WEIGHT="100.0" Z="0.8198179801101684">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="1.0977546604363049" CI_START="-3.6977546604363045" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-1.6" ORDER="21241" SD_1="5.7" SD_2="7.3" SE="1.2233666941584067" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="104" TOTAL_2="45" WEIGHT="12.870872275337607"/>
<CONT_DATA CI_END="2.1145853164141046" CI_START="-0.7145853164141043" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-4.7" ORDER="21242" SD_1="6.4" SD_2="5.3" SE="0.7217404644024956" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="193" TOTAL_2="91" WEIGHT="36.97934178867112"/>
<CONT_DATA CI_END="0.3147144346027153" CI_START="-2.114714434602716" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-5.0" ORDER="21243" SD_1="4.9" SD_2="6.1" SE="0.619763650854928" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="251" TOTAL_2="129" WEIGHT="50.149785935991275"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2816576383165725" CI_START="-2.881657638316572" DF="0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.03" NO="3" P_CHI2="1.0" P_Z="0.8198355799424392" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="0.22775645640815004">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="2.2816576383165725" CI_START="-2.881657638316572" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-1.6" ORDER="21244" SD_1="5.3" SD_2="7.3" SE="1.317196468241436" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2749579214485793" CI_END="-0.15252163344511294" CI_START="-1.1088941603847884" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6307078969149507" ESTIMABLE="YES" I2="8.395769595933006" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.3511433328175887" P_Q="0.705039288246817" P_Z="0.009734753804531999" Q="0.6990037636956506" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="668" TOTAL_2="348" UNITS="" WEIGHT="300.0" Z="2.585111403553058">
<NAME>NPI-NH AGITATION/AGGRESSION (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3406574502537293" CI_START="-1.140657450253729" DF="0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="1.0" P_Z="0.2898277615957381" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0" Z="1.0584995716271393">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="0.3406574502537293" CI_START="-1.140657450253729" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-1.3" ORDER="21245" SD_1="3.1" SD_2="3.7" SE="0.37789339809095507" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.5759541577529284" CI_END="-0.09529303004271639" CI_START="-1.4361295642822542" DF="1" EFFECT_SIZE="-0.7657112971624853" ESTIMABLE="YES" I2="61.179433376550236" ID="CMP-003.03.02" NO="2" P_CHI2="0.10849903330438804" P_Z="0.025185040331930565" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="174" WEIGHT="99.99999999999997" Z="2.238552614983877">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="-0.36111967464378014" CI_START="-3.4388803253562195" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-2.1" ORDER="21246" SD_1="3.9" SD_2="4.6" SE="0.785157450593333" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="104" TOTAL_2="45" WEIGHT="18.97937836874896"/>
<CONT_DATA CI_END="0.24481438130546285" CI_START="-1.2448143813054628" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-1.3" ORDER="21247" SD_1="3.1" SD_2="3.7" SE="0.38001432025305754" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="251" TOTAL_2="129" WEIGHT="81.02062163125102"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7528588818360484" CI_START="-2.7528588818360484" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.03" NO="3" P_CHI2="1.0" P_Z="0.26350177725108925" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="1.1181527531110045">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="0.7528588818360484" CI_START="-2.7528588818360484" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="-2.1" ORDER="21248" SD_1="4.1" SD_2="4.6" SE="0.8943321896026537" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4466966997923665" CI_END="-0.12852297519095518" CI_START="-1.082776211426966" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6056495933089605" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.69462620753947" P_Q="0.5553148275092812" P_Z="0.012849374300262327" Q="1.1764408988708341" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="668" TOTAL_2="348" UNITS="" WEIGHT="300.0" Z="2.4879169282551037">
<NAME>NPI-NH ANXIETY (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2996423594095864" CI_START="-1.1996423594095864" DF="0" EFFECT_SIZE="-0.44999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.23937940699981475" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0" Z="1.1765394283984556">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="0.2996423594095864" CI_START="-1.1996423594095864" EFFECT_SIZE="-0.44999999999999996" ESTIMABLE="YES" MEAN_1="-1.45" MEAN_2="-1.0" ORDER="21249" SD_1="3.0" SD_2="3.8" SE="0.3824776196515189" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.27025580092153245" CI_END="-0.16633118058393714" CI_START="-1.5083669263446002" DF="1" EFFECT_SIZE="-0.8373490534642687" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="0.6031602818232108" P_Z="0.014453206204112373" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="174" WEIGHT="100.0" Z="2.445797725526986">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="0.3230397677127572" CI_START="-2.7230397677127574" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-0.6" ORDER="21250" SD_1="4.0" SD_2="4.5" SE="0.7770753849184479" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="104" TOTAL_2="45" WEIGHT="19.41090076983748"/>
<CONT_DATA CI_END="-0.0025262644535031242" CI_START="-1.4974737355464969" EFFECT_SIZE="-0.75" ESTIMABLE="YES" MEAN_1="-1.75" MEAN_2="-1.0" ORDER="21251" SD_1="2.9" SD_2="3.8" SE="0.38137115857356274" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="251" TOTAL_2="129" WEIGHT="80.58909923016252"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5965340308347686" CI_START="-1.5965340308347686" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="0.0">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="1.5965340308347686" CI_START="-1.5965340308347686" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.6" ORDER="21252" SD_1="3.3" SD_2="4.5" SE="0.8145731469700593" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.011138147907055498" CI_END="0.6896011706131536" CI_START="-0.2388604114560978" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.22537037957852793" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.9159493766738775" P_Q="0.9159493766738775" P_Z="0.341348193448039" Q="0.011138147907055498" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="513" TOTAL_2="258" UNITS="" WEIGHT="200.0" Z="0.9515048025392385">
<NAME>NPI-NH APATHY/INDIFFERENCE (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8614394370256819" CI_START="-0.4614394370256818" DF="0" EFFECT_SIZE="0.20000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" NO="1" P_CHI2="1.0" P_Z="0.5534248097454602" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0" Z="0.5926359617604582">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="0.8614394370256819" CI_START="-0.4614394370256818" EFFECT_SIZE="0.20000000000000007" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.1" ORDER="21253" SD_1="3.4" SD_2="3.0" SE="0.3374753017111701" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9017116165322024" CI_START="-0.4017116165322022" DF="0" EFFECT_SIZE="0.2500000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" NO="2" P_CHI2="1.0" P_Z="0.4521397830742624" STUDIES="1" TAU2="0.0" TOTAL_1="251" TOTAL_2="129" WEIGHT="100.0" Z="0.7518524815351398">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="0.9017116165322024" CI_START="-0.4017116165322022" EFFECT_SIZE="0.2500000000000001" ESTIMABLE="YES" MEAN_1="-0.85" MEAN_2="-1.1" ORDER="21254" SD_1="3.2" SD_2="3.0" SE="0.3325120367888494" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="251" TOTAL_2="129" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.556465435515901" CI_END="-0.023918865169914594" CI_START="-0.4037039955477753" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.21381143035884495" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.906322170614516" P_Q="0.83439574912338" P_Z="0.027325167876618494" Q="0.3620950400932832" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="668" TOTAL_2="348" UNITS="" WEIGHT="300.0" Z="2.206841023867316">
<NAME>NPI-NH EUPHORIA/ELATION (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.13192146518376793" CI_START="-0.43192146518376795" DF="0" EFFECT_SIZE="-0.15" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" NO="1" P_CHI2="1.0" P_Z="0.2970296189329422" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0" Z="1.0428244528644546">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="0.13192146518376793" CI_START="-0.43192146518376795" EFFECT_SIZE="-0.15" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-0.1" ORDER="21255" SD_1="1.2" SD_2="1.4" SE="0.14384012533267368" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.19437039542261753" CI_END="0.0022922662542405603" CI_START="-0.5396844167206847" DF="1" EFFECT_SIZE="-0.26869607523322203" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" NO="2" P_CHI2="0.6593038059514735" P_Z="0.051969679551537994" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="174" WEIGHT="100.00000000000001" Z="1.9433848236926645">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="0.4431941247388166" CI_START="-0.7431941247388166" EFFECT_SIZE="-0.15" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-0.1" ORDER="21256" SD_1="1.9" SD_2="1.6" SE="0.30265562501038595" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="104" TOTAL_2="45" WEIGHT="20.86928317785198"/>
<CONT_DATA CI_END="0.004633778345441819" CI_START="-0.6046337783454419" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.1" ORDER="21257" SD_1="1.5" SD_2="1.4" SE="0.15542825314564668" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="251" TOTAL_2="129" WEIGHT="79.13071682214803"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5577098504996849" CI_START="-1.057709850499685" DF="0" EFFECT_SIZE="-0.24999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.03" NO="3" P_CHI2="1.0" P_Z="0.5440882965928303" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="0.6066423429550643">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="0.5577098504996849" CI_START="-1.057709850499685" EFFECT_SIZE="-0.24999999999999997" ESTIMABLE="YES" MEAN_1="-0.35" MEAN_2="-0.1" ORDER="21258" SD_1="2.4" SD_2="1.6" SE="0.4121044350155396" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8959487771649639" CI_END="0.09556017615249018" CI_START="-0.8042588309964254" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.35434932742196756" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="0.8264054672428944" P_Q="0.7458423530086846" P_Z="0.12266823487794334" Q="0.5864821251029186" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="668" TOTAL_2="348" UNITS="" WEIGHT="300.0" Z="1.5436702585192439">
<NAME>NPI-NH IRRITABILITY/LABILITY (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.47546214000172726" CI_START="-0.8754621400017272" DF="0" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" NO="1" P_CHI2="1.0" P_Z="0.5616902533860457" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0" Z="0.5803327436042653">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="0.47546214000172726" CI_START="-0.8754621400017272" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-1.1" ORDER="21259" SD_1="3.0" SD_2="3.3" SE="0.3446298734720058" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="262" TOTAL_2="129" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3094666520620455" CI_END="0.11003694615797299" CI_START="-1.1650369301954977" DF="1" EFFECT_SIZE="-0.5274999920187624" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" NO="2" P_CHI2="0.5780077598101141" P_Z="0.10487185498149945" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="174" WEIGHT="100.0" Z="1.621680132226836">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="0.6693455256982679" CI_START="-2.569345525698268" EFFECT_SIZE="-0.95" ESTIMABLE="YES" MEAN_1="-2.65" MEAN_2="-1.7" ORDER="21260" SD_1="4.7" SD_2="4.6" SE="0.8262118786219842" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="104" TOTAL_2="45" WEIGHT="15.499998403752482"/>
<CONT_DATA CI_END="0.2435487507441474" CI_START="-1.1435487507441473" EFFECT_SIZE="-0.44999999999999996" ESTIMABLE="YES" MEAN_1="-1.55" MEAN_2="-1.1" ORDER="21261" SD_1="3.2" SD_2="3.3" SE="0.35385790566294656" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="251" TOTAL_2="129" WEIGHT="84.50000159624751"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.8128521765444314" CI_START="-1.9128521765444315" DF="0" EFFECT_SIZE="-0.050000000000000044" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.03" NO="3" P_CHI2="1.0" P_Z="0.9580454095753029" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="0.052606535537773204">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="1.8128521765444316" CI_START="-1.9128521765444317" EFFECT_SIZE="-0.050000000000000044" ESTIMABLE="YES" MEAN_1="-1.75" MEAN_2="-1.7" ORDER="21262" SD_1="4.7" SD_2="4.6" SE="0.9504522487343502" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03886228653462802" CI_END="0.862410259015993" CI_START="-1.0966609461643286" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.11712534357416778" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" NO="8" P_CHI2="0.8437218259462004" P_Q="0.8437218259462004" P_Z="0.8147074976801212" Q="0.03886228653462802" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="90" UNITS="" WEIGHT="200.0" Z="0.2343574388467609">
<NAME>NPI-NH ABERRANT MOTOR (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.079999454498607" CI_START="-1.4799994544986068" DF="0" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" NO="1" P_CHI2="1.0" P_Z="0.7594184909278386" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="45" WEIGHT="100.0" Z="0.30624450309751083">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="1.079999454498607" CI_START="-1.4799994544986068" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.2" ORDER="21263" SD_1="4.2" SD_2="3.4" SE="0.6530729465414055" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="104" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5216835754482128" CI_START="-1.5216835754482128" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="0.0">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="1.5216835754482128" CI_START="-1.5216835754482128" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-1.2" ORDER="21264" SD_1="4.2" SD_2="3.4" SE="0.7763834373749" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4134905894888714" CI_END="1.0333905986917122" CI_START="-0.7458623836032086" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1437641075442518" ESTIMABLE="YES" I2="29.253154747807173" I2_Q="29.253154747807173" ID="CMP-003.09" NO="9" P_CHI2="0.23447803237102383" P_Q="0.23447803237102383" P_Z="0.7514475670898005" Q="1.4134905894888714" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="90" UNITS="" WEIGHT="200.0" Z="0.3167312078272761">
<NAME>NPI-NH DEPRESSION (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.851792004070073" CI_START="-1.4517920040700731" DF="0" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.01" NO="1" P_CHI2="1.0" P_Z="0.6097015952440127" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="45" WEIGHT="100.0" Z="0.5104994593505131">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="0.851792004070073" CI_START="-1.4517920040700731" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-1.0" ORDER="21265" SD_1="3.5" SD_2="3.2" SE="0.587659780054767" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="104" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2006446377997166" CI_START="-0.6006446377997168" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" NO="2" P_CHI2="1.0" P_Z="0.2629422775615522" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="1.1194639563216986">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="2.2006446377997166" CI_START="-0.6006446377997168" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.0" ORDER="21266" SD_1="3.8" SD_2="3.2" SE="0.7146277425747732" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.011659773780457445" CI_END="0.03719027610586745" CI_START="-1.7535289078264316" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.858169315860282" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" NO="10" P_CHI2="0.9140112154225555" P_Q="0.9140112154225555" P_Z="0.0603054768676215" Q="0.011659773780457445" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="90" UNITS="" WEIGHT="200.0" Z="1.8785535630773929">
<NAME>NPI-NH CARER DISTRESS (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.27395246630804193" CI_START="-2.0739524663080418" DF="0" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.01" NO="1" P_CHI2="1.0" P_Z="0.13294516639722764" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="45" WEIGHT="99.99999999999999" Z="1.5025885942669748">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="0.27395246630804193" CI_START="-2.0739524663080418" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-1.5" ORDER="21267" SD_1="3.0" SD_2="3.5" SE="0.5989663461002493" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="104" TOTAL_2="45" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5843630747634503" CI_START="-2.18436307476345" DF="0" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.02" NO="2" P_CHI2="1.0" P_Z="0.25736967198823846" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="1.1326300276392207">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="0.5843630747634503" CI_START="-2.18436307476345" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-1.5" ORDER="21268" SD_1="3.4" SD_2="3.5" SE="0.706320670013903" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.96937467662326" CI_END="0.4427650659455753" CI_START="-1.9930529890379751" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7751439615461999" ESTIMABLE="YES" I2="16.23913272556738" I2_Q="0.0" ID="CMP-003.11" NO="11" P_CHI2="0.309210585234716" P_Q="0.5650104663764715" P_Z="0.21224050135520467" Q="1.14182264437822" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="857" TOTAL_2="488" UNITS="" WEIGHT="300.0" Z="1.2474283490558267">
<NAME>BPRS TOTAL (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9692031386672612" CI_END="1.9485929047461739" CI_START="-2.034458668014353" DF="1" EFFECT_SIZE="-0.04293288163408953" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.01" NO="1" P_CHI2="0.3248791974973536" P_Z="0.9662974275737757" STUDIES="2" TAU2="0.0" TOTAL_1="329" TOTAL_2="213" WEIGHT="100.0" Z="0.042252479144786505">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="5.107515808068852" CI_START="-2.1475158080688517" EFFECT_SIZE="1.4800000000000004" ESTIMABLE="YES" MEAN_1="-3.25" MEAN_2="-4.73" ORDER="21269" SD_1="13.09" SD_2="11.49" SE="1.8508073804836382" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="89" TOTAL_2="88" WEIGHT="30.14069350302339"/>
<CONT_DATA CI_END="1.6827243278884851" CI_START="-3.0827243278884837" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-6.9" ORDER="21270" SD_1="9.1" SD_2="11.9" SE="1.2156980162304563" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="240" TOTAL_2="125" WEIGHT="69.85930649697661"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.8583488935777788" CI_END="0.5407650356161704" CI_START="-2.6882157582569066" DF="2" EFFECT_SIZE="-1.073725361320368" ESTIMABLE="YES" I2="48.16435591584266" ID="CMP-003.11.02" NO="2" P_CHI2="0.14526821400512713" P_Z="0.19240944070619576" STUDIES="3" TAU2="0.0" TOTAL_1="489" TOTAL_2="242" WEIGHT="100.0" Z="1.3034843944989405">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="-0.480565257996016" CI_START="-9.119434742003985" EFFECT_SIZE="-4.800000000000001" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="-1.4" ORDER="21271" SD_1="9.3" SD_2="11.1" SE="2.2038337316783037" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="77" TOTAL_2="33" WEIGHT="13.97066561960243"/>
<CONT_DATA CI_END="2.697649842330085" CI_START="-2.2976498423300846" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-3.7" ORDER="21272" SD_1="10.4" SD_2="9.3" SE="1.2743345602425493" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="182" TOTAL_2="84" WEIGHT="41.78378973884012"/>
<CONT_DATA CI_END="1.3271727825281059" CI_START="-3.527172782528105" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-6.9" ORDER="21273" SD_1="9.6" SD_2="11.9" SE="1.238376215927096" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="230" TOTAL_2="125" WEIGHT="44.245544641557444"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.5034566612537703" CI_START="-7.703456661253771" DF="0" EFFECT_SIZE="-2.6" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.03" NO="3" P_CHI2="1.0" P_Z="0.31802701728978255" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="33" WEIGHT="100.0" Z="0.9985205514711328">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="2.5034566612537703" CI_START="-7.703456661253771" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-1.4" ORDER="21274" SD_1="10.9" SD_2="11.1" SE="2.6038522654034386" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="39" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.959598429476605" CI_END="1.4662853681900723" CI_START="0.9297595102943645" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1676012872038954" ESTIMABLE="YES" EVENTS_1="324" EVENTS_2="174" I2="44.19392744712459" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.1662185008436405" LOG_CI_START="-0.031629370648753236" LOG_EFFECT_SIZE="0.06729456509744362" METHOD="MH" NO="12" P_CHI2="0.11068666627405044" P_Q="0.4070730928945535" P_Z="0.1824345661008254" Q="1.7975252467642657" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1003" TOTAL_2="564" WEIGHT="300.0" Z="1.3332963650442542">
<NAME>Number of dropouts before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.808271327826197E-4" CI_END="1.4020206854830528" CI_START="0.7072466961059811" DF="1" EFFECT_SIZE="0.9957783376234551" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="95" I2="0.0" ID="CMP-003.12.01" LOG_CI_END="0.14675442128033517" LOG_CI_START="-0.1504290726674264" LOG_EFFECT_SIZE="-0.0018373256935456462" NO="1" P_CHI2="0.97770738700252" P_Z="0.9806653149617266" STUDIES="2" TAU2="0.0" TOTAL_1="383" TOTAL_2="247" WEIGHT="100.0" Z="0.0242348061756925">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="1.6646568242949331" CI_START="0.6020850606019611" EFFECT_SIZE="1.0011318619128466" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="57" LOG_CI_END="0.2213247155141071" LOG_CI_START="-0.22034214870818905" LOG_EFFECT_SIZE="4.912834029590473E-4" ORDER="21275" O_E="0.0" SE="0.2594373023304146" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="120" TOTAL_2="118" VAR="0.06730771384048297" WEIGHT="45.16129032258064"/>
<DICH_DATA CI_END="1.5742326794961259" CI_START="0.6243127863160348" EFFECT_SIZE="0.9913695529145444" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="38" LOG_CI_END="0.19706892367291726" LOG_CI_START="-0.20459777035521923" LOG_EFFECT_SIZE="-0.0037644233411509966" ORDER="21276" O_E="0.0" SE="0.2359410043543294" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="263" TOTAL_2="129" VAR="0.05566815753572969" WEIGHT="54.83870967741935"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.313377253488456" CI_END="1.7758098188196918" CI_START="0.9234998317141543" DF="2" EFFECT_SIZE="1.2806092568915501" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="68" I2="72.6528533852673" ID="CMP-003.12.02" LOG_CI_END="0.24939645296298346" LOG_CI_START="-0.03456317936355661" LOG_EFFECT_SIZE="0.10741663679971343" NO="2" P_CHI2="0.02581793196689941" P_Z="0.1381180696395816" STUDIES="3" TAU2="0.0" TOTAL_1="567" TOTAL_2="270" WEIGHT="100.0" Z="1.4828356956439184">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="2.2718958034744996" CI_START="0.44909808321609196" EFFECT_SIZE="1.0101010101010102" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" LOG_CI_END="0.3563884093392701" LOG_CI_START="-0.34765879853436993" LOG_EFFECT_SIZE="0.0043648054024501125" ORDER="21277" O_E="0.0" SE="0.4135608149948619" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.1710325476992144" WEIGHT="17.957995049057626"/>
<DICH_DATA CI_END="4.263946748186366" CI_START="1.343314062217284" EFFECT_SIZE="2.3932863655200993" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="19" LOG_CI_END="0.629811772211474" LOG_CI_START="0.1281775610993182" LOG_EFFECT_SIZE="0.37899466665539605" ORDER="21278" O_E="0.0" SE="0.2946624187366727" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="204" TOTAL_2="94" VAR="0.08682594101574624" WEIGHT="24.969660189390307"/>
<DICH_DATA CI_END="1.4040370040928152" CI_START="0.5501986498985841" EFFECT_SIZE="0.878919372900336" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="38" LOG_CI_END="0.14737855399146477" LOG_CI_START="-0.259480479635747" LOG_EFFECT_SIZE="-0.056050962822141094" ORDER="21279" O_E="0.0" SE="0.23899101033732173" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="257" TOTAL_2="129" VAR="0.05711670302205382" WEIGHT="57.07234476155207"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.068662736942947" CI_START="0.6962686822161183" DF="0" EFFECT_SIZE="1.683116883116883" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="0.0" ID="CMP-003.12.03" LOG_CI_END="0.6094516914371684" LOG_CI_START="-0.15722313871298316" LOG_EFFECT_SIZE="0.22611427636209264" NO="3" P_CHI2="1.0" P_Z="0.2476408599749711" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="1.1560985717327985">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="4.068662736942948" CI_START="0.6962686822161182" EFFECT_SIZE="1.683116883116883" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.6094516914371685" LOG_CI_START="-0.1572231387129832" LOG_EFFECT_SIZE="0.22611427636209264" ORDER="21280" O_E="0.0" SE="0.4503485903318149" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.20281385281385284" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.19207290731636" CI_END="4.020381842507936" CI_START="1.6133827549659148" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="2.546844073177703" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="25" I2="3.699349195303143" I2_Q="31.85648942689414" ID="CMP-003.13" LOG_CI_END="0.6042673028901449" LOG_CI_START="0.20773741056952763" LOG_EFFECT_SIZE="0.40600235672983626" METHOD="MH" NO="13" P_CHI2="0.3928923563655361" P_Q="0.23050310759604586" P_Z="5.9807566208852785E-5" Q="2.934982338273218" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1003" TOTAL_2="564" WEIGHT="300.0" Z="4.013568773702703">
<NAME>Number of dropouts due to adverse events before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8468782878713538" CI_END="3.1540474610962494" CI_START="0.795957802642959" DF="1" EFFECT_SIZE="1.5844521723819165" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" I2="0.0" ID="CMP-003.13.01" LOG_CI_END="0.49886822416635374" LOG_CI_START="-0.0991099555852955" LOG_EFFECT_SIZE="0.19987913429052911" NO="1" P_CHI2="0.35743703558672635" P_Z="0.19010511232002292" STUDIES="2" TAU2="0.0" TOTAL_1="383" TOTAL_2="247" WEIGHT="100.0" Z="1.3102682262860663">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="2.9949699318895506" CI_START="0.41500372129812435" EFFECT_SIZE="1.114864864864865" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4763924666318412" LOG_CI_START="-0.3819480089939434" LOG_EFFECT_SIZE="0.047222228818948914" ORDER="21281" O_E="0.0" SE="0.5041934442364648" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="120" TOTAL_2="118" VAR="0.2542110292110292" WEIGHT="54.7255359422459"/>
<DICH_DATA CI_END="5.844281948363326" CI_START="0.7924649439015796" EFFECT_SIZE="2.152066115702479" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.7667311596347188" LOG_CI_START="-0.10101994047531028" LOG_EFFECT_SIZE="0.3328556095797042" ORDER="21282" O_E="0.0" SE="0.5097212916418525" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="263" TOTAL_2="129" VAR="0.25981579515303854" WEIGHT="45.2744640577541"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5378364805011184" CI_END="6.592598858297939" CI_START="1.6883573829442644" DF="2" EFFECT_SIZE="3.3362648209033487" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="10" I2="0.0" ID="CMP-003.13.02" LOG_CI_END="0.8190566509101259" LOG_CI_START="0.2274643812780763" LOG_EFFECT_SIZE="0.5232605160941012" NO="2" P_CHI2="0.46351433814756937" P_Z="5.259937308199186E-4" STUDIES="3" TAU2="0.0" TOTAL_1="567" TOTAL_2="270" WEIGHT="100.0" Z="3.467157428254262">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="11.141536199539946" CI_START="0.49303470940809974" EFFECT_SIZE="2.34375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.0469450756659717" LOG_CI_START="-0.3071225055223835" LOG_EFFECT_SIZE="0.36991128507179405" ORDER="21283" O_E="0.0" SE="0.7953859999326672" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.632638888888889" WEIGHT="20.844093553607813"/>
<DICH_DATA CI_END="19.61013256668134" CI_START="1.7474123653463836" EFFECT_SIZE="5.853801169590644" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="3" LOG_CI_END="1.2924805295567994" LOG_CI_START="0.24239540461753034" LOG_EFFECT_SIZE="0.7674379670871648" ORDER="21284" O_E="0.0" SE="0.6168252003945274" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="204" TOTAL_2="94" VAR="0.38047332784174887" WEIGHT="28.59396076148496"/>
<DICH_DATA CI_END="6.28021010179201" CI_START="0.8582994330143373" EFFECT_SIZE="2.3217021276595746" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="5" LOG_CI_END="0.7979741731197744" LOG_CI_START="-0.0663611743664019" LOG_EFFECT_SIZE="0.36580649937668624" ORDER="21285" O_E="0.0" SE="0.5077148616423532" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="257" TOTAL_2="129" VAR="0.2577743807325139" WEIGHT="50.56194568490723"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.515129870754442E-32" CI_END="22.512560963050923" CI_START="0.9408487240062041" DF="0" EFFECT_SIZE="4.602272727272727" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="100.0" ID="CMP-003.13.03" LOG_CI_END="1.3524249018800392" LOG_CI_START="-0.026480199751039414" LOG_EFFECT_SIZE="0.6629723510644999" NO="3" P_CHI2="0.0" P_Z="0.059472172951288566" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="1.884686523090282">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="22.51256096305093" CI_START="0.9408487240062043" EFFECT_SIZE="4.6022727272727275" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3524249018800394" LOG_CI_START="-0.026480199751039313" LOG_EFFECT_SIZE="0.6629723510644999" ORDER="21286" O_E="0.0" SE="0.809975682388432" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.6560606060606061" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.13102721463266884" CI_END="5.5646608636054316" CI_START="0.7772135779207848" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="2.0796465997179765" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="0.745438701545336" LOG_CI_START="-0.10945962088161744" LOG_EFFECT_SIZE="0.3179895403318592" METHOD="MH" NO="14" P_CHI2="0.9365863117700692" P_Q="0.7825097140810735" P_Z="0.14482302387731608" Q="0.07620357139309827" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="723" TOTAL_2="352" WEIGHT="200.0" Z="1.458063561855087">
<NAME>Number of deaths before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.478833896834168" CI_START="0.35557193292720324" DF="0" EFFECT_SIZE="1.736328125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-003.14.01" LOG_CI_END="0.9283361273753771" LOG_CI_START="-0.44907252738661113" LOG_EFFECT_SIZE="0.23963179999438294" NO="1" P_CHI2="1.0" P_Z="0.49526342750566976" STUDIES="1" TAU2="0.0" TOTAL_1="263" TOTAL_2="129" WEIGHT="99.99999999999999" Z="0.6819612987267798">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="8.478833896834162" CI_START="0.35557193292720335" EFFECT_SIZE="1.736328125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9283361273753769" LOG_CI_START="-0.449072527386611" LOG_EFFECT_SIZE="0.23963179999438294" ORDER="21287" O_E="0.0" SE="0.8090966620899966" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="263" TOTAL_2="129" VAR="0.6546374086051743" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.059373759575028176" CI_END="8.127593571538508" CI_START="0.6560846961372713" DF="1" EFFECT_SIZE="2.3091967778234235" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" ID="CMP-003.14.02" LOG_CI_END="0.9099619781520351" LOG_CI_START="-0.18304009249822742" LOG_EFFECT_SIZE="0.36346094282690383" NO="2" P_CHI2="0.8074884931095557" P_Z="0.19240020944266012" STUDIES="2" TAU2="0.0" TOTAL_1="460" TOTAL_2="223" WEIGHT="100.0" Z="1.3035114513623764">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="23.866390215206586" CI_START="0.3361624563645245" EFFECT_SIZE="2.83248730964467" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3777867370558337" LOG_CI_START="-0.4734507915038622" LOG_EFFECT_SIZE="0.4521679727759858" ORDER="21288" O_E="0.0" SE="1.0874260880495232" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="1.1824954969706893" WEIGHT="33.95520388661654"/>
<DICH_DATA CI_END="9.74920279985114" CI_START="0.42693290240678294" EFFECT_SIZE="2.040160642570281" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.9889691045415558" LOG_CI_START="-0.36964037416519" LOG_EFFECT_SIZE="0.3096643651881829" ORDER="21289" O_E="0.0" SE="0.7980539330177251" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="257" TOTAL_2="129" VAR="0.6368900800050596" WEIGHT="66.04479611338346"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2008805083683902" CI_END="1.8797506065543679" CI_START="0.7509874092868345" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1881367926807167" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="0.27410023363500974" LOG_CI_START="-0.12436734411845264" LOG_EFFECT_SIZE="0.07486644475827854" METHOD="MH" NO="15" P_CHI2="0.5485703188261256" P_Q="0.4271490300883193" P_Z="0.461426931691563" Q="0.6305631945953554" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="362" TOTAL_2="188" WEIGHT="200.0" Z="0.7364992464584952">
<NAME>Number of adverse events due to accidental injury before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5554812329398853" CI_END="1.816493528255484" CI_START="0.61191568128637" DF="1" EFFECT_SIZE="1.054296388542964" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="23" I2="0.0" ID="CMP-003.15.01" LOG_CI_END="0.2592338549111263" LOG_CI_START="-0.2133084171925052" LOG_EFFECT_SIZE="0.02296271885931054" NO="1" P_CHI2="0.4560867756314104" P_Z="0.8489291142689742" STUDIES="2" TAU2="0.0" TOTAL_1="309" TOTAL_2="141" WEIGHT="100.0" Z="0.19048497714717555">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="1.849313884250054" CI_START="0.3906854353678272" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.2670106302659599" LOG_CI_START="-0.40817277883737446" LOG_EFFECT_SIZE="-0.07058107428570728" ORDER="21290" O_E="0.0" SE="0.39660607671907616" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.15729638009049773" WEIGHT="53.42465753424658"/>
<DICH_DATA CI_END="2.785105415279185" CI_START="0.5962372801316353" EFFECT_SIZE="1.2886363636363636" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="10" LOG_CI_END="0.4448416377171605" LOG_CI_START="-0.22458087290372233" LOG_EFFECT_SIZE="0.11013038240671913" ORDER="21291" O_E="0.0" SE="0.3932220964335767" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.1546236171236171" WEIGHT="46.57534246575342"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6964458914727434" CI_START="0.6797025318727776" DF="0" EFFECT_SIZE="1.5850815850815851" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" ID="CMP-003.15.02" LOG_CI_END="0.5677843533830425" LOG_CI_START="-0.16768111234001834" LOG_EFFECT_SIZE="0.2000516205215121" NO="2" P_CHI2="1.0" P_Z="0.28631195790499575" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="1.0662471306808592">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="3.6964458914727434" CI_START="0.6797025318727776" EFFECT_SIZE="1.5850815850815851" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.5677843533830425" LOG_CI_START="-0.16768111234001834" LOG_EFFECT_SIZE="0.2000516205215121" ORDER="21292" O_E="0.0" SE="0.43201605517849634" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.1866378719319896" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2592086477676783" CI_END="5.891580615908618" CI_START="2.2198487803890123" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="3.6164095515840424" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="22" I2="7.953116102131646" I2_Q="31.345326439647017" ID="CMP-003.16" LOG_CI_END="0.7702318246133819" LOG_CI_START="0.34632339063106216" LOG_EFFECT_SIZE="0.5582776076222221" METHOD="MH" NO="16" P_CHI2="0.35336057067799875" P_Q="0.23303540956797641" P_Z="2.437326112730784E-7" Q="2.9131301574711284" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="482" TOTAL_2="306" WEIGHT="300.0" Z="5.162454514223588">
<NAME>Number of adverse events due to somnolence before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.151331260158809" CI_START="0.868678763801333" DF="0" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" I2="0.0" ID="CMP-003.16.01" LOG_CI_END="0.7119194784057762" LOG_CI_START="-0.06114079535892439" LOG_EFFECT_SIZE="0.3253893415234259" NO="1" P_CHI2="1.0" P_Z="0.09895528451285654" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="118" WEIGHT="100.0" Z="1.6499396282086882">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="5.151331260158809" CI_START="0.868678763801333" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.7119194784057762" LOG_CI_START="-0.06114079535892439" LOG_EFFECT_SIZE="0.3253893415234259" ORDER="21293" O_E="0.0" SE="0.45409943151945664" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="120" TOTAL_2="118" VAR="0.2062062937062937" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.33581044266889903" CI_END="7.251745697081959" CI_START="1.9047663985118872" DF="1" EFFECT_SIZE="3.7165685160312703" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="11" I2="0.0" ID="CMP-003.16.02" LOG_CI_END="0.8604425659294693" LOG_CI_START="0.27984172118851525" LOG_EFFECT_SIZE="0.5701421435589923" NO="2" P_CHI2="0.5622577195233635" P_Z="1.1844810934935745E-4" STUDIES="2" TAU2="0.0" TOTAL_1="309" TOTAL_2="141" WEIGHT="100.00000000000001" Z="3.8493160234469346">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="17.469267925490087" CI_START="1.4383397527809318" EFFECT_SIZE="5.012658227848101" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.2422747056365266" LOG_CI_START="0.1578614836336152" LOG_EFFECT_SIZE="0.7000680946350709" ORDER="21294" O_E="0.0" SE="0.636989694536532" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.40575587094574433" WEIGHT="26.93460068188863"/>
<DICH_DATA CI_END="7.168407945324286" CI_START="1.463324807365192" EFFECT_SIZE="3.238782051282051" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="8" LOG_CI_END="0.8554227125248753" LOG_CI_START="0.1653407351408847" LOG_EFFECT_SIZE="0.5103817238328799" ORDER="21295" O_E="0.0" SE="0.40535756947623597" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.16431475913168145" WEIGHT="73.06539931811139"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.99241809675754" CI_START="2.239756108910492" DF="0" EFFECT_SIZE="8.196078431372548" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" I2="0.0" ID="CMP-003.16.03" LOG_CI_END="1.4770114815562354" LOG_CI_START="0.3502007297979621" LOG_EFFECT_SIZE="0.9136061056770988" NO="3" P_CHI2="1.0" P_Z="0.001481742566501257" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="3.178235671587096">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="29.99241809675754" CI_START="2.239756108910492" EFFECT_SIZE="8.196078431372548" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="1.4770114815562354" LOG_CI_START="0.3502007297979621" LOG_EFFECT_SIZE="0.9136061056770988" ORDER="21296" O_E="0.0" SE="0.6618942133859887" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.4381039497138568" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.911540296796697" CI_END="4.045888918375785" CI_START="0.8534345573066453" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8581984334203654" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="0.6070139548562674" LOG_CI_START="-0.06882977565091794" LOG_EFFECT_SIZE="0.2690920896026747" METHOD="MH" NO="17" P_CHI2="0.33970619432504634" P_Q="0.3397769205526372" P_Z="0.1185832707154167" Q="0.9112733420065344" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="159" TOTAL_2="94" WEIGHT="200.0" Z="1.5607477892857673">
<NAME>Number of adverse events due to pain before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7806262657361756" CI_START="0.4321905250117225" DF="0" EFFECT_SIZE="1.2782608695652173" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" I2="0.0" ID="CMP-003.17.01" LOG_CI_END="0.5775637472512327" LOG_CI_START="-0.36432475846210394" LOG_EFFECT_SIZE="0.1066194943945644" NO="1" P_CHI2="1.0" P_Z="0.6572404517182483" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="47" WEIGHT="100.0" Z="0.4437263387240368">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="3.7806262657361756" CI_START="0.4321905250117225" EFFECT_SIZE="1.2782608695652173" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.5775637472512327" LOG_CI_START="-0.36432475846210394" LOG_EFFECT_SIZE="0.1066194943945644" ORDER="21297" O_E="0.0" SE="0.5532699706793118" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.30610766045548654" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.355430002022862" CI_START="0.8919828181428893" DF="0" EFFECT_SIZE="2.73" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-003.17.02" LOG_CI_END="0.9219688052408149" LOG_CI_START="-0.04964351115930293" LOG_EFFECT_SIZE="0.436162647040756" NO="2" P_CHI2="1.0" P_Z="0.07846218379050238" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="1.759679380699612">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="8.355430002022866" CI_START="0.891982818142889" EFFECT_SIZE="2.73" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.9219688052408151" LOG_CI_START="-0.049643511159303044" LOG_EFFECT_SIZE="0.436162647040756" ORDER="21298" O_E="0.0" SE="0.5707298842119631" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.3257326007326008" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1526928848161817" CI_END="13.974998784880976" CI_START="2.1452849090835833" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="5.47543185490118" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="1.1453517787967786" LOG_CI_START="0.3314849777450199" LOG_EFFECT_SIZE="0.7384183782708993" METHOD="MH" NO="18" P_CHI2="0.56194791015783" P_Q="0.5704511140058091" P_Z="3.757765204696806E-4" Q="0.3219285050120411" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="362" TOTAL_2="188" WEIGHT="200.0" Z="3.556536340008285">
<NAME>Number of adverse events due to abnormal gait before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.754021895052915" CI_END="13.572628027085283" CI_START="1.6702701774395863" DF="1" EFFECT_SIZE="4.7612977036855435" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="4" I2="0.0" ID="CMP-003.18.01" LOG_CI_END="1.1326639469344173" LOG_CI_START="0.2227867268844967" LOG_EFFECT_SIZE="0.6777253369094569" NO="1" P_CHI2="0.3852058887849329" P_Z="0.0035028697560526225" STUDIES="2" TAU2="0.0" TOTAL_1="309" TOTAL_2="141" WEIGHT="100.0" Z="2.9197725198130176">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="72.72455297238925" CI_START="1.2173466610258716" EFFECT_SIZE="9.409090909090908" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="1.861681060380131" LOG_CI_START="0.08541426888929197" LOG_EFFECT_SIZE="0.9735476646347114" ORDER="21299" O_E="0.0" SE="1.0433879059841429" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="1.0886583223539745" WEIGHT="23.731306692816865"/>
<DICH_DATA CI_END="11.447290305361548" CI_START="0.9600534007203513" EFFECT_SIZE="3.31511839708561" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" LOG_CI_END="1.0587026967458388" LOG_CI_START="-0.017704609675873253" LOG_EFFECT_SIZE="0.5204990435349829" ORDER="21300" O_E="0.0" SE="0.6322869800942142" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.39978682519666126" WEIGHT="76.26869330718313"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="77.36963061818321" CI_START="1.1442602352909625" DF="0" EFFECT_SIZE="9.409090909090908" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-003.18.02" LOG_CI_END="1.8885705234329173" LOG_CI_START="0.058524805836505614" LOG_EFFECT_SIZE="0.9735476646347114" NO="2" P_CHI2="1.0" P_Z="0.03703997646612746" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="2.0853231605855647">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="77.36963061818321" CI_START="1.1442602352909625" EFFECT_SIZE="9.409090909090908" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.8885705234329173" LOG_CI_START="0.058524805836505614" LOG_EFFECT_SIZE="0.9735476646347114" ORDER="21301" O_E="0.0" SE="1.074977913388534" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="1.1555775142731666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.180188389048207" CI_END="1.741296567353916" CI_START="0.4930398977403576" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9265682281968287" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" I2="28.232899554006128" I2_Q="43.09017147628053" ID="CMP-003.19" LOG_CI_END="0.2408727438896891" LOG_CI_START="-0.30711793535283743" LOG_EFFECT_SIZE="-0.033122595731574174" METHOD="MH" NO="19" P_CHI2="0.24265303438289276" P_Q="0.18497854799495572" P_Z="0.8127071918295337" Q="1.757165723286637" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="885" TOTAL_2="446" WEIGHT="200.0" Z="0.23693503253778517">
<NAME>Number of adverse events due to anorexia before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.19.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="264" TOTAL_2="129" WEIGHT="0.0" Z="0.0">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21302" O_E="0.0" SE="0.0" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="264" TOTAL_2="129" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.213064098704735" CI_END="1.4732628294830263" CI_START="0.3410511586164102" DF="2" EFFECT_SIZE="0.7088427152349644" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" I2="9.627561118967932" ID="CMP-003.19.02" LOG_CI_END="0.16828023171147585" LOG_CI_START="-0.46718047074840585" LOG_EFFECT_SIZE="-0.14945011951846504" NO="2" P_CHI2="0.330704117893843" P_Z="0.3565787124681743" STUDIES="3" TAU2="0.0" TOTAL_1="568" TOTAL_2="270" WEIGHT="99.99999999999999" Z="0.9219039056467558">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="1.4585630939855725" CI_START="0.067214004096632" EFFECT_SIZE="0.3131067961165049" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.16392522041497307" LOG_CI_START="-1.1725402318827445" LOG_EFFECT_SIZE="-0.5043075057338856" ORDER="21303" O_E="0.0" SE="0.7850464222903633" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.6162978851508993" WEIGHT="33.08323466353618"/>
<DICH_DATA CI_END="1.8397958984856417" CI_START="0.294053792414767" EFFECT_SIZE="0.7355263157894737" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.2647696463367154" LOG_CI_START="-0.5315732151254515" LOG_EFFECT_SIZE="-0.13340178439436806" ORDER="21304" O_E="0.0" SE="0.4677757387836162" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.21881414179455796" WEIGHT="62.8766389898334"/>
<DICH_DATA CI_END="68.93557012591432" CI_START="0.18118302497651417" EFFECT_SIZE="3.53411306042885" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8384433717367883" LOG_CI_START="-0.7418824937694033" LOG_EFFECT_SIZE="0.5482804389836924" ORDER="21305" O_E="0.0" SE="1.5156961862173686" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="259" TOTAL_2="129" VAR="2.2973349289138763" WEIGHT="4.040126346630401"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.811479135899882" CI_START="0.5362044874750724" DF="0" EFFECT_SIZE="1.9111111111111112" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-003.19.03" LOG_CI_END="0.8332414306802876" LOG_CI_START="-0.27066955574383944" LOG_EFFECT_SIZE="0.28128593746822406" NO="3" P_CHI2="1.0" P_Z="0.31787653594101906" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="0.9988310897804388">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="6.811479135899885" CI_START="0.5362044874750723" EFFECT_SIZE="1.9111111111111112" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8332414306802878" LOG_CI_START="-0.27066955574383955" LOG_EFFECT_SIZE="0.28128593746822406" ORDER="21306" O_E="0.0" SE="0.6484427778730446" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.4204780361757106" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.31478191033301434" CI_END="1.7137609288523552" CI_START="0.3833125346361827" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8104974061641746" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="0.23395023735271853" LOG_CI_START="-0.41644697872551034" LOG_EFFECT_SIZE="-0.09124837068639588" METHOD="MH" NO="20" P_CHI2="0.574760647914557" P_Q="0.5748791795426402" P_Z="0.5823525199018661" Q="0.314586837842706" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="159" TOTAL_2="94" WEIGHT="200.0" Z="0.5499516780581831">
<NAME>Number of adverse events due to ecchymosis before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8295677505624952" CI_START="0.23928394817614052" DF="0" EFFECT_SIZE="0.6616541353383458" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" ID="CMP-003.20.01" LOG_CI_END="0.2623484964411765" LOG_CI_START="-0.6210864340750109" LOG_EFFECT_SIZE="-0.1793689688169172" NO="1" P_CHI2="1.0" P_Z="0.42609834285280324" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="47" WEIGHT="100.0" Z="0.7958859372242223">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="1.8295677505624952" CI_START="0.23928394817614052" EFFECT_SIZE="0.6616541353383458" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.2623484964411765" LOG_CI_START="-0.6210864340750109" LOG_EFFECT_SIZE="-0.1793689688169172" ORDER="21307" O_E="0.0" SE="0.5189340512586426" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.26929254955570747" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.052356708876981" CI_START="0.33809874887087754" DF="0" EFFECT_SIZE="1.0158730158730158" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-003.20.02" LOG_CI_END="0.4846352853917937" LOG_CI_START="-0.4709564363311827" LOG_EFFECT_SIZE="0.006839424530305442" NO="2" P_CHI2="1.0" P_Z="0.9776175120593534" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="0.028055968777562362">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="3.052356708876981" CI_START="0.33809874887087754" EFFECT_SIZE="1.0158730158730158" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4846352853917937" LOG_CI_START="-0.4709564363311827" LOG_EFFECT_SIZE="0.006839424530305442" ORDER="21308" O_E="0.0" SE="0.5613193075953874" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.31507936507936507" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3880929497687878" CI_END="17.447492094138262" CI_START="1.8531218225251915" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="5.686152332463787" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="1.241733010209132" LOG_CI_START="0.26790397037739744" LOG_EFFECT_SIZE="0.7548184902932646" METHOD="MH" NO="21" P_CHI2="0.942691090128187" P_Q="0.8933642517647675" P_Z="0.002378769710426682" Q="0.22552177492310138" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="482" TOTAL_2="306" WEIGHT="300.0" Z="3.038350665934793">
<NAME>Number of adverse events due to fever before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="171.94199445821442" CI_START="0.48740267543835275" DF="0" EFFECT_SIZE="9.15450643776824" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.21.01" LOG_CI_END="2.2353819600733615" LOG_CI_START="-0.3121120912265422" LOG_EFFECT_SIZE="0.9616349344234097" NO="1" P_CHI2="1.0" P_Z="0.13895199169594524" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="118" WEIGHT="100.0" Z="1.4797049961970923">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="171.94199445821442" CI_START="0.487402675438353" EFFECT_SIZE="9.15450643776824" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2353819600733615" LOG_CI_START="-0.31211209122654204" LOG_EFFECT_SIZE="0.9616349344234097" ORDER="21309" O_E="0.0" SE="1.4964106160324937" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="120" TOTAL_2="118" VAR="2.2392447317747473" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.14385172362814957" CI_END="19.839159418513024" CI_START="1.0441087964058138" DF="1" EFFECT_SIZE="4.551290021759402" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" I2="0.0" ID="CMP-003.21.02" LOG_CI_END="1.2975232672317165" LOG_CI_START="0.01874575462112455" LOG_EFFECT_SIZE="0.6581345109264206" NO="2" P_CHI2="0.7044816401467818" P_Z="0.043651004936922075" STUDIES="2" TAU2="0.0" TOTAL_1="309" TOTAL_2="141" WEIGHT="100.0" Z="2.017426683966827">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="46.5491409586232" CI_START="0.7408167232127651" EFFECT_SIZE="5.872340425531915" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.667911670701419" LOG_CI_START="-0.1302892224424184" LOG_EFFECT_SIZE="0.7688112241295002" ORDER="21310" O_E="0.0" SE="1.0562721058706683" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="1.1157107616404565" WEIGHT="48.21262045383898"/>
<DICH_DATA CI_END="27.38973796695518" CI_START="0.4027744905194658" EFFECT_SIZE="3.3214285714285716" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4375878774511213" LOG_CI_START="-0.3949380430276895" LOG_EFFECT_SIZE="0.5213249172117159" ORDER="21311" O_E="0.0" SE="1.0764347968388575" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="1.1587118718455125" WEIGHT="51.78737954616101"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="59.185928187245025" CI_START="0.827899494031418" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-003.21.03" LOG_CI_END="1.772218462853446" LOG_CI_START="-0.08202238282493242" LOG_EFFECT_SIZE="0.8450980400142568" NO="3" P_CHI2="1.0" P_Z="0.07400767912808381" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="1.7865658883459112">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="59.185928187245025" CI_START="0.8278994940314177" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.772218462853446" LOG_CI_START="-0.0820223828249326" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="21312" O_E="0.0" SE="1.0891902513916971" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="1.1863354037267082" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.031795137004437" CI_END="1.314783878184616" CI_START="0.6567225986345959" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9292191803467431" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="63" I2="37.747416178933875" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="0.11885437014461406" LOG_CI_START="-0.18261803884650402" LOG_EFFECT_SIZE="-0.03188183435094496" METHOD="MH" NO="22" P_CHI2="0.15449213942887075" P_Q="0.5020627311621595" P_Z="0.6784735270758009" Q="1.3780606163586955" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1005" TOTAL_2="564" WEIGHT="300.0" Z="0.41454703797298426">
<NAME>Number of adverse events due to agitation before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.516946214573543" CI_END="1.2571828180830276" CI_START="0.42970978124089154" DF="1" EFFECT_SIZE="0.7349991522024126" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" I2="77.8611488271969" ID="CMP-003.22.01" LOG_CI_END="0.09939843688362618" LOG_CI_START="-0.36682476060374336" LOG_EFFECT_SIZE="-0.13371316186005858" NO="1" P_CHI2="0.03356073265644066" P_Z="0.26091197470431904" STUDIES="2" TAU2="0.0" TOTAL_1="384" TOTAL_2="247" WEIGHT="100.0" Z="1.1242382743590935">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="1.9323709958995228" CI_START="0.5497630158745896" EFFECT_SIZE="1.030701754385965" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.286090510280368" LOG_CI_START="-0.25982447973780304" LOG_EFFECT_SIZE="0.013133015271282474" ORDER="21313" O_E="0.0" SE="0.32067316745945673" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="120" TOTAL_2="118" VAR="0.10283128032848078" WEIGHT="61.761020334735306"/>
<DICH_DATA CI_END="0.7845159746953819" CI_START="0.08445321019172969" EFFECT_SIZE="0.2574002574002574" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="-0.1053982086717936" LOG_CI_START="-1.0733838376020723" LOG_EFFECT_SIZE="-0.589391023136933" ORDER="21314" O_E="0.0" SE="0.5685995500397871" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="264" TOTAL_2="129" VAR="0.32330544830544833" WEIGHT="38.2389796652647"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2567670831833553" CI_END="1.7492592092144816" CI_START="0.6542757947275263" DF="2" EFFECT_SIZE="1.0698121140150028" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="26" I2="11.377651025517627" ID="CMP-003.22.02" LOG_CI_END="0.24285416899292714" LOG_CI_START="-0.18423914635411834" LOG_EFFECT_SIZE="0.029307511319404417" NO="2" P_CHI2="0.3235561806314964" P_Z="0.7879382748187648" STUDIES="3" TAU2="0.0" TOTAL_1="568" TOTAL_2="270" WEIGHT="100.00000000000001" Z="0.26898883498495846">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="4.131571372885023" CI_START="0.3750073921662105" EFFECT_SIZE="1.2447368421052631" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.6161152595933432" LOG_CI_START="-0.42596017135134046" LOG_EFFECT_SIZE="0.0950775441210014" ORDER="21315" O_E="0.0" SE="0.6121202664934833" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.37469122065205296" WEIGHT="16.021308005095715"/>
<DICH_DATA CI_END="2.756365053215816" CI_START="0.6997354394586082" EFFECT_SIZE="1.3887859128822984" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="13" LOG_CI_END="0.44033673504190224" LOG_CI_START="-0.15506612984439652" LOG_EFFECT_SIZE="0.14263530259875284" ORDER="21316" O_E="0.0" SE="0.34974259012592646" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.1223198793479918" WEIGHT="46.87063042064923"/>
<DICH_DATA CI_END="1.4655528759987875" CI_START="0.2386481048050567" EFFECT_SIZE="0.5913978494623656" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.1660014920615484" LOG_CI_START="-0.622242010180931" LOG_EFFECT_SIZE="-0.22812025905969124" ORDER="21317" O_E="0.0" SE="0.46301813508549694" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="259" TOTAL_2="129" VAR="0.21438579341805147" WEIGHT="37.10806157425506"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.194297012127583" CI_START="0.3625742307673144" DF="0" EFFECT_SIZE="1.372340425531915" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-003.22.03" LOG_CI_END="0.7155267791477554" LOG_CI_START="-0.44060306574865465" LOG_EFFECT_SIZE="0.13746185669955033" NO="3" P_CHI2="1.0" P_Z="0.6411634536794735" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="0.4660727159123979">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="5.194297012127583" CI_START="0.3625742307673144" EFFECT_SIZE="1.372340425531915" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7155267791477554" LOG_CI_START="-0.44060306574865465" LOG_EFFECT_SIZE="0.13746185669955033" ORDER="21318" O_E="0.0" SE="0.6791163938271818" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.46119907636483587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.544903578010187" CI_END="2.721531201044643" CI_START="0.31926556232455144" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9321433308699525" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="60.70578042167391" I2_Q="60.65536392049851" ID="CMP-003.23" LOG_CI_END="0.43481331765873027" LOG_CI_START="-0.49584792423853685" LOG_EFFECT_SIZE="-0.0305173032899033" METHOD="MH" NO="23" P_CHI2="0.11065099772484388" P_Q="0.11087971551504272" P_Z="0.8977229763229351" Q="2.541642520162993" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="159" TOTAL_2="94" WEIGHT="200.0" Z="0.12853831804913335">
<NAME>Number of adverse events due to weight loss before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7470307708646906" CI_START="0.04553607585709395" DF="0" EFFECT_SIZE="0.28205128205128205" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.23.01" LOG_CI_END="0.24230055438135656" LOG_CI_START="-1.341644398117905" LOG_EFFECT_SIZE="-0.5496719218682742" NO="1" P_CHI2="1.0" P_Z="0.17372821426147364" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="47" WEIGHT="100.0" Z="1.360321478943864">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="1.7470307708646904" CI_START="0.04553607585709395" EFFECT_SIZE="0.28205128205128205" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.2423005543813565" LOG_CI_START="-1.341644398117905" LOG_EFFECT_SIZE="-0.5496719218682742" ORDER="21319" O_E="0.0" SE="0.9304171057520334" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.8656759906759905" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.265783822218129E-32" CI_END="7.946983001022313" CI_START="0.44113076228174364" DF="0" EFFECT_SIZE="1.8723404255319152" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="99.99999999999999" ID="CMP-003.23.02" LOG_CI_END="0.9002022840411664" LOG_CI_START="-0.3554326556122641" LOG_EFFECT_SIZE="0.2723848142144512" NO="2" P_CHI2="0.0" P_Z="0.3951306756924755" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="0.850349745672593">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="7.946983001022313" CI_START="0.44113076228174364" EFFECT_SIZE="1.872340425531915" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9002022840411664" LOG_CI_START="-0.3554326556122641" LOG_EFFECT_SIZE="0.27238481421445115" ORDER="21320" O_E="0.0" SE="0.7375661790456186" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.5440038684719535" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18633125424913233" CI_END="4.245656765861039" CI_START="0.5826599144508975" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5728235781499675" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.24" LOG_CI_END="0.627944881323656" LOG_CI_START="-0.23458485925944858" LOG_EFFECT_SIZE="0.1966800110321037" METHOD="MH" NO="24" P_CHI2="0.6659877936820677" P_Q="0.6664994770428361" P_Z="0.37140261712732003" Q="0.18572413309096802" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="159" TOTAL_2="94" WEIGHT="200.0" Z="0.8938491508507521">
<NAME>Number of adverse events due to increased cough before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.972822672135654" CI_START="0.502760335938288" DF="0" EFFECT_SIZE="1.872340425531915" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-003.24.01" LOG_CI_END="0.8434086206771356" LOG_CI_START="-0.2986389922482333" LOG_EFFECT_SIZE="0.27238481421445115" NO="1" P_CHI2="1.0" P_Z="0.34982696920588274" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="47" WEIGHT="100.0" Z="0.9349249886849424">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="6.972822672135654" CI_START="0.502760335938288" EFFECT_SIZE="1.872340425531915" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.8434086206771356" LOG_CI_START="-0.2986389922482333" LOG_EFFECT_SIZE="0.27238481421445115" ORDER="21321" O_E="0.0" SE="0.6708444210592198" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.4500322372662798" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.648322466457371" CI_START="0.2537880584173609" DF="0" EFFECT_SIZE="1.1972789115646258" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.24.02" LOG_CI_END="0.7519194829101278" LOG_CI_START="-0.5955288167781803" LOG_EFFECT_SIZE="0.07819533306597372" NO="2" P_CHI2="1.0" P_Z="0.8200490573538743" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.00000000000001" Z="0.22748188053504487">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="5.648322466457371" CI_START="0.2537880584173609" EFFECT_SIZE="1.1972789115646258" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7519194829101278" LOG_CI_START="-0.5955288167781803" LOG_EFFECT_SIZE="0.07819533306597372" ORDER="21322" O_E="0.0" SE="0.7914978012135676" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.6264687693259121" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.704478482986036" CI_END="4.500564970637085" CI_START="0.7675486594005062" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8586023269536098" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.25" LOG_CI_END="0.6532670356039725" LOG_CI_START="-0.1148940825097183" LOG_EFFECT_SIZE="0.2691864765471271" METHOD="MH" NO="25" P_CHI2="0.4264592219251081" P_Q="0.5194441555585054" P_Z="0.1695475043015256" Q="0.4149968424487258" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="362" TOTAL_2="188" WEIGHT="200.0" Z="1.3736592147573885">
<NAME>Number of adverse events due to peripheral oedema before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.475891325661948" CI_END="6.724159125562355" CI_START="0.7443130148473425" DF="1" EFFECT_SIZE="2.2371587228135126" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="4" I2="32.244333806115925" ID="CMP-003.25.01" LOG_CI_END="0.8276379823605253" LOG_CI_START="-0.12824438699097637" LOG_EFFECT_SIZE="0.34969679768477446" NO="1" P_CHI2="0.2244187986716778" P_Z="0.15155705568021174" STUDIES="2" TAU2="0.0" TOTAL_1="309" TOTAL_2="141" WEIGHT="100.0" Z="1.4340532913817385">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="4.729386957039688" CI_START="0.3030999165639527" EFFECT_SIZE="1.1972789115646258" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6748048493150344" LOG_CI_START="-0.5184141831830869" LOG_EFFECT_SIZE="0.07819533306597372" ORDER="21323" O_E="0.0" SE="0.7009027662188666" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.4912646876932591" WEIGHT="74.82646922720963"/>
<DICH_DATA CI_END="41.88954363420536" CI_START="0.6777088875335402" EFFECT_SIZE="5.328125" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.622105628964085" LOG_CI_START="-0.16895681894686373" LOG_EFFECT_SIZE="0.7265744050086106" ORDER="21324" O_E="0.0" SE="1.052078947804996" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="1.1068701124144673" WEIGHT="25.17353077279038"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.648322466457371" CI_START="0.2537880584173609" DF="0" EFFECT_SIZE="1.1972789115646258" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.25.02" LOG_CI_END="0.7519194829101278" LOG_CI_START="-0.5955288167781803" LOG_EFFECT_SIZE="0.07819533306597372" NO="2" P_CHI2="1.0" P_Z="0.8200490573538743" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.00000000000001" Z="0.22748188053504487">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="5.648322466457371" CI_START="0.2537880584173609" EFFECT_SIZE="1.1972789115646258" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7519194829101278" LOG_CI_START="-0.5955288167781803" LOG_EFFECT_SIZE="0.07819533306597372" ORDER="21325" O_E="0.0" SE="0.7914978012135676" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="0.6264687693259121" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.840817604480502" CI_END="2.004877511432538" CI_START="0.499878342173417" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0010968218287695" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.26" LOG_CI_END="0.30208784442057635" LOG_CI_START="-0.30113567916725864" LOG_EFFECT_SIZE="4.760826266588504E-4" METHOD="MH" NO="26" P_CHI2="0.3983562111396388" P_Q="0.47775577503521316" P_Z="0.9975315660003556" Q="0.5039818902466366" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="362" TOTAL_2="188" WEIGHT="200.0" Z="0.003093728163539387">
<NAME>Number of adverse events due to nervousness before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3938032351416645" CI_END="2.265112735753102" CI_START="0.5211605963676573" DF="1" EFFECT_SIZE="1.0865024179471772" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="11" I2="28.253861464286157" ID="CMP-003.26.01" LOG_CI_END="0.3550898219325464" LOG_CI_START="-0.28302842762369707" LOG_EFFECT_SIZE="0.036030697154424716" NO="1" P_CHI2="0.23776408204873656" P_Z="0.8248318014206706" STUDIES="2" TAU2="0.0" TOTAL_1="309" TOTAL_2="141" WEIGHT="99.99999999999999" Z="0.22133474104416112">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="11.141536199539946" CI_START="0.49303470940809974" EFFECT_SIZE="2.34375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.0469450756659717" LOG_CI_START="-0.3071225055223835" LOG_EFFECT_SIZE="0.36991128507179405" ORDER="21326" O_E="0.0" SE="0.7953859999326672" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="47" VAR="0.632638888888889" WEIGHT="18.130311614730875"/>
<DICH_DATA CI_END="1.9019128235690335" CI_START="0.3433357114460983" EFFECT_SIZE="0.8080808080808081" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.27919060665471157" LOG_CI_START="-0.46428102186592424" LOG_EFFECT_SIZE="-0.09254520760560633" ORDER="21327" O_E="0.0" SE="0.43671891483693687" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.19072341057635173" WEIGHT="81.86968838526911"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.93163253593628" CI_START="0.037963621938946854" DF="0" EFFECT_SIZE="0.4326923076923077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.26.02" LOG_CI_END="0.6929907091320088" LOG_CI_START="-1.4206323601788822" LOG_EFFECT_SIZE="-0.36382082552343664" NO="2" P_CHI2="1.0" P_Z="0.49983934736715463" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="47" WEIGHT="100.0" Z="0.6747425548151803">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="4.93163253593628" CI_START="0.037963621938946854" EFFECT_SIZE="0.4326923076923077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6929907091320088" LOG_CI_START="-1.4206323601788822" LOG_EFFECT_SIZE="-0.36382082552343664" ORDER="21328" O_E="0.0" SE="1.2415526535161492" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="53" TOTAL_2="47" VAR="1.5414529914529913" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7114962712390798" CI_END="8.364249618622782" CI_START="1.4520234103531318" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="3.4849800941006155" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.27" LOG_CI_END="0.9224269852136401" LOG_CI_START="0.16197361836491864" LOG_EFFECT_SIZE="0.5422003017892794" METHOD="MH" NO="27" P_CHI2="0.398948008289681" P_Q="0.41215497864305395" P_Z="0.005191682447866736" Q="0.6725768397941888" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="323" TOTAL_2="212" WEIGHT="200.0" Z="2.794893441835835">
<NAME>Number of adverse events due to hostility before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.1299552157474855" CI_START="0.9973570514728122" DF="0" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" I2="0.0" ID="CMP-003.27.01" LOG_CI_END="0.8530868019956488" LOG_CI_START="-0.0011493374510864996" LOG_EFFECT_SIZE="0.4259687322722811" NO="1" P_CHI2="1.0" P_Z="0.05061968381824063" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="118" WEIGHT="100.0" Z="1.9546898925034624">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="7.1299552157474855" CI_START="0.9973570514728122" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.8530868019956488" LOG_CI_START="-0.0011493374510864996" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="21329" O_E="0.0" SE="0.5017825368480995" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="120" TOTAL_2="118" VAR="0.2517857142857143" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.186161489951644" CI_START="0.8922770283473593" DF="0" EFFECT_SIZE="6.888888888888889" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" I2="0.0" ID="CMP-003.27.02" LOG_CI_END="1.725798647889906" LOG_CI_START="-0.049500287772047596" LOG_EFFECT_SIZE="0.838149180058929" NO="2" P_CHI2="1.0" P_Z="0.06421769669965768" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.850665455364283">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="53.186161489951644" CI_START="0.8922770283473593" EFFECT_SIZE="6.888888888888889" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.725798647889906" LOG_CI_START="-0.049500287772047596" LOG_EFFECT_SIZE="0.838149180058929" ORDER="21330" O_E="0.0" SE="1.042819382679292" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="1.0874722648916197" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.798094130046784" CI_END="2.853925966902886" CI_START="0.8827223843202137" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5872064560660932" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="19" I2="44.38555894879756" I2_Q="43.92153740452794" ID="CMP-003.28" LOG_CI_END="0.4554427029823501" LOG_CI_START="-0.0541758603125255" LOG_EFFECT_SIZE="0.20063342133491235" METHOD="MH" NO="28" P_CHI2="0.17994321893045395" P_Q="0.18175507404912483" P_Z="0.12277026706071234" Q="1.783215790371441" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="323" TOTAL_2="212" WEIGHT="200.0" Z="1.5432494349070442">
<NAME>Number of adverse events due to confusion before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3781493255389714" CI_START="0.4785167160189661" DF="0" EFFECT_SIZE="1.0667634252539913" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-003.28.01" LOG_CI_END="0.37623912077111415" LOG_CI_START="-0.320102886417976" LOG_EFFECT_SIZE="0.028068117176569075" NO="1" P_CHI2="1.0" P_Z="0.8744534487255327" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="118" WEIGHT="99.99999999999999" Z="0.15800425139363145">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="2.3781493255389714" CI_START="0.4785167160189661" EFFECT_SIZE="1.0667634252539913" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.37623912077111415" LOG_CI_START="-0.320102886417976" LOG_EFFECT_SIZE="0.028068117176569075" ORDER="21331" O_E="0.0" SE="0.40903474197139883" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="120" TOTAL_2="118" VAR="0.1673094201396088" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.107272157672961" CI_START="0.9783923964266341" DF="0" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" I2="0.0" ID="CMP-003.28.02" LOG_CI_END="0.7858472738425899" LOG_CI_START="-0.009486931076827161" LOG_EFFECT_SIZE="0.3881801713828814" NO="2" P_CHI2="1.0" P_Z="0.05572166351393669" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.913206173498144">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="6.107272157672961" CI_START="0.9783923964266341" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" LOG_CI_END="0.7858472738425899" LOG_CI_START="-0.009486931076827161" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="21332" O_E="0.0" SE="0.46718324893747454" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.21826018808777428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.621128951373271" CI_END="1.3969773323889023" CI_START="0.38842623944502974" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7366292499010413" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" I2="44.76860595529128" I2_Q="0.0" ID="CMP-003.29" LOG_CI_END="0.1451893592292242" LOG_CI_START="-0.41069143978033135" LOG_EFFECT_SIZE="-0.13275104027555354" METHOD="MH" NO="29" P_CHI2="0.16356185177762106" P_Q="0.42938277233338273" P_Z="0.3492082856197647" Q="0.6244929506488235" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="643" TOTAL_2="376" WEIGHT="200.0" Z="0.9361260842752678">
<NAME>Number of adverse events due to anxiety before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5479540480321106" CI_END="2.1598878121774723" CI_START="0.3909325608728301" DF="1" EFFECT_SIZE="0.9188963345299368" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="71.81474206086027" ID="CMP-003.29.01" LOG_CI_END="0.33443119382796793" LOG_CI_START="-0.40789815556295456" LOG_EFFECT_SIZE="-0.036733480867493305" NO="1" P_CHI2="0.059619066544713606" P_Z="0.846196234173958" STUDIES="2" TAU2="0.0" TOTAL_1="384" TOTAL_2="247" WEIGHT="100.0" Z="0.19397400786093297">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="171.94199445821442" CI_START="0.487402675438353" EFFECT_SIZE="9.15450643776824" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2353819600733615" LOG_CI_START="-0.31211209122654204" LOG_EFFECT_SIZE="0.9616349344234097" ORDER="21333" O_E="0.0" SE="1.4964106160324937" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="120" TOTAL_2="118" VAR="2.2392447317747473" WEIGHT="4.466848035262973"/>
<DICH_DATA CI_END="1.4175765891359822" CI_START="0.2010244545074788" EFFECT_SIZE="0.5338235294117647" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.15154653235546614" LOG_CI_START="-0.6967511076957138" LOG_EFFECT_SIZE="-0.2726022876701238" ORDER="21334" O_E="0.0" SE="0.49829423290710423" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="264" TOTAL_2="129" VAR="0.24829714254847943" WEIGHT="95.53315196473703"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4461511533170501" CI_START="0.2050133205785305" DF="0" EFFECT_SIZE="0.5445" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-003.29.02" LOG_CI_END="0.16021368827023402" LOG_CI_START="-0.6882179200866465" LOG_EFFECT_SIZE="-0.26400211590820627" NO="2" P_CHI2="1.0" P_Z="0.22256199720822956" STUDIES="1" TAU2="0.0" TOTAL_1="259" TOTAL_2="129" WEIGHT="100.0" Z="1.2197438990387113">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="1.4461511533170501" CI_START="0.2050133205785305" EFFECT_SIZE="0.5445" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.16021368827023402" LOG_CI_START="-0.6882179200866465" LOG_EFFECT_SIZE="-0.26400211590820627" ORDER="21335" O_E="0.0" SE="0.4983729265530266" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="259" TOTAL_2="129" VAR="0.24837557392102846" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="171.94199445821442" CI_START="0.48740267543835275" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="9.15450643776824" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.30" LOG_CI_END="2.2353819600733615" LOG_CI_START="-0.3121120912265422" LOG_EFFECT_SIZE="0.9616349344234097" METHOD="MH" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.13895199169594524" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="118" WEIGHT="100.0" Z="1.4797049961970923">
<NAME>Number of adverse events due to dry mouth before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="171.94199445821442" CI_START="0.48740267543835275" DF="0" EFFECT_SIZE="9.15450643776824" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.30.01" LOG_CI_END="2.2353819600733615" LOG_CI_START="-0.3121120912265422" LOG_EFFECT_SIZE="0.9616349344234097" NO="1" P_CHI2="1.0" P_Z="0.13895199169594524" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="118" WEIGHT="100.0" Z="1.4797049961970923">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="171.94199445821442" CI_START="0.487402675438353" EFFECT_SIZE="9.15450643776824" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2353819600733615" LOG_CI_START="-0.31211209122654204" LOG_EFFECT_SIZE="0.9616349344234097" ORDER="21336" O_E="0.0" SE="1.4964106160324937" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="120" TOTAL_2="118" VAR="2.2392447317747473" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.357397507661599" CI_END="1.8006086266731396" CI_START="0.28234630090579704" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7130183624004562" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="54.101043191872996" I2_Q="53.02271377605773" ID="CMP-003.31" LOG_CI_END="0.2554193265080225" LOG_CI_START="-0.5492178976976843" LOG_EFFECT_SIZE="-0.14689928559483084" METHOD="MH" NO="31" P_CHI2="0.11318880357494288" P_Q="0.1189933361634099" P_Z="0.474210575915213" Q="4.25737661913022" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="260" TOTAL_2="198" WEIGHT="300.0" Z="0.7156450148195619">
<NAME>Number of adverse events due to akathisia before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.956460980786675" CI_START="0.4664028872284792" DF="0" EFFECT_SIZE="1.5204301075268818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-003.31.01" LOG_CI_END="0.6951716915905589" LOG_CI_START="-0.33123876977666794" LOG_EFFECT_SIZE="0.18196646090694552" NO="1" P_CHI2="1.0" P_Z="0.4870918500834066" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="106" WEIGHT="100.0" Z="0.6949416889160647">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="4.956460980786675" CI_START="0.4664028872284792" EFFECT_SIZE="1.5204301075268818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6951716915905589" LOG_CI_START="-0.33123876977666794" LOG_EFFECT_SIZE="0.18196646090694552" ORDER="21337" O_E="0.0" SE="0.6029185858208351" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="100" TOTAL_2="106" VAR="0.36351082112819577" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7759897071142356" CI_START="0.00393224304783279" DF="0" EFFECT_SIZE="0.0835680751173709" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.31.02" LOG_CI_END="0.24944044446260258" LOG_CI_START="-2.4053596467222897" LOG_EFFECT_SIZE="-1.0779596011298438" NO="2" P_CHI2="1.0" P_Z="0.11146240127225625" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="46" WEIGHT="100.0" Z="1.5916543034776576">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="1.7759897071142365" CI_START="0.0039322430478327865" EFFECT_SIZE="0.0835680751173709" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2494404444626028" LOG_CI_START="-2.40535964672229" LOG_EFFECT_SIZE="-1.0779596011298438" ORDER="21338" O_E="0.0" SE="1.5594427150344004" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="106" TOTAL_2="46" VAR="2.431861581473862" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4900879083312706" CI_START="0.00764100779324165" DF="0" EFFECT_SIZE="0.163302752293578" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.31.03" LOG_CI_END="0.5428363661059894" LOG_CI_START="-2.116849357369449" LOG_EFFECT_SIZE="-0.7870064956317296" NO="3" P_CHI2="1.0" P_Z="0.24608352551654933" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="46" WEIGHT="99.99999999999999" Z="1.159914777466011">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<DICH_DATA CI_END="3.4900879083312706" CI_START="0.00764100779324165" EFFECT_SIZE="0.163302752293578" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5428363661059894" LOG_CI_START="-2.116849357369449" LOG_EFFECT_SIZE="-0.7870064956317296" ORDER="21339" O_E="0.0" SE="1.5623125596261365" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="54" TOTAL_2="46" VAR="2.4408205339655704" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5710428660285475" CI_END="2.3807933627740576" CI_START="0.8303790110337086" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4060443940558702" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-003.32" LOG_CI_END="0.37672170313215736" LOG_CI_START="-0.080723636744464" LOG_EFFECT_SIZE="0.14799903319384666" METHOD="MH" NO="32" P_CHI2="0.7516222553955305" P_Q="0.6774357596992984" P_Z="0.20471612788006044" Q="0.17302704968939495" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="726" TOTAL_2="352" WEIGHT="200.0" Z="1.2682292266215835">
<NAME>Number of adverse events due to falls before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9697003136844846" CI_START="0.4845235524195836" DF="0" EFFECT_SIZE="1.1995373048004627" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" I2="0.0" ID="CMP-003.32.01" LOG_CI_END="0.4727126248458191" LOG_CI_START="-0.3146851072876199" LOG_EFFECT_SIZE="0.07901375877909961" NO="1" P_CHI2="1.0" P_Z="0.6940559814951727" STUDIES="1" TAU2="0.0" TOTAL_1="264" TOTAL_2="129" WEIGHT="100.0" Z="0.3933567882411076">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="2.9697003136844846" CI_START="0.4845235524195836" EFFECT_SIZE="1.1995373048004627" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.4727126248458191" LOG_CI_START="-0.3146851072876199" LOG_EFFECT_SIZE="0.07901375877909961" ORDER="21340" O_E="0.0" SE="0.46252132553681713" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="264" TOTAL_2="129" VAR="0.2139259765763344" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4117325265983448" CI_END="2.9050990262064174" CI_START="0.7948486267855549" DF="1" EFFECT_SIZE="1.5195769054760682" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="13" I2="0.0" ID="CMP-003.32.02" LOG_CI_END="0.463160940789007" LOG_CI_START="-0.09971557173504188" LOG_EFFECT_SIZE="0.18172268452698254" NO="2" P_CHI2="0.5210914660829874" P_Z="0.2056796946930214" STUDIES="2" TAU2="0.0" TOTAL_1="462" TOTAL_2="223" WEIGHT="100.0" Z="1.2655348337406518">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="4.768643865859206" CI_START="0.7365099457859775" EFFECT_SIZE="1.874074074074074" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.6783948894568318" LOG_CI_START="-0.13282138409520822" LOG_EFFECT_SIZE="0.27278675268081176" ORDER="21341" O_E="0.0" SE="0.47651245466978487" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.2270641194554238" WEIGHT="45.441236751185805"/>
<DICH_DATA CI_END="3.0315949560318103" CI_START="0.4944467382547063" EFFECT_SIZE="1.2243211334120425" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.4816711758151835" LOG_CI_START="-0.3058804836985154" LOG_EFFECT_SIZE="0.08789534605833406" ORDER="21342" O_E="0.0" SE="0.4626117432419346" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="259" TOTAL_2="129" VAR="0.21400962498534165" WEIGHT="54.558763248814195"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.524596857598832" CI_END="8.528736668387916" CI_START="0.8664282526151355" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="2.718370542918308" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" I2="43.2559217180225" I2_Q="71.4685231099116" ID="CMP-003.33" LOG_CI_END="0.9308847054252819" LOG_CI_START="-0.062267394615884396" LOG_EFFECT_SIZE="0.4343086554046988" METHOD="MH" NO="33" P_CHI2="0.1716499348443461" P_Q="0.06118763413880046" P_Z="0.08649249713636176" Q="3.5049009339835178" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="726" TOTAL_2="352" WEIGHT="200.0" Z="1.7141972971349366">
<NAME>Number of adverse events due to weight increase before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.002882202527587" CI_START="0.006551482470682254" DF="0" EFFECT_SIZE="0.16194076874606175" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.33.01" LOG_CI_END="0.6023728098040814" LOG_CI_START="-2.1836604166511884" LOG_EFFECT_SIZE="-0.7906438034235537" NO="1" P_CHI2="1.0" P_Z="0.26595335795069286" STUDIES="1" TAU2="0.0" TOTAL_1="264" TOTAL_2="129" WEIGHT="100.0" Z="1.1124299341408528">
<NAME>Olanzapine less than 5 mg/day</NAME>
<DICH_DATA CI_END="4.002882202527587" CI_START="0.006551482470682254" EFFECT_SIZE="0.16194076874606175" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6023728098040814" LOG_CI_START="-2.1836604166511884" LOG_EFFECT_SIZE="-0.7906438034235537" ORDER="21343" O_E="0.0" SE="1.6365297083067163" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="264" TOTAL_2="129" VAR="2.6782294861704656" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0318576172173655" CI_END="20.38724464829914" CI_START="1.0852224350775272" DF="1" EFFECT_SIZE="4.703689539260481" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" I2="0.0" ID="CMP-003.33.02" LOG_CI_END="1.3093585345128753" LOG_CI_START="0.03551876346189195" LOG_EFFECT_SIZE="0.6724386489873837" NO="2" P_CHI2="0.8583405553784249" P_Z="0.038521298719771356" STUDIES="2" TAU2="0.0" TOTAL_1="462" TOTAL_2="223" WEIGHT="100.0" Z="2.0692642258149343">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="41.88954363420536" CI_START="0.6777088875335402" EFFECT_SIZE="5.328125" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.622105628964085" LOG_CI_START="-0.16895681894686373" LOG_EFFECT_SIZE="0.7265744050086106" ORDER="21344" O_E="0.0" SE="1.052078947804996" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="1.1068701124144673" WEIGHT="49.982890843582055"/>
<DICH_DATA CI_END="32.9748598490406" CI_START="0.5047420786917215" EFFECT_SIZE="4.079681274900398" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.5181829583679813" LOG_CI_START="-0.2969304880504338" LOG_EFFECT_SIZE="0.6106262351587738" ORDER="21345" O_E="0.0" SE="1.0662066233826444" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="259" TOTAL_2="129" VAR="1.13679656374502" WEIGHT="50.01710915641795"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.039605607147882" CI_START="0.9711623543755369" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.614689265536723" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.34" LOG_CI_END="0.8475483285402188" LOG_CI_START="-0.012708160704408248" LOG_EFFECT_SIZE="0.4174200839179053" METHOD="MH" NO="34" P_CHI2="1.0" P_Q="1.0" P_Z="0.057163735909769336" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.9020567496588432">
<NAME>Number of adverse events due to hallucination before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.039605607147882" CI_START="0.9711623543755369" DF="0" EFFECT_SIZE="2.614689265536723" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" I2="0.0" ID="CMP-003.34.01" LOG_CI_END="0.8475483285402188" LOG_CI_START="-0.012708160704408248" LOG_EFFECT_SIZE="0.4174200839179053" NO="1" P_CHI2="1.0" P_Z="0.057163735909769336" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.9020567496588432">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="7.039605607147882" CI_START="0.9711623543755369" EFFECT_SIZE="2.614689265536723" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="0.8475483285402188" LOG_CI_START="-0.012708160704408248" LOG_EFFECT_SIZE="0.4174200839179053" ORDER="21346" O_E="0.0" SE="0.5053189201205933" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.25534721103184255" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.84880305019333" CI_START="1.2659455676352083" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="9.603260869565217" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.35" LOG_CI_END="1.8624224204441464" LOG_CI_START="0.10241503255030868" LOG_EFFECT_SIZE="0.9824187264972276" METHOD="MH" NO="35" P_CHI2="1.0" P_Q="1.0" P_Z="0.028664864694798786" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="2.188065044404708">
<NAME>Number of adverse events due to urinary incontinence before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.84880305019333" CI_START="1.2659455676352083" DF="0" EFFECT_SIZE="9.603260869565217" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" I2="0.0" ID="CMP-003.35.01" LOG_CI_END="1.8624224204441464" LOG_CI_START="0.10241503255030868" LOG_EFFECT_SIZE="0.9824187264972276" NO="1" P_CHI2="1.0" P_Z="0.028664864694798786" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="2.188065044404708">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="72.84880305019333" CI_START="1.2659455676352083" EFFECT_SIZE="9.603260869565217" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="1.8624224204441464" LOG_CI_START="0.10241503255030868" LOG_EFFECT_SIZE="0.9824187264972276" ORDER="21347" O_E="0.0" SE="1.0338370518259186" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="1.0688190497281072" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.388558994930026" CI_START="0.8219430244943587" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.6702127659574466" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.36" LOG_CI_END="1.2145407688198648" LOG_CI_START="-0.08515828587271375" LOG_EFFECT_SIZE="0.5646912414735754" METHOD="MH" NO="36" P_CHI2="1.0" P_Q="1.0" P_Z="0.0885448167036596" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="203" TOTAL_2="94" WEIGHT="99.99999999999999" Z="1.7031242604622923">
<NAME>Number of adverse events due to asthenia before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.388558994930026" CI_START="0.8219430244943587" DF="0" EFFECT_SIZE="3.6702127659574466" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" I2="0.0" ID="CMP-003.36.01" LOG_CI_END="1.2145407688198648" LOG_CI_START="-0.08515828587271375" LOG_EFFECT_SIZE="0.5646912414735754" NO="1" P_CHI2="1.0" P_Z="0.0885448167036596" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="94" WEIGHT="99.99999999999999" Z="1.7031242604622923">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="16.388558994930026" CI_START="0.8219430244943586" EFFECT_SIZE="3.6702127659574466" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.2145407688198648" LOG_CI_START="-0.08515828587271382" LOG_EFFECT_SIZE="0.5646912414735754" ORDER="21348" O_E="0.0" SE="0.7634496583405014" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.5828553808202283" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8373789944702297" CI_START="0.04958032903813809" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3018242122719735" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.37" LOG_CI_END="0.2641987470681788" LOG_CI_START="-1.3046905953783319" LOG_EFFECT_SIZE="-0.5202459241550765" METHOD="MH" NO="37" P_CHI2="1.0" P_Q="1.0" P_Z="0.1936511311990533" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.2998536568011276">
<NAME>Number of adverse events due to flu syndrome before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8373789944702297" CI_START="0.04958032903813809" DF="0" EFFECT_SIZE="0.3018242122719735" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.37.01" LOG_CI_END="0.2641987470681788" LOG_CI_START="-1.3046905953783319" LOG_EFFECT_SIZE="-0.5202459241550765" NO="1" P_CHI2="1.0" P_Z="0.1936511311990533" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.2998536568011276">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="1.8373789944702292" CI_START="0.04958032903813811" EFFECT_SIZE="0.3018242122719735" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.2641987470681787" LOG_CI_START="-1.3046905953783317" LOG_EFFECT_SIZE="-0.5202459241550765" ORDER="21349" O_E="0.0" SE="0.9215733658805758" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="0.8492974687004538" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2563384130238304" CI_START="0.0032840566665780146" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.06423306423306423" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.38" LOG_CI_END="0.0991066386947285" LOG_CI_START="-2.4835893577128236" LOG_EFFECT_SIZE="-1.1922413595090475" METHOD="MH" NO="38" P_CHI2="1.0" P_Q="1.0" P_Z="0.07036663866843167" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.8095433057294774">
<NAME>Number of adverse events due to dyspnea before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2563384130238304" CI_START="0.0032840566665780146" DF="0" EFFECT_SIZE="0.06423306423306423" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.38.01" LOG_CI_END="0.0991066386947285" LOG_CI_START="-2.4835893577128236" LOG_EFFECT_SIZE="-1.1922413595090475" NO="1" P_CHI2="1.0" P_Z="0.07036663866843167" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.8095433057294774">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="1.2563384130238304" CI_START="0.0032840566665780146" EFFECT_SIZE="0.06423306423306423" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0991066386947285" LOG_CI_START="-2.4835893577128236" LOG_EFFECT_SIZE="-1.1922413595090475" ORDER="21350" O_E="0.0" SE="1.5170884128411648" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="2.3015572523769245" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9124760639806784" CI_START="0.0043213418277850135" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.39" LOG_CI_END="0.2815960083505378" LOG_CI_START="-2.364381378666988" LOG_EFFECT_SIZE="-1.041392685158225" METHOD="MH" NO="39" P_CHI2="1.0" P_Q="1.0" P_Z="0.12288202454557498" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.5427888134556167">
<NAME>Number of adverse events due to angina pectoris before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9124760639806784" CI_START="0.0043213418277850135" DF="0" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.39.01" LOG_CI_END="0.2815960083505378" LOG_CI_START="-2.364381378666988" LOG_EFFECT_SIZE="-1.041392685158225" NO="1" P_CHI2="1.0" P_Z="0.12288202454557498" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.5427888134556167">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="1.9124760639806784" CI_START="0.0043213418277850135" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2815960083505378" LOG_CI_START="-2.364381378666988" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="21351" O_E="0.0" SE="1.554260214933399" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="2.4157248157248157" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="95.68955625821388" CI_START="0.28659157850715294" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="5.236775818639798" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.40" LOG_CI_END="1.9808645406301935" LOG_CI_START="-0.5427365754934852" LOG_EFFECT_SIZE="0.7190639825683541" METHOD="MH" MODIFIED="2008-06-20 15:32:27 +0100" MODIFIED_BY="Helen Collins" NO="40" P_CHI2="1.0" P_Q="1.0" P_Z="0.2640254228014971" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.116927314233159">
<NAME>Number of cerebrovascular adverse events before end of treatment at 6-10 weeks</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="95.68955625821388" CI_START="0.28659157850715294" DF="0" EFFECT_SIZE="5.236775818639798" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-003.40.01" LOG_CI_END="1.9808645406301935" LOG_CI_START="-0.5427365754934852" LOG_EFFECT_SIZE="0.7190639825683541" NO="1" P_CHI2="1.0" P_Z="0.2640254228014971" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="94" WEIGHT="100.0" Z="1.116927314233159">
<NAME>Olanzapine 5-10 mg/day</NAME>
<DICH_DATA CI_END="95.68955625821388" CI_START="0.28659157850715294" EFFECT_SIZE="5.236775818639798" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9808645406301935" LOG_CI_START="-0.5427365754934852" LOG_EFFECT_SIZE="0.7190639825683541" ORDER="21352" O_E="0.0" SE="1.4823757876380426" STUDY_ID="STD-F1D_x002d_MC_x002d_HGGU_x002f_Deberdt" TOTAL_1="203" TOTAL_2="94" VAR="2.1974379757755074" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.008863428535977949" CI_END="-0.012106776034087913" CI_START="-0.4283608321111225" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2202338040726052" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.41" MODIFIED="2008-06-20 15:32:27 +0100" MODIFIED_BY="Helen Collins" NO="41" P_CHI2="0.9249933524476787" P_Q="0.9249933524476786" P_Z="0.038081600963723886" Q="0.008863428535977973" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="514" TOTAL_2="258" UNITS="" WEIGHT="199.99999999999997" Z="2.073975342023685">
<NAME>CGI (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.06095440151531489" CI_START="-0.5209544015153149" DF="0" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-003.41.01" NO="1" P_CHI2="1.0" P_Z="0.12129635572689917" STUDIES="1" TAU2="0.0" TOTAL_1="262" TOTAL_2="129" WEIGHT="99.99999999999999" Z="1.5493552051333523">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="0.06095440151531489" CI_START="-0.5209544015153149" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="2.93" MEAN_2="3.16" ORDER="21353" SD_1="1.36" SD_2="1.39" SE="0.14844885100457256" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="262" TOTAL_2="129" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.336069814561267E-32" CI_END="0.08783845076319272" CI_START="-0.5078384507631926" DF="0" EFFECT_SIZE="-0.20999999999999994" ESTIMABLE="YES" I2="100.0" ID="CMP-003.41.02" NO="2" P_CHI2="0.0" P_Z="0.16699263202341438" STUDIES="1" TAU2="0.0" TOTAL_1="252" TOTAL_2="129" WEIGHT="99.99999999999999" Z="1.3819318348545362">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="0.08783845076319269" CI_START="-0.5078384507631926" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="2.95" MEAN_2="3.16" ORDER="21354" SD_1="1.43" SD_2="1.39" SE="0.15196118556897184" STUDY_ID="STD-F1D_x002d_MC_x002d_HGIV_x002f_DeDeyn" TOTAL_1="252" TOTAL_2="129" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.221551681808416" CI_END="1.209131272909405" CI_START="-0.2866678757492446" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.46123169858008023" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.42" MODIFIED="2008-06-20 15:32:27 +0100" MODIFIED_BY="Helen Collins" NO="42" P_CHI2="0.542929758355924" P_Q="0.542929758355924" P_Z="0.22677233608290015" Q="1.221551681808416" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="245" TOTAL_2="177" UNITS="" WEIGHT="300.0" Z="1.2087151119932733">
<NAME>MMSE (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.268803055760681" CI_START="-0.7488030557606811" DF="0" EFFECT_SIZE="0.25999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-003.42.01" NO="1" P_CHI2="1.0" P_Z="0.6134578229031404" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="91" WEIGHT="100.0" Z="0.5051438267067507">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="1.268803055760681" CI_START="-0.7488030557606811" EFFECT_SIZE="0.25999999999999995" ESTIMABLE="YES" MEAN_1="-0.33" MEAN_2="-0.59" ORDER="21355" SD_1="3.26" SD_2="3.76" SE="0.5147048944358115" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="97" TOTAL_2="91" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.7411951069007383" CI_START="-0.32119510690073816" DF="0" EFFECT_SIZE="1.21" ESTIMABLE="YES" I2="0.0" ID="CMP-003.42.02" NO="2" P_CHI2="1.0" P_Z="0.12142329784309082" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="43" WEIGHT="100.0" Z="1.5488270636481372">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="2.7411951069007383" CI_START="-0.32119510690073816" EFFECT_SIZE="1.21" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="-1.02" ORDER="21356" SD_1="3.63" SD_2="4.53" SE="0.7812363487179406" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="99" TOTAL_2="43" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7651375443583461" CI_START="-1.4851375443583459" DF="0" EFFECT_SIZE="0.14" ESTIMABLE="YES" I2="0.0" ID="CMP-003.42.03" NO="3" P_CHI2="1.0" P_Z="0.865919234808997" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="43" WEIGHT="100.00000000000001" Z="0.16884414416993063">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="1.7651375443583461" CI_START="-1.4851375443583459" EFFECT_SIZE="0.14" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-1.02" ORDER="21357" SD_1="3.21" SD_2="4.53" SE="0.8291670444851148" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="49" TOTAL_2="43" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.9395965965442992" CI_START="-2.7395965965443" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.43" MODIFIED="2008-06-20 15:32:27 +0100" MODIFIED_BY="Helen Collins" NO="43" P_CHI2="1.0" P_Q="1.0" P_Z="0.7375539175976065" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="105" UNITS="" WEIGHT="100.0" Z="0.3350943470229048">
<NAME>BEHAVE-AD TOTAL (change from baseline at 6-10 weeks)</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9395965965442992" CI_START="-2.7395965965443" DF="0" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-003.43.01" NO="1" P_CHI2="1.0" P_Z="0.7375539175976065" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="105" WEIGHT="100.0" Z="0.3350943470229048">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="1.9395965965442992" CI_START="-2.7395965965443" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="-3.72" MEAN_2="-3.32" ORDER="21358" SD_1="8.24" SD_2="8.85" SE="1.1936936673320218" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="100" TOTAL_2="105" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03707983835533329" CI_END="0.17691146967089594" CI_START="-0.07308295326753796" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.051914258201678984" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.44" MODIFIED="2008-06-20 15:32:27 +0100" MODIFIED_BY="Helen Collins" NO="44" P_CHI2="0.9816308927622638" P_Q="0.9816308927622638" P_Z="0.4156342056589317" Q="0.03707983835533329" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="271" TOTAL_2="207" UNITS="" WEIGHT="300.0" Z="0.8140187702064211">
<NAME>CGI-Severity (change from baseline at 6-10 weeks) ITT</NAME>
<GROUP_LABEL_1>Olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26982856403257766" CI_START="-0.16982856403257768" DF="0" EFFECT_SIZE="0.04999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.44.01" NO="1" P_CHI2="1.0" P_Z="0.6557462404927393" STUDIES="1" TAU2="0.0" TOTAL_1="112" TOTAL_2="115" WEIGHT="100.0" Z="0.4457937468603024">
<NAME>Olanzapine less than 5 mg/day</NAME>
<CONT_DATA CI_END="0.2698285640325777" CI_START="-0.1698285640325777" EFFECT_SIZE="0.04999999999999999" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="-0.29" ORDER="21359" SD_1="0.92" SD_2="0.76" SE="0.1121594915858441" STUDY_ID="STD-F1D_x002d_MC_x002d_HGAO_x002f_Satterle" TOTAL_1="112" TOTAL_2="115" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.24084921645119506" CI_START="-0.16084921645119504" DF="0" EFFECT_SIZE="0.039999999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-003.44.02" NO="2" P_CHI2="1.0" P_Z="0.6962885502160785" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="46" WEIGHT="100.0" Z="0.3903354006892651">
<NAME>Olanzapine 5-10 mg/day</NAME>
<CONT_DATA CI_END="0.24084921645119506" CI_START="-0.16084921645119504" EFFECT_SIZE="0.039999999999999994" ESTIMABLE="YES" MEAN_1="-0.07" MEAN_2="-0.11" ORDER="21360" SD_1="0.53" SD_2="0.6" SE="0.1024759730461723" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="105" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3023670726696188" CI_START="-0.1623670726696188" DF="0" EFFECT_SIZE="0.07" ESTIMABLE="YES" I2="0.0" ID="CMP-003.44.03" NO="3" P_CHI2="1.0" P_Z="0.5548995553144824" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="46" WEIGHT="100.0" Z="0.5904342527603822">
<NAME>Olanzapine greater than 10 mg/day</NAME>
<CONT_DATA CI_END="0.3023670726696188" CI_START="-0.16236707266961878" EFFECT_SIZE="0.07" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="-0.11" ORDER="21361" SD_1="0.58" SD_2="0.6" SE="0.11855680742222846" STUDY_ID="STD-F1D_x002d_MC_x002d_HGEU_x002f_Clark_x002f_St" TOTAL_1="54" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>ARIPIPRAZOLE VS PLACEBO</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4379812205382927" CI_START="-2.497981220538293" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0300000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.16907047663377334" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" UNITS="" WEIGHT="100.0" Z="1.3751966822409334">
<NAME>BEHAVE-AD PSYCHOSIS (change from baseline at 10 weeks) ITT</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4379812205382927" CI_START="-2.497981220538293" DF="0" EFFECT_SIZE="-1.0300000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" NO="1" P_CHI2="1.0" P_Z="0.16907047663377334" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="1.3751966822409334">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<CONT_DATA CI_END="0.4379812205382927" CI_START="-2.497981220538293" EFFECT_SIZE="-1.0300000000000002" ESTIMABLE="YES" MEAN_1="-6.55" MEAN_2="-5.52" ORDER="21362" SD_1="5.4" SD_2="5.4" SE="0.7489837732313152" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.668523315120596E-32" CI_END="0.7141140669028279" CI_START="-4.614114066902827" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9499999999999995" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.15140199975938465" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" UNITS="" WEIGHT="100.0" Z="1.4345968955812387">
<NAME>BPRS TOTAL (change from baseline at 10 weeks) ITT</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.668523315120596E-32" CI_END="0.7141140669028279" CI_START="-4.614114066902827" DF="0" EFFECT_SIZE="-1.9499999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-004.02.01" NO="1" P_CHI2="0.0" P_Z="0.15140199975938465" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="1.4345968955812387">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<CONT_DATA CI_END="0.7141140669028285" CI_START="-4.614114066902827" EFFECT_SIZE="-1.9499999999999993" ESTIMABLE="YES" MEAN_1="-8.53" MEAN_2="-6.58" ORDER="21363" SD_1="9.8" SD_2="9.8" SE="1.3592668477160905" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.0483411581090446" CI_START="-1.2716588418909551" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6599999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.03444140576337225" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" UNITS="" WEIGHT="100.0" Z="2.114865577349163">
<NAME>BPRS - PSYCHOSIS SUBSCALE (change from baseline at 10 weeks) ITT</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.0483411581090446" CI_START="-1.2716588418909551" DF="0" EFFECT_SIZE="-0.6599999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" NO="1" P_CHI2="1.0" P_Z="0.03444140576337225" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="2.114865577349163">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<CONT_DATA CI_END="-0.0483411581090446" CI_START="-1.2716588418909551" EFFECT_SIZE="-0.6599999999999999" ESTIMABLE="YES" MEAN_1="-1.93" MEAN_2="-1.27" ORDER="21364" SD_1="2.25" SD_2="2.25" SE="0.31207657217971463" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.958071134970295" CI_START="0.46533397511485775" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.29182846528320466" LOG_CI_START="-0.3322352374597785" LOG_EFFECT_SIZE="-0.02020338608828695" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.899016839756866" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="0.12690342003469524">
<NAME>Number of dropouts before end of treatment at 10 weeks</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.958071134970295" CI_START="0.46533397511485775" DF="0" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.29182846528320466" LOG_CI_START="-0.3322352374597785" LOG_EFFECT_SIZE="-0.02020338608828695" NO="1" P_CHI2="1.0" P_Z="0.899016839756866" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="0.12690342003469524">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<DICH_DATA CI_END="1.958071134970295" CI_START="0.46533397511485775" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.29182846528320466" LOG_CI_START="-0.3322352374597785" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="21365" O_E="0.0" SE="0.3665781081563783" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" VAR="0.13437950937950938" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1751034301112453" CI_START="0.3865637057974993" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1078717201166182" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.5017578771539599" LOG_CI_START="-0.4127789240058805" LOG_EFFECT_SIZE="0.0444894765740397" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.8487663141156473" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="0.19069275652017428">
<NAME>Number of dropouts due to adverse events before end of treatment at 10 weeks</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1751034301112453" CI_START="0.3865637057974993" DF="0" EFFECT_SIZE="1.1078717201166182" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.5017578771539599" LOG_CI_START="-0.4127789240058805" LOG_EFFECT_SIZE="0.0444894765740397" NO="1" P_CHI2="1.0" P_Z="0.8487663141156473" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="0.19069275652017428">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<DICH_DATA CI_END="3.1751034301112453" CI_START="0.3865637057974993" EFFECT_SIZE="1.1078717201166182" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5017578771539599" LOG_CI_START="-0.4127789240058805" LOG_EFFECT_SIZE="0.0444894765740397" ORDER="21366" O_E="0.0" SE="0.537203444031467" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" VAR="0.2885875402792696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="169.31578203733852" CI_START="0.47839604214884957" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="2.2286974408749365" LOG_CI_START="-0.32021242199628663" LOG_EFFECT_SIZE="0.9542425094393249" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.14223617769111477" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="1.4675143897881262">
<NAME>Number of deaths before end of treatment at 10 weeks</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="169.31578203733852" CI_START="0.47839604214884957" DF="0" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="2.2286974408749365" LOG_CI_START="-0.32021242199628663" LOG_EFFECT_SIZE="0.9542425094393249" NO="1" P_CHI2="1.0" P_Z="0.14223617769111477" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="1.4675143897881262">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<DICH_DATA CI_END="169.31578203733852" CI_START="0.47839604214884957" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2286974408749365" LOG_CI_START="-0.32021242199628663" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="21367" O_E="0.0" SE="1.497242270757867" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" VAR="2.2417344173441736" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.566156160593608" CI_START="0.23933999974496611" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6122448979591837" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" I2_Q="100.0" ID="CMP-004.07" LOG_CI_END="0.19483506315158622" LOG_CI_START="-0.6209847137692887" LOG_EFFECT_SIZE="-0.21307482530885122" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.3059287920415681" Q="1.3418278635000087E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="1.023802058816763">
<NAME>Number of adverse events due to urinary tract infection before end of treatment at 10 weeks</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.566156160593608" CI_START="0.23933999974496611" DF="0" EFFECT_SIZE="0.6122448979591837" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="0.19483506315158622" LOG_CI_START="-0.6209847137692887" LOG_EFFECT_SIZE="-0.21307482530885122" NO="1" P_CHI2="1.0" P_Z="0.3059287920415681" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="1.023802058816763">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<DICH_DATA CI_END="1.566156160593608" CI_START="0.23933999974496611" EFFECT_SIZE="0.6122448979591837" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.19483506315158622" LOG_CI_START="-0.6209847137692887" LOG_EFFECT_SIZE="-0.21307482530885122" ORDER="21368" O_E="0.0" SE="0.47921657533634776" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" VAR="0.2296485260770975" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.01193212726768" CI_START="0.5004101400331472" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.583673469387755" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="100.0" ID="CMP-004.08" LOG_CI_END="0.700005181046632" LOG_CI_START="-0.3006738985872824" LOG_EFFECT_SIZE="0.19966564122967476" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.434130078852732" Q="8.918578173560903E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="0.7821437935994906">
<NAME>Number of adverse events due to accidental injury before end of treatment at 10 weeks</NAME>
<GROUP_LABEL_1>Ari piprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.01193212726768" CI_START="0.5004101400331472" DF="0" EFFECT_SIZE="1.583673469387755" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-004.08.01" LOG_CI_END="0.700005181046632" LOG_CI_START="-0.3006738985872824" LOG_EFFECT_SIZE="0.19966564122967476" NO="1" P_CHI2="1.0" P_Z="0.434130078852732" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="0.7821437935994906">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<DICH_DATA CI_END="5.011932127267681" CI_START="0.5004101400331471" EFFECT_SIZE="1.583673469387755" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.700005181046632" LOG_CI_START="-0.3006738985872825" LOG_EFFECT_SIZE="0.19966564122967476" ORDER="21369" O_E="0.0" SE="0.5878038448182936" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" VAR="0.34551335998316857" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.15100263660322" CI_START="1.012320586264738" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="8.244897959183673" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="1.8270525015362804" LOG_CI_START="0.0053180686279024735" LOG_EFFECT_SIZE="0.9161852850820913" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.048677321535665584" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="1.9714071705387517">
<NAME>Number of adverse events due to somnolence before end of treatment at 10 weeks</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.15100263660322" CI_START="1.012320586264738" DF="0" EFFECT_SIZE="8.244897959183673" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="1.8270525015362804" LOG_CI_START="0.0053180686279024735" LOG_EFFECT_SIZE="0.9161852850820913" NO="1" P_CHI2="1.0" P_Z="0.048677321535665584" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="1.9714071705387517">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<DICH_DATA CI_END="67.15100263660322" CI_START="1.012320586264738" EFFECT_SIZE="8.244897959183673" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8270525015362804" LOG_CI_START="0.0053180686279024735" LOG_EFFECT_SIZE="0.9161852850820913" ORDER="21370" O_E="0.0" SE="1.07009582362126" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" VAR="1.1451050717316629" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.138323810090926" CI_START="0.48172081763802393" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.98" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="0.9105349657013342" LOG_CI_START="-0.31720458517827205" LOG_EFFECT_SIZE="0.2966651902615311" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.34354050786390244" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" WEIGHT="99.99999999999999" Z="0.9471928927641784">
<NAME>Number of adverse events due to bronchitis before end of treatment at 10 weeks</NAME>
<GROUP_LABEL_1>Ari piprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.138323810090926" CI_START="0.48172081763802393" DF="0" EFFECT_SIZE="1.98" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-004.10.01" LOG_CI_END="0.9105349657013342" LOG_CI_START="-0.31720458517827205" LOG_EFFECT_SIZE="0.2966651902615311" NO="1" P_CHI2="1.0" P_Z="0.34354050786390244" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="99.99999999999999" Z="0.9471928927641784">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<DICH_DATA CI_END="8.138323810090926" CI_START="0.48172081763802393" EFFECT_SIZE="1.98" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9105349657013342" LOG_CI_START="-0.31720458517827205" LOG_EFFECT_SIZE="0.2966651902615311" ORDER="21371" O_E="0.0" SE="0.7211802895954729" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" VAR="0.5201010101010101" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.649800476171763" CI_START="0.3163698671974844" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2128712871287128" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="0.6674343176304456" LOG_CI_START="-0.4998048877946282" LOG_EFFECT_SIZE="0.08381471491790868" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.778346764392348" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="0.28147413460768633">
<NAME>Number of adverse events due to extrapyramidal symptoms before end of treatment at 10 weeks</NAME>
<GROUP_LABEL_1>Aripiprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aripiprazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.649800476171763" CI_START="0.3163698671974844" DF="0" EFFECT_SIZE="1.2128712871287128" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="0.6674343176304456" LOG_CI_START="-0.4998048877946282" LOG_EFFECT_SIZE="0.08381471491790868" NO="1" P_CHI2="1.0" P_Z="0.778346764392348" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="0.28147413460768633">
<NAME>aripiprazole 2-15 mg/day flexible dosing (mean dose 10mg/day)</NAME>
<DICH_DATA CI_END="4.649800476171763" CI_START="0.3163698671974844" EFFECT_SIZE="1.2128712871287128" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6674343176304456" LOG_CI_START="-0.4998048877946282" LOG_EFFECT_SIZE="0.08381471491790868" ORDER="21372" O_E="0.0" SE="0.6856420871939404" STUDY_ID="STD-DeDeyn-2003" TOTAL_1="106" TOTAL_2="102" VAR="0.470105071731663" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>QUETIAPINE VS PLACEBO</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.847214282059866" CI_START="-6.447214282059867" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6180270058938322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.49864853874778386">
<NAME>CMAI TOTAL (change from baseline at 6 weeks) ITT</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours quetiapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.847214282059866" CI_START="-6.447214282059867" DF="0" EFFECT_SIZE="2.2" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="1.0" P_Z="0.6180270058938322" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="0.49864853874778386">
<NAME>quetiapine 50-100 mg/day in two doses</NAME>
<CONT_DATA CI_END="10.847214282059866" CI_START="-6.447214282059867" EFFECT_SIZE="2.2" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-6.2" ORDER="21373" SD_1="15.4" SD_2="17.6" SE="4.411925091618004" STUDY_ID="STD-Ballard-2005" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.503221395080178" CI_START="-6.703221395080177" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.816535948190614" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.232002659718348">
<NAME>CMAI TOTAL (change from baseline at 26 weeks) ITT</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours quetiapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.503221395080178" CI_START="-6.703221395080177" DF="0" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" NO="1" P_CHI2="1.0" P_Z="0.816535948190614" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="30" WEIGHT="100.0" Z="0.232002659718348">
<NAME>quetiapine 50-100 mg/day in two doses</NAME>
<CONT_DATA CI_END="8.503221395080178" CI_START="-6.703221395080177" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="-8.1" MEAN_2="-9.0" ORDER="21374" SD_1="12.7" SD_2="16.5" SE="3.879265871747347" STUDY_ID="STD-Ballard-2005" TOTAL_1="27" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.2710508828470424" CI_START="-24.128949117152956" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.01003245251844391" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="2.5747087541193268">
<NAME>SIB (change from baseline at 6 weeks) ITT</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours quetiapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.2710508828470424" CI_START="-24.128949117152956" DF="0" EFFECT_SIZE="-13.7" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" NO="1" P_CHI2="1.0" P_Z="0.01003245251844391" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="18" WEIGHT="100.0" Z="2.5747087541193268">
<NAME>quetiapine 50-100 mg/day in two doses</NAME>
<CONT_DATA CI_END="-3.2710508828470424" CI_START="-24.128949117152956" EFFECT_SIZE="-13.7" ESTIMABLE="YES" MEAN_1="-10.5" MEAN_2="3.2" ORDER="21375" SD_1="14.8" SD_2="15.1" SE="5.3209901811539275" STUDY_ID="STD-Ballard-2005" TOTAL_1="14" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.485304174000696" CI_START="-25.714695825999307" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-14.600000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.010036707920633346" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="2.5745620593006215">
<NAME>SIB (change from baseline at 26 weeks) ITT</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours quetiapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.485304174000696" CI_START="-25.714695825999307" DF="0" EFFECT_SIZE="-14.600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" NO="1" P_CHI2="1.0" P_Z="0.010036707920633346" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="19" WEIGHT="100.0" Z="2.5745620593006215">
<NAME>quetiapine 50-100 mg/day in two doses</NAME>
<CONT_DATA CI_END="-3.485304174000696" CI_START="-25.714695825999307" EFFECT_SIZE="-14.600000000000001" ESTIMABLE="YES" MEAN_1="-11.3" MEAN_2="3.3" ORDER="21376" SD_1="15.6" SD_2="17.4" SE="5.670867380049128" STUDY_ID="STD-Ballard-2005" TOTAL_1="15" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="18.242558401674998" CI_START="0.56634779100461" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="1.2610857452760595" LOG_CI_START="-0.2469167890818484" LOG_EFFECT_SIZE="0.5070844780971057" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.1874620759150489" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="29" WEIGHT="99.99999999999999" Z="1.3181241961410834">
<NAME>Number of dropouts by end of treatment at 26 weeks</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours quetiapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.242558401674998" CI_START="0.56634779100461" DF="0" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="1.2610857452760595" LOG_CI_START="-0.2469167890818484" LOG_EFFECT_SIZE="0.5070844780971057" NO="1" P_CHI2="1.0" P_Z="0.1874620759150489" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="29" WEIGHT="99.99999999999999" Z="1.3181241961410834">
<NAME>quetiapine 50-100 mg/day in two doses</NAME>
<DICH_DATA CI_END="18.242558401674998" CI_START="0.56634779100461" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.2610857452760595" LOG_CI_START="-0.2469167890818484" LOG_EFFECT_SIZE="0.5070844780971057" ORDER="21377" O_E="0.0" SE="0.8858081534147699" STUDY_ID="STD-Ballard-2005" TOTAL_1="26" TOTAL_2="29" VAR="0.7846560846560846" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>